The Role of Ambulatory oxygen to improve skeletal muscle gene expression in Chronic Obstructive Pulmonary Disease in patients with exercise induced hypoxaemia

By

Stanley Ikenna Ejiofor

A thesis is submitted to the University of Birmingham for degree
Doctor of Medicine

School of Clinical experimental medicine
College of Medical and Dental Sciences
Institute of Inflammation and Ageing
University of Birmingham
October 2017
This unpublished thesis/dissertation is copyright of the author and/or third
parties. The intellectual property rights of the author or third parties in respect
of this work are as defined by The Copyright Designs and Patents Act 1988 or
as modified by any successor legislation.

Any use made of information contained in this thesis/dissertation must be in
accordance with that legislation and must be properly acknowledged. Further
distribution or reproduction in any format is prohibited without the permission
of the copyright holder.
Abstract

Rationale

Hypoxaemia plays a role in the aetiology of abnormal skeletal muscle function in Chronic obstructive pulmonary disease (COPD) via abnormal protein synthesis and mitochondrial function. Patients exhibiting exercise-induced desaturation (EID) have exercise intolerance, perhaps a consequence of muscle hypoxia. Ambulatory oxygen therapy (AOT) is indicated in these patients; however the evidence is derived from single assessment studies. This thesis explores the role of longer term AOT and whether it favourably alters skeletal muscle gene expression in patients with COPD and EID.

Methods

A 12 week randomised controlled trial of AOT against air in 25 patients with COPD and EID was undertaken. Participants underwent skeletal muscle biopsies and exercise assessments. In parallel a systematic review of published literature from 1980-2014 for trials in which AOT was compared to placebo in COPD was completed.

Results

The systematic review showed that AOT had no statistical effect on improving exercise capacity (6 minute walk or endurance shuttle walk tests); p=0.44 and p=0.29 respectively.

Gene set enrichment analysis show the KEGG pathways of oxidative phosphorylation, PPAR signalling and fatty acid metabolism to be up-regulated following AOT (q<2%) in the clinical trial of AOT versus Air.

Conclusion
AOT has limited long term benefit in improving functional exercise capacity. It may however favourably alter gene expression in patients with COPD and EID.
Dedication

This thesis is dedicated to my parents; for their constant love and support.
Acknowledgments

I would like to thank Paul Newby at the University of Birmingham for his help and direction with laboratory techniques, to Dr Phillip Antczak at the University of Liverpool for my bespoke training in computational biology and bioinformatics. Dr Peter Nightingale at the Wellcome Trust clinical research facility for his advice on statistics. Dr Elaine Wallace in biosciences for performing the microarrays and RNA extraction.

I would like to thank my supervisors Dr Alice Turner and Dr Michael White at the University of Birmingham for their support and advice throughout my MD.

Finally, to Amy Clare Oakes for her love and patience whilst writing this thesis.
# Contents

Chapter 1: Introduction Chronic Obstructive Pulmonary Disease | Page
--- | ---
1.1 Diagnosis and Clinical features | 1
1.1.0 Pulmonary Physiology in COPD | 4
1.1.1 Heterogeneity in COPD | 5
1.2 Pathogenesis | 7
1.2.0 Inflammation | 7
1.2.1 Protease anti Protease Imbalance | 9
1.2.2 Oxidative Stress | 10
1.3 Management | 12
1.3.0 Non Pharmacological | 12
1.3.1 Pharmacological | 12
1.3.2 Interventional | 14
1.4 Oxygen in COPD | 15
1.4.0 Long Term Oxygen Therapy (LTOT) | 16
1.4.1 Ambulatory Oxygen Therapy (AOT) | 18
   - Exercise Induced Desaturation
   - AOT assessment
   - Field Tests
1.4.2 Short Burst oxygen therapy (SBOT) | 23
1.5 Muscle Disease in COPD | 24
1.5.0 Skeletal muscle structure | 25
1.5.1 Clinical observations | 26
   - Skeletal muscle strength and endurance
1.5.2 Laboratory Observations

Muscle Mass

Skeletal Muscle dysfunction (SKMD) Pathological changes

1.6 Aetiology of SKMD in COPD

1.6.0 Inflammation

1.6.1 Hypoxia

1.6.2 Oxidative stress

1.6.3 Disuse

1.7 Aims

Chapter 2 Methods

2.1 Systematic Review

2.1.0 Objective 1 Clinical effectiveness of ambulatory oxygen

2.1.1 Objective 2 Clinical effectiveness of methods of delivering ambulatory oxygen

2.1.2 Objective 3 Cost-effectiveness of ambulatory O2

2.1.3 Search strategy

2.1.4 Study selection, data extraction and risk of bias

2.1.5 Statistical methods

2.2 Clinical trial Methods

2.2.0 Ethics and Governance

2.2.1 Participant Selection

2.2.2 Demographic data

2.2.3 Spirometry and arterial blood gas sampling

2.2.4 Muscle biopsy

2.2.5 Blood sampling
2.2.6 HRQoL and activity monitoring

2.2.7 6MWT

2.2.8 Blinding, Treatment allocation and statistical analysis

2.2.9 Trial monitoring and safety

2.3 Clinical Trial Laboratory Methods

2.3.0 Enzyme linked immunosorbent assay

2.3.1 RNA extraction

2.3.2 RNA amplification

2.4 Microarrays

2.4.0 Normalisation

Chapter 3 Systematic Review

3.1 Results

3.1.0 Included studies

3.1.1 Risk of bias

3.2 Clinical effectiveness of ambulatory oxygen

3.2.0 Exercise capacity

3.2.1 Quality of life

3.3 Impact of device on ambulatory oxygen delivery

3.3.0 Exercise capacity

3.3.1 Oxygen utilisation

3.3.2 Other outcomes

3.4 Cost Effectiveness

3.5 Discussion

Chapter 4 Clinical Outcomes
List of Tables

Table 1.1 Severity of airflow obstruction by FEV1% 3
Table 1.2 Protease and antiproteases involved in the pathogenesis of COPD. 9
Table 1.3 Borg Dyspnoea Scale 21
Table 1.4 Muscle fibre classification 25
Table 3.1 Clinical effectiveness of Ambulatory oxygen studies. 72
Table 3.2 Impact of device on Ambulatory oxygen delivery studies 75
Table 3.3 Risk of bias in included studies 76
Table 4.1 Baseline demographic data for trial participants 98
Table 4.2 Change from baseline in 6MWT distance following interventions and home activity (VMU/min) at the end of each intervention period. 100
Table 4.3 Change from baseline scores CAT and HAD 102
Table 4.4: Systemic cytokine response to oxygen and air during clinical trial 103
Table 5.1 Demographic data for patients included in gene expression data analysis 113
Table 5.2a Enriched KEGG pathways during ambulatory oxygen treatment 119
Table 5.2b Enriched KEGG pathways during air treatment. 120
Table 5.3a: Clinical outcome data for trial patients whom underwent muscle biopsies 131
Table 5.3b Correlation of OXPHOS pathway and patient clinical data. 132
## List of Figures

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>Severity Matrix COPD</td>
<td>3</td>
</tr>
<tr>
<td>1.1 and 1.2</td>
<td>CT thorax cross sectional images of emphysema.</td>
<td>6</td>
</tr>
<tr>
<td>1.3</td>
<td>Inflammatory cells and cytokines involved in COPD pathogenesis.</td>
<td>9</td>
</tr>
<tr>
<td>1.4</td>
<td>Nice guidelines for COPD management.</td>
<td>14</td>
</tr>
<tr>
<td>1.5</td>
<td>Kaplan Meier survival curves for LTOT trial.</td>
<td>17</td>
</tr>
<tr>
<td>1.6</td>
<td>The muscle motor unit</td>
<td>26</td>
</tr>
<tr>
<td>1.7</td>
<td>Hypertrophy and atrophy signalling pathways in muscle.</td>
<td>29</td>
</tr>
<tr>
<td>2.1</td>
<td>Trial flow diagram</td>
<td>47</td>
</tr>
<tr>
<td>2.2</td>
<td>Equipment used for muscle biopsy sampling.</td>
<td>53</td>
</tr>
<tr>
<td>2.3</td>
<td>Bergstrom's Procedure</td>
<td>53</td>
</tr>
<tr>
<td>2.4</td>
<td>Standard Elisa lab well</td>
<td>57</td>
</tr>
<tr>
<td>2.5</td>
<td>Sandwich Elisa process</td>
<td>58</td>
</tr>
<tr>
<td>2.6</td>
<td>RNA extraction process</td>
<td>61</td>
</tr>
<tr>
<td>2.7</td>
<td>Schematic diagram detailing the microarray process.</td>
<td>65</td>
</tr>
<tr>
<td>2.8</td>
<td>MA plots a) before and b) after normalisation</td>
<td>67</td>
</tr>
<tr>
<td>3.1</td>
<td>Prisma flow diagram</td>
<td>70</td>
</tr>
<tr>
<td>3.2</td>
<td>Forest plots showing the effect of ambulatory oxygen therapy on exercise capacity.</td>
<td>80</td>
</tr>
<tr>
<td>3.3</td>
<td>Forest plot showing the effect of ambulatory oxygen on end test exercise induced dyspnoea</td>
<td>81</td>
</tr>
<tr>
<td>3.4</td>
<td>Forest plots showing the results of ambulatory oxygen on HRQoL in the Pulmonary Rehab studies.</td>
<td>82</td>
</tr>
</tbody>
</table>
Figure 3.5 Forest plots showing results of ambulatory oxygen on HRQoL in domiciliary studies.

Figure 3.6 Forest plot showing the effect of OCDs on exercise capacity and exercise saturations

Figure 4.0 Study design diagram

Figure 4.1 Trial flow diagram

Figure 4.2 Correlation of baseline 6MWT and FEV1% predicted

Figure 4.3a-c) Correlations of home activity with 6MWT at baseline

Figure 4.4: HADs score during treatment arms

Figure 4.5 Plasma IL-6 during treatment arms

Figure 5.1 Box plot of individual normalised microarray data

Figure 5.2 False heat map of distance between microarrays

Figure 5.3a Enrichment plot for KEGG ribosome pathway

Figure 5.3b Enrichment plot for KEGG oxidative phosphorylation

Figure 5.3c Enrichment plot for the only KEGG pathway up-regulated during air

Figure 5.4 Functional grouping for KEGG pathways during oxygen treatment.

Figure 5.5 Plot of principal components against variance

Figure 5.6: Biplot of OXPHOS gene and principal components

Figure 5.7 Heatmap of genes enriched in OXPHOS pathway

Figure 5.8 Interaction between KEGG pathways, genes and clinical data
Appendices

Appendix 1 Search Strategy for systematic review. 148
Appendix 2 Clinical trial documents
Appendix 2.1 Good clinical practice certificate 151
Appendix 2.2 IRAS application 152
Appendix 2.3 MHRA acceptance letter 162
Appendix 2.4 Local Research and development letter approval 164
Appendix 2.5 NRES approval letter 165
Appendix 2.6 Patient information sheet 168
Appendix 2.7 Ambulatory oxygen in COPD Prescription 175
Appendix 2.8 Case report form 176
Appendix 3 Top 400 genes from pre-ranked list. 178

References 181
Abbreviations

COPD  Chronic Obstructive Pulmonary Disease
FEV1  Forced expiratory volume
FVC  Forced Vital Capacity
TLC  Total lung capacity
RV  Residual volume
FRC  Functional residual capacity
AATD  Alpha One antitrypsin deficiency
NF-κB  Nuclear factor Kappa B
FFM  Fat free mass
MMP  Matrix metalloproteinase
AAT  Alpha One antitrypsin
NE  Neutrophil Elastase
TIMPs  Tissue inhibitors of matrix metalloproteinases
ROS  Reactive Oxygen species
HRQoL  Health related quality of life
PR  Pulmonary Rehab
SABA  short acting beta 2 agonist
SAMA  short acting muscarinic antagonist
LAMA  Long acting muscarinic antagonist
LABA  Long acting beta 2 agonist
LABA/ICS  Long acting beta 2 agonist with inhaled corticosteroid
ICS  Inhaled corticosteroid
LVRS  Lung volume reduction surgery
LTOT  Long term oxygen therapy
EID  Exercise induced desaturation
6MWT  6 minute walk test
ESWT Endurance shuttle walk test
ISWT Incremental shuttle walk test
DODs Demand oxygen devices
PRC Pendant reservoir cannulae
CFNC Continuous flow nasal cannula
SBOT Short Burst Oxygen therapy
SKMD Skeletal muscle dysfunction
AMPK AMP-activated protein kinase
DNA Deoxyribonucleic acid
RNA Ribonucleic acid
LTB4 Leukotriene B4
PPAR Peroxisome-proliferator activated receptors
MHRA Medicines and Healthcare products regulatory agency
RNS Reactive nitrogen species
SNOSE Sequentially numbered, opaque sealed envelopes
CRF Case Report form
MRC Medical research council
CAT COPD assessment test
GCP Good clinical practice
TNF Tumour necrosis factor
IL Interleukin
HIF-α Hypoxia inducible factor alpha
KEGG Kyoto Encyclopedia of Genes and Genomes
HRG Healthcare resource group
OXPHOS Oxidative phosphorylation
GSEA Gene set enrichment analysis
Chapter 1

Introduction

Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is the 4th leading cause of death worldwide and predicted to be the 3rd by 2020 with the incidence of the disease increasing due to persistent exposure to risk factors and an ageing population(1). In the UK 900,000 people are diagnosed with COPD with another 2 million remaining undiagnosed(2). Estimated costs to the NHS are in the region of £800 million in direct healthcare costs(2), highlighting the need to study the disease to develop effective treatments.

1.1 Diagnosis and Clinical Features

COPD is characterised by airflow limitation that is usually progressive and not fully reversible(3). The airflow limitation is a consequence of chronic inflammation which affects both small airways and lung parenchyma resulting in narrowed small airways and loss of elastic recoil. Tobacco smoking is recognised as an important aetiological risk factor(in the Western world) however, only 15-20% of smokers develop clinically significant disease(4). From this it can be inferred that development of the disease is due to the interplay between genetic susceptibility and inhalation of noxious particles, most commonly from cigarette smoke but also environmental pollutants.

Diagnosis is based on physiological testing using post bronchodilator spirometry where the ratio between forced expiratory volume in the first second (FEV1) and forced vital
capacity (FVC) ratio is <70% in the presence of symptoms in individuals exposed to COPD risk factors(3). The predominant symptoms are:

- Dyspnoea which is generally progressive, persistent and worse with activity or exercise.
- Cough-with or without sputum production.
- Wheeze

The use of fixed FEV1/FVC ratio of <70% has been suggested and used by the Global initiative for chronic obstructive lung disease (GOLD)(3) due to its relative simplicity; however this remains a controversial issue. This is largely due to prevalence studies demonstrating disparity between the fixed ratio and lower limit of normal (the lower 5th percentile for reference population) when used for diagnosis. The use of the fixed ratio may result in misclassification at extremes of age; an overestimation and underestimation of disease in older and young older patients respectively(5, 6). The use of the lower limit of normal is less likely to cause this and in contrast to GOLD and National institute for clinical excellence (NICE)(7) is used by the ATS (American Thoracic Society) and ERS (European Respiratory Society).

The classification of severity airflow obstruction is based on the reduction in FEV1 compared to that predicted by age, gender and height. The FEV1 % predicted (table 1) is standardised, as such classification of severity in the UK-NICE guideline (7) is the same as that across America and Europe; ATS/ERS guidelines(8).

Although airflow obstruction has been used in several international guidelines to define severity, its use alone to define symptoms and management is outdated has been replaced by multicomponent system(3).
<table>
<thead>
<tr>
<th>GOLD</th>
<th>Severity</th>
<th>FEV1%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mild</td>
<td>&gt;80%</td>
</tr>
<tr>
<td>2</td>
<td>Moderate</td>
<td>50-79%</td>
</tr>
<tr>
<td>3</td>
<td>Severe</td>
<td>30-49%</td>
</tr>
<tr>
<td>4</td>
<td>Very Severe</td>
<td>&lt;30%</td>
</tr>
</tbody>
</table>

Table 1.1: Severity of airflow obstruction by FEV1%

This multicomponent system incorporates; exacerbation history, quality of life and level of dyspnoea. Quality of life and dyspnoea scores are quantified by the COPD assessment tool (CAT) and modified Medical research council (mMRC) respectively. The former is scored out of 40 and the mMRC out of 4 with higher scores indicating greater symptoms. Patients are categorised by these features (figure 1) into groups; A to D which indicate both their symptom burden and exacerbation history. Group A low symptoms and exacerbation burden, group B high symptoms and low exacerbation burden, group C low symptoms and high exacerbation burden and group D high symptom and exacerbation burden.

**Exacerbation history**

<table>
<thead>
<tr>
<th>Exacerbation History</th>
<th>CAT &lt;10</th>
<th>CAT &gt;10</th>
<th>mMRC 0-1</th>
<th>mMRC &gt;2</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>D</td>
<td>&gt;2 or &gt;1 leading to hospital admission</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>B</td>
<td>0 or 1 not leading to hospital admission</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 1.0: Severity Matrix COPD
1.1.0 Pulmonary Physiology in COPD

Physiological testing is the cornerstone of COPD diagnosis. FEV1 has been well characterised in patients with COPD. A lower FEV1% predicted is associated with worse health related quality of life (HRQoL) (9), symptom burden (10), a higher frequency of exacerbations(11) and mortality(12). The transfer factor for carbon monoxide (DLCO/TLCO) measures gas exchange within the lungs. Although less well characterised than FEV1, impairment of DLCO may indicate patients with reduced exercise capacity and those more likely to be affected by exercise induced desaturation (13). KCO (transfer factor per alveolar volume) is a measure of DLCO corrected for alveolar volume and normally indicates parenchymal involvement, which in the context of COPD suggests emphysema (section 1.1.1). The measurement of lung volumes FRC (functional residual capacity), TLC (Total lung capacity) and RV (residual volume) can be made using body plethysmography or inert gas dilution. In COPD these often reveal evidence of gas trapping suggested by raised RV:TLC ratio, raised RV and reduced inspiratory capacity.

Physiological testing via lung function can also indicate bronchodilator reversibility or small airways disease. Bronchodilator reversibility: an increase of 12 % and at least 200ml in FEV1 is common in COPD and more likely when the FEV1 is low(3). It may also suggest coexisting asthma which is likely to have implications for long term management. Small airway disease, measured physiologically by mid expiratory flow (FEF25-75%) is of interest in COPD as changes in their function may be the earliest signs of disease. Cross sectional studies have previously shown that even if pathology was present in the small airways FEV1 remained normal however as pathology progressed FEV1 subsequently declined(14).
1.1.1 Heterogeneity in COPD

Despite its spirometric definition COPD is a heterogeneous disease that encompasses a spectrum of clinical presentations which may co-exist. Typical clinical presentations include chronic bronchitis and emphysema.

Chronic bronchitis is classically defined as chronic cough with sputum production for at least 3 months of 2 consecutive years(15). It is caused by mucus overproduction and hypersecretion by goblet cells. This contributes to airflow limitation by causing luminal obstruction and altering airway surface tension increasing the tendency for them to collapse(16). Those affected are more likely to have a more rapid decline in lung function(17) and higher exacerbation(18) frequency than those without chronic bronchitis.

Emphysema is the destruction of alveolar walls with permanent abnormal enlargement of airspaces distal to terminal bronchioles(19). The use of computed tomography (CT) has enabled this diagnosis to be made in vivo from radiology in addition to its widely accepted histological diagnosis. Emphysema may be subdivided in its distribution on high resolution computer tomography (HRCT) both in terms of its relative geographic position within the lung as a whole (upper vs lower) or position relative to the secondary pulmonary lobule (centrilobular vs panlobular)-figure1.1/1.2.
Figure 1.1 and 1.2: CT thorax cross sectional images of emphysema.

Centrilobular emphysema

Panlobular emphysema
Emphysema in patients with COPD is typically upper lobe predominant and centrilobular in its distribution. However in Alpha one anti trypsin deficiency, a condition where there is a genetic predisposition to emphysema, it is typically lower zone predominant and panlobular (20). The distribution of emphysema within the lung may represent distinct clinical phenotypes. For example, lung volume reduction surgery a procedure which has been shown to improve functional and quality of life outcomes (21) is only effective for upper lobe predominant emphysema. It is important to note that both chronic bronchitis and emphysema; quantified by computer tomography can occur in the absence of airflow obstruction (16, 22).

1.2 Pathogenesis

The pathogenesis of COPD is complex and not completely understood. It involves several inflammatory cell types, molecular pathways and cytokines. Over the years a number of overarching concepts contributing to COPD pathogenesis have emerged; inflammation, protease anti-protease imbalance and oxidative stress.

1.2.0 Inflammation

The concept of inflammation is supported by studies demonstrating increased inflammatory cell infiltrate in the sputum, bronchoalveolar (BAL) fluid and lung biopsies of patients with COPD compared to healthy controls (23). There is some evidence to suggest that the intensity of the inflammatory cell infiltrates correlates with the degree of disease progression (24-27). The key inflammatory cells implicated are macrophages, neutrophils and cytotoxic T cells (CD8+) (28, 29).
Cigarette smoke activates macrophages to release pro-inflammatory mediators including interleukin 8 (IL8), tumour necrosis alpha (TNF-α) as well as chemoattractants such as leukotriene B4 (LTB4)(28, 29).

TNF-α enhances inflammation by activating nuclear factor Kb (NF-kB) which switches on the transcription of inflammatory genes(28). Serum levels of TNF-α have been shown to be higher in patients with COPD than controls and are also associated with the loss of fat free mass (FFM) in patients with COPD(30).

Macrophages also secrete protease enzymes; matrix metalloproteinases (MMP), cathepsins and neutrophil elastase (largely taken up from neutrophils) which degrade the extracellular matrix within the lung. Furthermore, macrophages from patients with COPD have greater elastolytic activity at baseline than smokers without COPD which is accentuated by cigarette smoke(31, 32). Neutrophils migrate to the lungs and respiratory tract under the chemotactic influence of IL8 and LTB4. They secrete oxidants as well as serine proteases most commonly neutrophil elastase which contributes to alveolar destruction. The chemotaxis of neutrophils in COPD has been shown to be aberrant (33) which may potentiate the amount of destruction that occurs during migration in the lung.

CD8+ T cells are found in increased numbers of the lung parenchyma of patients with COPD(34, 35). Although their role in COPD pathogenesis is not fully understood they have the ability to induce alveolar cell apoptosis by activating FAS-FAS ligand pathways(36). Majo et al demonstrated association between CD8+ cells and apoptosis of alveolar cells in patients with emphysema(36). The interaction between inflammatory cells and cytokines in the pathogenesis of COPD is summarised in figure 1.3.
1.2.1 Protease-Anti protease imbalance

The concept of protease-anti protease balance contributing to pathogenesis in COPD arose from early studies of alpha one antitrypsin (AAT) deficient patients developing early onset emphysema(37). AAT is an anti-protease which predominantly acts to block the action of neutrophil elastase (NE). Proteases break down the extracellular matrix within
the lung parenchyma. One of the key components is elastin and its destruction reduces the elasticity of the lung parenchyma and development of emphysema. There are two main types of proteases; serine (NE and proteinase 3) and cysteine (cathepsins and MMPs). Each protease is inhibited by one or more anti-proteases (table 1.2).

<table>
<thead>
<tr>
<th>Protease</th>
<th>Antiprotease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutrophil elastase</td>
<td>α 1 antitrypsin</td>
</tr>
<tr>
<td>Proteinase 3</td>
<td></td>
</tr>
<tr>
<td>Cathepsins</td>
<td>Secretory leukoproteinase inhibitor</td>
</tr>
<tr>
<td>MMPs</td>
<td>Tissue inhibitors of MMPs</td>
</tr>
</tbody>
</table>

Table 1.2: Protease and antiproteases involved in the pathogenesis of COPD.

MMPs are increasingly recognised to play a role in COPD pathogenesis(38). They predominantly break down collagen and gelatin; other components of the extracellular lung matrix and are inhibited by tissue inhibitors of matrix metalloproteinases (TIMPs) (39, 40). Previous studies have demonstrated increased activity of MMP 9 in the lung parenchyma of patients with COPD (40). Animal models support the role of MMPs in pathogenesis as mice lacking MMP9 are protected from small airway fibrosis(41) and those lacking MMP12 are protected from cigarette smoke induced emphysema(42).

1.2.2 Oxidative Stress

There is considerable evidence for the role of oxidative stress in patients with COPD (43-45). Oxidative stress occurs when reactive oxygen species (ROS) such as $O_2^-$ and hydrogen peroxide are produced in excess or overwhelm that of natural antioxidant defence mechanisms. This has deleterious effects and results in damage to tissue by mechanisms including lipid peroxidation, tissue remodelling and DNA damage. Cigarette smoke is a
potent source of oxidants, which can directly damage elastin and collagen(46).

Furthermore, the interaction between cigarette smoke, epithelial cells and inflammatory cells increases ROS formation(47, 48). In addition to the direct damage of elastin and collagen, oxidants detrimental effects are also mediated by inactivating anti-proteases but activating certain MMPs(49, 50).

Studies have shown several markers of oxidative stress, for example, hydrogen peroxide, myeloperoxidase (51) and markers of oxidative tissue damage, such as 8-isoprostane(52) to be elevated in exhaled breath or exhaled breath condensate from patients with COPD. The major antioxidants in the respiratory tract lining fluid include reduced glutathione, uric acid, vitamin E and ascorbic acid(53). Reduced glutathione production is upregulated in response to oxidative stress in healthy subjects(54). Interestingly studies have shown that glutathione is elevated in BAL fluid from chronic smokers(43, 55) which may suggest that up-regulation of antioxidants occur in an attempt to restore the oxidant anti-oxidant imbalance.

1.3 Management

The treatment of COPD is multifaceted; involving patient education, exercise programs and pharmacological therapy. The main aims are to improve patient’s health status, exercise tolerance and reduce patient’s symptoms and exacerbations. Patient education of the disease process and recognition of changing symptoms are important. Acute exacerbations are defined as a sustained increase in cough, dyspnoea or sputum production beyond normal day to day variability and have deleterious impacts on patient health related quality of life (HRQoL) and lung function(56, 57). Thus patient recognition
of changes in their symptoms can allow prompt treatment to mitigate these effects. The roles of both pharmacological and non-pharmacological therapies are discussed below.

1.3.0 Non Pharmacological

Pulmonary rehabilitation (PR) is an individualised exercise programme with an educational component and it has established itself as a key non-pharmacological treatment in COPD. In the UK PR programmes are of between 6-12 weeks duration and usually include 2 supervised sessions per week. PR is undertaken in stable patients and recent evidence suggests benefit in those who have had recent exacerbations (58). The principal training methods are endurance (continuous or interval) and resistance training as the benefit in muscle strength from a combination of training modalities seem to be greater than endurance alone (59). The educational components of PR are targeted towards smoking cessation, general information about COPD, self-management and decision making during exacerbations (3).

1.3.1 Pharmacological

The spectrum of pharmacological therapy within COPD is widening (60); however the mainstay of treatment encompasses bronchodilators, inhaled corticosteroids and oxygen therapy. Bronchodilators are broadly subdivided into Beta 2 agonists and anti-muscarinic agents. Their action reduces dynamic hyperinflation by reducing air trapping and facilitates emptying of the lungs. This improves inspiratory lung volumes which reduces breathlessness and improves exercise capacity. Short and long acting bronchodilators are used, with long acting bronchodilators having the advantage of once to twice daily administration which has been suggested to aid compliance. Inhaled corticosteroids (ICS)
target airway inflammation and although this is thought to be predominantly neutrophilic in COPD(61) inhaled corticosteroids have been shown to reduce acute exacerbations and improve HRQoL when combined with long acting bronchodilators when the FEV1 % predicted is <60%. (62). These therapeutic agents are introduced in a stepwise manner either as symptoms or airflow limitation progresses (7) (figure 1.4).

The advent of dual bronchodilators LABA/LAMA is likely to change current guidance. They have been shown to be superior to combination LABA/ICS in improving breathlessness and to reduce exacerbations in landmark clinical trial (63). Notwithstanding current guidance, the concept of defining a patient’s “treatable traits” has developed over the last few years (64). This management strategy guides treatment based on a phenotypic presentation or understanding of the causal biological pathway. As such patients with chronic bronchitis defined as persistent productive cough for more than 3 months over 2 consecutive years benefit from the addition of anti-inflammatory agents such as Roflumilast to their treatment regimen whilst COPD patients without this phenotype do not. Roflumilast has subsequently been licensed by NICE as add on to triple therapy (LABA/ICS and LAMA) in this group. Review of previous clinical trials have shown that LABA/ICS treatment is likely to be more effective in reducing exacerbations and slowing lung function decline in COPD patients with eosinophilic inflammation (65) (a peripheral blood eosinophil count of >2%); a hypothesis that has been tested in recent clinical trials (63, 66). Here, the higher blood eosinophil count acts as a biomarker to identify patient who would derive greater benefit particularly from the inhaled corticosteroid in the LABA/ICS combination. Thus, the use of guidelines in concert with
the concept of treatable traits is likely to offer greater precision in the choice of therapy for patients and will likely translate to improved outcomes.

![COPD Management Diagram](image)

**Figure 1.4**: Nice guidelines for COPD management. SAMA-short acting muscarinic antagonist, SABA-short acting beta 2 agonist, LABA-long acting beta 2 agonist, LAMA-long acting muscarinic antagonist.

### 1.3.2 Intervventional

Interventional treatments are used as an adjunct to both pharmacological and non-pharmacological treatments or in advanced disease in certain patients. Lung volume reduction surgery (LVRS) is a procedure whereby parts of the lung are resected in an attempt to reduce hyperinflation. It has been shown to improve exercise capacity and
survival in patients with upper zone predominant emphysema and low baseline exercise capacity(67). Other selection criteria for LVRS include FEV1%>20, DLCO>20% and PaCO2 <7.3kPa(21). Lung volume reduction using similar selection criteria can also be undertaken bronchoscopically; a recent meta-analysis (68) concluding it is a safe and effective treatment for patients with emphysema. Finally, lung transplantation in carefully selected patients with very severe COPD transplantation has been shown to improve functional capacity and quality of life outcomes (69).

1.4 Oxygen in COPD

Hypoxaemia is a hallmark feature of COPD as in many individuals gaseous exchange becomes more impaired as the disease progresses, leading to hypoxemia at rest and in some individuals on exercise alone. The mechanisms underlying this are multifactorial and include diffusion limitation, ventilation/perfusion mismatches and shunting. Despite current advances in medical therapy oxygen therapy in the form of LTOT (long term oxygen therapy) is the only treatment in COPD which has demonstrated a mortality benefit in hypoxaemic individuals with COPD(70, 71). Oxygen therapy however, is also used outside of this setting to improve exercise capacity or ameliorate dyspnoea. Use of oxygen therapy during exercise has been shown to reduce dynamic hyperinflation and thus reduce dyspnoea(72). Other postulated mechanisms by which supplemental oxygen exerts beneficial effects are reductions in anaerobic respiration of peripheral muscles; indicated by reduced blood lactate levels(73) and possibly reduced peripheral chemoreceptor activity(74).
1.4.0 Long Term Oxygen Therapy (LTOT)

The indications to use oxygen therapy in hypoxaemic individuals with COPD are derived from two landmark trials (NOTT, MRC) published in the 1980’s (70, 71). The MRC was a randomised controlled trial (RCT) designed to assess whether the use of supplementary oxygen for 15hrs/day compared to no supplemental oxygen conferred a survival advantage over 3 years. 87 participants with severe COPD, hypoxaemia (PaO2<8kPa) and hypercapnia (PaCO2>7.4) were enrolled in which oxygen was administered at 2L/min or higher (to achieve PaO2>8kPa). Results showed improved survival in those randomised to oxygen vs controls (p<0.05). The NOTT trial provided further evidence for the use of supplementary oxygen in resting hypoxaemia in COPD. This RCT assessed whether continuous supplemental oxygen improved survival compared to nocturnal oxygen alone. Enrolled participants had resting hypoxaemia (PaO2<7.3) or PaO2<8kPa in the presence of polycythaemia or electrocardiographic evidence of right heart strain. Results demonstrated a survival advantage with continuous oxygen compared to nocturnal (P=0.01). Of the important secondary outcomes there was significant reduction in polycythaemia and pulmonary vascular resistance (75). Kaplan Meier survival curves for the LTOT trials are shown in figure 1.5.
Figure 1.5: Kaplan Meier survival curves for LTOT trial. COT-continuous oxygen therapy, NOT-nocturnal oxygen therapy COT-Continuous oxygen, NOT-Nocturnal oxygen MRC (Medical research council)

Long term oxygen therapy (LTOT) is indicated in stable hypoxaemic COPD when:

- \( \text{PaO}_2 \leq 7.3\text{kPa} \)
- \( \text{PaO}_2 7.3-8 \text{kPa} \) in the presence of pulmonary hypertension, nocturnal hypoxaemia or raised haematocrit.

In contrast to the above studies supplemental oxygen therapy has not been shown to improve survival in moderately hypoxaemic individuals with COPD(76) (77). The study by Albert et al(77) which initially recruited patients with stable resting desaturation was re-designed to include those with exercise induced desaturation. It did not demonstrate any benefit of supplementary oxygen with regards to improved survival, reduction in hospital admissions or exercise capacity.
1.4.1 Ambulatory Oxygen Therapy (AOT)

Ambulatory oxygen therapy, defined as the use of supplementary oxygen during activities of daily living is used in patients who meet LTOT criteria(78). It is also used in non-hypoxaemic patients whom exhibit exercise induced desaturation if there is a demonstrable improvement in exercise capacity or breathlessness scores(78). Theoretically the use of ambulatory oxygen therapy (AOT) to mitigate desaturation on exertion may improve oxygen utilisation in peripheral muscles, reduce dynamic hyperinflation (79) and reduce dyspnoea.

Exercise Induced desaturation
Patients with COPD experience exercise induced desaturation (EID) in an unpredictable fashion, exhibiting variability both in the magnitude and temporal onset of EID with mobilisation(80). There is no uniform definition of EID however in the UK it is defined as fall in oxygen saturations by ≥4% (nadir ≤90%)(81). In the United States the nadir of <88% is used and forms the basis for the remuneration policy employed by Medicare. Evidence from two studies(82, 83) suggests that the prevalence of EID increases with increasing severity of airflow obstruction and is associated with worse HRQoL, higher mortality and is likely to contribute to exercise limitation in COPD(82). A number of studies(80, 84) have attempted to propose predictors of EID in COPD without consistent consensus. Nevertheless, reduced pulmonary physiology (DLCO<50% and FEV1<45%), baseline arterial PaO2 <10kPa and female gender seem to be the strongest predictors of EID(80).

The precise mechanism leading to arterial hypoxaemia and desaturation is thought to be due to altered pulmonary physiology. During exercise both ventilatory demand and ventilatory workload are increased. Ventilation and perfusion within the lung are crucial
for normal arterial oxygen haemostasis. This is deleteriously affected in patients with COPD either due to airflow limitation or parenchymal destruction; in those with co-existing emphysema. Low ventilation/perfusion ratio areas within the lung in addition to worsened alveolar deadspace significantly contribute to hypoxaemia in COPD especially during exercise(85, 86). This is potentiated by dynamic hyperinflation which occurs during exercise and which worsens alveolar deadspace and thus hypoxia. Adverse pulmonary mechanics; raised inspiratory capacity and dynamic hyperinflation may contribute to sensation of breathlessness and exercise limitation(87). The impact of exercising muscle is also important. A number of studies have demonstrated higher lactic acid generation at lower workloads in patients with COPD(88). Theoretically arterial hypoxaemia may exacerbate peripheral muscle oxygen utilisation, increase lactic acid production and cause peripheral muscle fatigue. This is supported in one study in which the degree of quadriceps fatigue correlated with peak oxygen utilisation(89). Interestingly muscle afferents in COPD have been shown to abnormal and may mediate enhance respiratory effort and perception of dyspnoea(90). Since AOT has some effect on dynamic hyperinflation and will improve arterial oxygenation in areas of V/Q mismatch and potential muscle oxygenation it may provide a means to improve exercise intolerance in selected patients. Increasing arterial oxygenation will also directly inhibit carotid body stimulation reducing the sensation of dyspnoea which has been shown to limit exercise capacity.

**AOT assessment**
In the assessment of ambulatory oxygen therapy exercise capacity is assessed using specific field tests. The three main types of field tests are: 6 minute walk test (6MWT),
endurance shuttle walk test (ESWT) and incremental shuttle walk test (ISWT). Importantly cycle ergometry should not be used in the assessment of ambulatory oxygen(81). The magnitude of desaturation in greater in walking field test compared to cycling. The study by Mahler et al demonstrated that enhanced alveolar ventilation and subsequent higher partial pressure of alveolar oxygen during cycle ergometry minimised the decrease in arterial oxygen and thus had a “protective” effect against desaturation(91).

Field Tests

The 6MWT is a practical and simple test which has been shown to be a predictor of mortality and morbidity in COPD(92). The test is self-paced in which participants are instructed to walk up and down a 20-50metre corridor for 6 minutes.

“The object of this test is to walk as far as possible for 6 minutes. You will walk back and forth in this hallway. Six minutes is a long time to walk, so you will be exerting yourself. You will probably get out of breath or become exhausted. You are permitted to slow down, to stop, and to rest as necessary. You may lean against the wall while resting, but resume walking as soon as you are able.”(93)

The distance walked, number of stops, Borg dyspnoea score (table 1.3) and oxygen saturations (baseline and nadir) are noted. There is some debate regarding whether a practice walk is needed as in many individuals there is a learning effect with an increase 6MWD on the subsequent by as much as 17% of the original distance (93). Evidence suggest that the 6MWT is less sensitive to change with interventions such as bronchodilators(94, 95)than other exercise tests. Nevertheless it provides robust information of functional status and relates well to activities of daily living (96). As stated
although there has been debate about the use of practice walks updated guidance suggest that they should be undertaken if the 6MWT is being used to measure change over time(97).

<table>
<thead>
<tr>
<th>Borg Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Nothing at all</td>
</tr>
<tr>
<td>0.5</td>
<td>Very, very slight (just noticeable)</td>
</tr>
<tr>
<td>1</td>
<td>Very slight</td>
</tr>
<tr>
<td>2</td>
<td>Slight (light)</td>
</tr>
<tr>
<td>3</td>
<td>Moderate</td>
</tr>
<tr>
<td>4</td>
<td>Somewhat severe</td>
</tr>
<tr>
<td>5</td>
<td>Severe(heavy)</td>
</tr>
<tr>
<td>6</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Very Severe</td>
</tr>
<tr>
<td>8</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Very, very severe (maximal)</td>
</tr>
</tbody>
</table>

Table 1.3 Borg Dyspnoea Scale

The ISWT uses a 10m course and the walking speed is externally paced by signals from an audio cassette. Incremental increases in walking speed occur each minute, to a point at which the test is terminated because of; breathlessness, the inability to sustain the walking speed or achievement of 85% of maximal heart rate. The ISWT has been shown to produce maximal response in patients with COPD(98)and is responsive to interventions of exercise training. The ESWT is also externally paced whereby participants walk for as long as possible performed at a speed 85% of their maximal capacity (calculated from ISWT). The test enables participants to achieve standardisation of exercise intensity
which is sustained until limited by symptoms. The ESWT has been shown to be repeatable (99) and responsive to interventions of exercise training and bronchodilators.

During ambulatory oxygen assessments participants will perform one of these tests on air and is then repeated with oxygen therapy. Patients are deemed to qualify for AOT if there is a 10% increase in exercise capacity or reduction in Borg score of 1 (81).

The mode of delivery of ambulatory oxygen therapy is variable but can broadly be divided into liquid oxygen against compressed cylinder oxygen delivered via continuous flow devices or oxygen conserving devices. Oxygen conserving devices can be further subdivided to Demand oxygen devices (DODs) or Pendant reservoir cannula (PRC). DODs deliver oxygen during inspiration only whilst PRC are nasal cannulae with a storage reservoir which increase the proportion of oxygen delivered during inspiration theoretically allowing lower flow rates to be used. Oxygen conserving devices deliver oxygen only during inspiration whereas continuous flow systems deliver oxygen throughout the respiratory cycle. Cylinder types can also be further subdivided into lightweight systems some of which are refillable. During the test the participant should carry, push or pull the ambulatory oxygen system alone without help from the assessor.

Ambulatory oxygen does have an acute effect in improving exercise capacity. The 2005 Cochrane review demonstrated clear benefit of short term ambulatory oxygen in improving exercise capacity in moderate to severe COPD (100). However, the review encompassed mainly single assessment studies whereby patients underwent a modality of exercise testing with ambulatory oxygen and compressed air generally over 1 day. Whether the acute improvement in exercise capacity is sustained has not been proven. Interestingly in a subsequent Cochrane review in which ambulatory oxygen was
evaluated in the context of pulmonary rehabilitation programs no benefit was demonstrated(101). Given that most pulmonary rehabilitation programs run longer than 6 weeks it is unclear whether longer term use of ambulatory oxygen still provides continued benefit in improving functional exercise capacity.

1.4.2 Short Burst oxygen Therapy (SBOT)

SBOT is used for the symptomatic relief of dyspnoea in patients who do not meet LTOT or AOT therapy criteria. It is commonly used prior to or following short periods of exertion in patients with COPD. The use of SBOT is controversial and studies investigating its effects have been limited by inconsistency of exercises performed, outcome measures and heterogeneous patient selection. Nevertheless early studies by Woodcock et al(102) and Evans et al(103) have shown some benefit of SBOT by improving submaximal treadmill distance and shortened dyspnoea recover time post exercise respectively. Interestingly however, the study by Evan et al(103) specifically tested the reproducibility of SBOT’s ability to improve dyspnoea recovery time. Despite testing the subjects who responded to SBOT initially reproducibility was poor. Subsequent studies(104-106) have shown no benefit in SBOT’s ability to improve dyspnoea, exercise tolerance (6MWT) or HRQoL. The largest of these (106) in which 78 patients recently discharged following an exacerbation were randomised to SBOT (2l/min) or cylinder air for 6 months to be used to relieve distressing dyspnoea. SBOT did not improve HRQoL, hospital readmission or healthcare utilisation.
1.5 Muscle disease in COPD

Although characterised by airflow obstruction many patients with COPD exhibit systemic manifestations such as muscle dysfunction, loss of fat free mass, cardiovascular disease(107), diabetes(108), depression and osteoporosis(109). Skeletal muscle dysfunction is characterised by reduced muscle strength and or endurance(3) and is an important systemic manifestation in COPD which contributes to the morbidity of the disease. Although SKMD can occur in upper limbs and to some degree respiratory muscles this thesis concentrates on skeletal lower limb muscle in patients with COPD. One of the key observations is that SKMD is likely to have a detrimental impact on exercise capacity. Exertional dyspnoea and reduction in exercise capacity are common features of COPD, however studies of patient self-reported symptoms suggest that perceived leg effort or fatigue were the predominant limitations to their exercise ability (110, 111). Interestingly in lung transplant recipient patients exercise capacity remains abnormally low, by as much as 50% predicted workload for age and gender despite normalisation of lung function(112). Also pulmonary rehabilitation provides significant improvement in exercise capacity without significant change in lung function (59). These observations taken together suggest that SKMD plays an important role in exercise performance. Furthermore SKMD is recognised to contribute independently of lung function to mortality (113). Reduced mid-thigh cross sectional area and quadriceps strength have been shown to be strong predictors of mortality after adjusting for FEV1, age and sex(113-115). Finally SKMD is likely to contribute to poor health status and healthcare utilisation (116, 117).
1.5.0 Skeletal Muscle Structure

Skeletal muscle is composed of a motor unit (figure 1.6); the muscle fibre and its innervating motor neuron. The functional units of muscle are called sarcomeres. Within each sarcomere are the myofibrillar proteins myosin and actin. The myosin heavy chain in the head region contains an adenosine triphosphate (ATP) binding site for the conversion of ATP into ADP (adenosine diphosphate) and phosphate. The heavy chains contain the myosin heads that form cross bridges with actin which facilitate muscle contraction.

Muscle fibres are classified as fast twitch or slow twitch depending on their contractile speed. Fast twitch fibres are further subdivided to fast twitch fatigue resistant, fast twitch intermediate and fast twitch fatigable. This classification corresponds broadly to muscle fibre identification by myosin heavy chain (MHC) immunoreactivity and myofibrillar ATPase staining (table 1.4).

<table>
<thead>
<tr>
<th>Fibre</th>
<th>ATPase</th>
<th>MHC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Slow twitch</td>
<td>I</td>
<td>MHCI</td>
</tr>
<tr>
<td>Fast twitch fatigue Resistant</td>
<td>IIa</td>
<td>MHCIIa</td>
</tr>
<tr>
<td>Fast twitch Fatigable</td>
<td>IIb</td>
<td>MHCIIx/d</td>
</tr>
<tr>
<td>Fast twitch Intermediate</td>
<td>IIx</td>
<td></td>
</tr>
</tbody>
</table>

Table 1.4: Muscle fibre classification


1.5.1 Clinical Observations

Skeletal Muscle Strength and Endurance

Skeletal muscle strength is defined as the capacity of the muscle to generate force. This is mediated by three factors; “cross sectional area of the muscle fibres within the motor unit, the number of muscle fibres innervated by the motor neuron and the specific force of the muscle fibre” (118). In general fast twitch intermediate and fatigable generate more force per unit area than slow twitch or fast twitch fatigue resistant (118). The force generated by each fibre depends on intracellular calcium levels, which are important for sarcoplasmic reticulum excitation/contraction and also neuronal activation. The contribution of neuronal activation to muscle strength is important as in the early stages of muscle training gains in strength are mediated by neural adaptation rather than by muscle hypertrophy(119). In COPD especially in severe disease quadriceps muscle strength may be reduced by as much as 30%(120, 121). This difference however
disappears when quadriceps strength is normalised to mid-thigh cross sectional area, implying therefore that muscle atrophy is important in determining muscle strength.

Endurance relates to the ability of muscle to maintain a certain force over time; normally a percentage of maximal force or exercise capacity. In health, oxygen delivery and utilisation rather than ventilatory function or compromised cardiac function limits endurance. This is a complex interplay between muscle enzyme concentration, capillarity, mitochondrial volume density and bioenergetics(118). The energy for skeletal muscle contraction is derived from the de-phosphorylation of ATP. Low intracellular stores of ATP mean that skeletal muscle can only sustain contraction for a few seconds before this is replenished or further ATP generated. One mechanism is the breakdown of Phosphocreatine to phosphate and creatine mediated by the enzyme creatine kinase. Other more effective mechanisms are that of oxidative phosphorylation, Krebs Cycle and to a lesser degree glycolysis. Skeletal muscle endurance is also perturbed in COPD. A number of studies have reported a reduction in quadriceps endurance in patients with COPD(122, 123). Interestingly in one of these studies(122) an artificial stimulation protocol was used thus negating the impact of central fatigue.

Fatigue is another determinant of endurance, of which two types are recognised; central and peripheral. Central fatigue indicates contractile reserve within the muscle, in that additional force can be generated by nerve stimulation in the event of voluntary “task failure”. Peripheral fatigue implies that there is no contractile reserve within the muscle which may be due to transmission at the neuromuscular junction, muscle membrane or muscle microfilaments. There is a complex interplay between central and peripheral fatigue which is not completely understood. In health several studies(124, 125) have
shown that arterial oxygen concentration affects central fatigue and peripheral fatigue; both deleteriously affected by hypoxia. The study Amann et al suggest that central fatigue is likely to be the dominant of the two (126). The study used varying oxygen concentrations; normoxia to hypoxic (15% Oxygen) to show that exercise performance switches from a predominantly peripheral origin during normoxia to central origin during increasing hypoxia. It is highly likely that lowered arterial oxygen concentration may play a role in limiting exercise tolerance in patients with COPD in this manner.

1.5.2 Laboratory observations

Muscle mass

Muscle mass homeostasis is a dynamic process involving a balance between protein synthesis and protein degradation. Protein synthesis is mediated by hypertrophic signalling and protein degradation by atrophic signalling and autophagy. Anabolic hormones, namely Insulin and Insulin like growth factor 1 (IGF-1) stimulate the hypertrophic signalling pathway. They act on the phosphoinositide 3 kinase (PI3 K)/AKT (protein kinase B) pathway (127). AKT in its phosphorylated form stimulates mTOR (mammalian target of rapamycin) which can promote protein synthesis by activation of the 70-kD ribosomal S6 protein kinase (p70S6K) and inhibition of 4E-BP1 (eukaryotic initiation factor 4E binding protein respectively. AKT also directly inhibits glycogen synthase kinase-3 (GSK-3), which represses protein synthesis (127). Atrophy signalling is mediated by the ubiquitin proteasome pathway. Proteins identified for degradation are attached to ubiquitin by E3 (ubiquitin ligating) enzymes of which two have been identified; atrogin 1 (muscle atrophy F-Box) and MuRF1 (muscle ring finger-1). MuRF1 is stimulated upstream by pro-inflammatory cytokines largely mediated by NF-kB. Atrogin
1 is stimulated upstream by p38 MAPK (mitogen activated kinase), for which oxidative stress and inflammation are potent stimuli. There is a degree of cross talk between these pathways. AKT can block protein degradation by down regulating atrogin 1 and MuRF-1. This is mediated by phosphorylation of FoxO (forkhead box O) transcription factor. The atrophy and hypertrophy pathways are summarised in figure 1.7.

Fig 1.7: Hypertrophy and atrophy signalling pathways in muscle.
Autophagy is a constitutively active process in limb skeletal muscle (118) and is the process whereby proteins are degraded in autophagosomes. Autophagosomes are then delivered to the lysosomes for degradation of their contents. Autophagy is initiated by the ULK1 complex which is under the control of AMP-activated protein kinase (AMPK) and mTOR pathways (128). mTOR phosphorylates and inactivates ULK1 thus inhibiting autophagy whilst AMPK is able to inactivate mTOR. Although the role of autophagy in skeletal muscle has not fully been elucidated, it has been shown to significantly induced in limb muscles following denervation (129).

**SKMD-pathological changes**

One of the key structural alterations in skeletal muscle of patients with COPD is that of skeletal muscle atrophy and fibre type shift. Fat free mass (FFM) a surrogate for skeletal muscle mass is reduced in COPD (130). The degree of thigh muscle mass lost is relatively greater to that of the whole body weight indicating a preferential loss of muscle tissue over body tissue in COPD (121). Cross sectional studies have demonstrated increased mRNA levels of atrogin-1 and MuRF-1 (131, 132) in the quadriceps of COPD patients compared to controls indicating upregulation of atrophic pathways. This however bore no relationship to quadriceps function and no difference was found between COPD patients with and without preserved muscle mass (127). COPD patients have a reduction in proportions of type 1 accompanied by increased proportions of type IIx fibres, which is contrary to what occurs in normal ageing (118). The reduction in type 1 fibres mirrors disease severity. Gosker et al (133) showed that as FEV1 declined the proportion of type 1 fibres also decreased. Type I fibres are advantageous as they confer greater oxidative capacity. Thus the switch to type IIx fibres may explain the increased fatigability and
reduced endurance in COPD limb muscle. Although there is atrophy of all fibre types there is some evidence (134) to suggest this occurs preferentially in the type IIx fibre.

Capillary density is important in skeletal muscle as oxidative metabolism is dependent on the capillary supply and mitochondrial volume density. Capillary density has been shown to be reduced in COPD muscles(135), although this is not a consistent observation(136). This is may be due to the heterogeneity between studies with some carried out in the context of exercise training(136) which is known to improve capillarity.

Finally mitochondrial bioenergetics is altered in COPD with reduced oxidative enzyme capacity. Key enzymes involved in oxidative phosphorylation such as citrate synthase and succinate dehydrogenase have been shown to be reduced(137, 138). In line with these observations expression of PGC-1 α/PPAR (peroxisome-proliferator activated receptors) a regulator of cellular oxidative phosphorylation is reduced in the musculature of COPD patients(139).

1.6 Aetiology of SKMD in COPD

1.6.0 Inflammation

Inflammation is a key concept in COPD and its role in the pathogenesis of the disease has been discussed. It may play a role in SKMD. Whether this is a consequence of systemic and or local inflammation is not completely clear, however a number of studies lend support that pro-inflammatory cytokines can adversely affect skeletal muscle growth. A number of pro-inflammatory cytokines have been implicated in pathogenesis; TNFα, IL-6
and IL-8. Spruit et al demonstrated an inverse relationship between quadriceps muscle strength and serum IL-8 levels (140) albeit during exacerbations, whilst elevated IL-6 levels are associated with radiological evidence of quadriceps wasting in COPD (141). In vitro studies have shown that TNFα induces apoptosis in skeletal muscle cells and myoblasts (142).

The predominant system whereby inflammation is thought to exert its role is by increasing activity of the ubiquitin proteasome pathway via NfkB activation. A significant increase in NfkB nuclear binding has been observed in the limb muscles of patients with COPD (143). Furthermore NfkB has been shown to directly inhibit MyoD a myogenic regulatory factor involved in satellite cell differentiation (144).

1.6.1 Hypoxia

In health, under hypoxic conditions such as at altitude functional, structural and morphological changes in skeletal muscle occurs which bear close resemblance to those found in COPD (145). Skeletal muscle endurance, strength (145, 146) and muscle mass are reduced. Furthermore, evidence suggests that hypoxia may have a deleterious impact on the force of muscle contraction by altering the strength of actin myosin cross bridges (147). Interestingly in this study (147) this contractile dysfunction was reversed following re-oxygenation. Hypoxia has been shown to impair the mTOR pathway (148) and thus may contribute to muscle wasting. Further to this, in vitro studies have shown that hypoxia inhibits myoblast differentiation by degradation of MyoD (149). In addition, tissue hypoxia could also play a part in determining systemic inflammation as there is a relationship between extent of arterial hypoxaemia and circulating levels of TNFα, and its receptors, in COPD patients (150). It may also potentiate oxidative stress (118, 147).
During hypoxia the transcription factor hypoxia inducible factor-1α (HIF-1α) is increased which may alter bioenergetic pathways by down and up regulating oxidative and glycolytic enzymes respectively (151). This also mirrors the reduced proportion of type I fibres observed in hypoxaemic patients with COPD compared to non-hypoxaemic patients (152). Finally studies of limb muscle transcriptomic have shown this to be altered in COPD. Turan et al (153) used a systems biology approach and found a failure of COPD limb muscles to co-ordinate several tissue remodelling and bioenergetics pathways. This study suggested that this abnormality is linked to an altered expression of histone modifiers with correlate with peak oxygen uptake, suggesting that cell hypoxia may play a role in SKMD through epigenetic mechanisms.

### 1.6.2 Oxidative Stress

Mitochondria are the main sources of RNS (reactive nitrogen species); derived from nitric oxide and ROS production especially during skeletal muscle contraction. In normal skeletal muscle ROS and RNS are produced at relatively low levels and play a positive role in normal physiological functions (154). However, in COPD the production of these species is at a higher rate and overcomes the antioxidant ability; this is particularly true during acute episodes of exercise or following exacerbations (118). ROS and RNS may particularly target key contractile proteins and enzymes within muscle fibres (154); implicated in myosin heavy chain carbonylation and reduced creatine kinase enzymes. Further evidence for the role of oxidative stress is provided by the identification of oxidation of proteins, DNA and lipids. COPD patients exhibit higher levels of peroxidation, oxidized glutathione, and protein carbonylation in the blood and limb muscles (137, 155-157). The level of oxidative stress may have functional implications.
Koechlin et al (158) reported that use of n-acetylcysteine (an anti-oxidant) improved quadriceps endurance time in patients with COPD. Oxidative stress may also relate to protein degradation and hence muscle loss. ROS species are able to trigger the ubiquitin proteasome and p38 MAPK pathways (118, 154).

1.6.3 Disuse

Physical activity in patients with COPD is generally lower than the average population with more having a sedentary lifestyle (159). This is thought to be a consequence of deconditioning heralded by the dyspnoea spiral in which patients do not exert themselves to avoid dyspnoea which in turn causes a decline in fitness. Physical inactivity leads to a number of adaptive changes in skeletal muscles including altered mitochondrial biogenesis, reduced capillary density and reduced proportions of type I muscle fibres (139, 160) which all negatively affect strength and endurance. The preferential loss of thigh muscle mass relative to body weight may suggest that muscles that are least used, in this case the lower limbs are more susceptible. This is supported in some respect as other muscles such as the diaphragm shows an increase in oxidative capacity and increase in type I fibres in severe COPD (161).
1.7 Aims

This thesis sets out to explore 3 aims

1) Systematic review of ambulatory oxygen in COPD
2) To assess the biological response in muscle to oxygen therapy
3) To assess the clinical effectiveness of ambulatory oxygen therapy in patients with exercise induced desaturation.

Aim 1

Chapter 2 of this thesis will set out the methodology to explore aim 1. Ambulatory oxygen therapy (AOT) is widely used currently in patients with COPD who exhibit exercise induced desaturation, if they show an improvement in exercise capacity or breathlessness scores. The evidence base for this has come largely from single assessment studies whereby AOT was evaluated generally over one day by a given exercise modality(100). In general the majority of trials to date have shown that use of ambulatory oxygen in this setting is likely to be of benefit, in terms of duration of exercise, dyspnoea on exertion and quality of life. The caveat to this is that many of the trials in the review had small sample sizes with no generation of power calculations with reviewers describing methodological quality as low(100). A subsequent review evaluated AOT use in the context of pulmonary rehabilitation and found no clear benefit(101). Since most pulmonary rehabilitation sessions last longer than 6 weeks the longer term benefit is doubtful and has not been clinically proven. Despite this, continued prescriptions for AOT occur on the basis of eligibility tests demonstrating benefit but without knowledge of its longer term efficacy. Furthermore, it remains less clear
whether domiciliary ambulatory oxygen use is beneficial and whether there are long term gains with regard to exercise capacity or quality of life in the patients who use it in this way. Finally, neither of the reviews explored the economic impact of AOT which in the current climate of assessing cost effectiveness of interventions is an important factor. Thus, there are several unanswered questions; does the acute effect of ambulatory oxygen on exercise capacity persist? Does use of AOT provide clinical benefit in a domiciliary setting and is AOT cost effective? Using 3 linked systematic reviews specific objectives were to explore the:

1. The clinical effectiveness of long term ambulatory oxygen therapy (defined by more than 6 weeks duration) in patients with COPD exhibiting EID or exertional dyspnoea who do not meet the criteria for LTOT.
2. The relative clinical effectiveness of different methods of delivering ambulatory oxygen in COPD patients and the optimum mode of delivery of the intervention;
3. The cost-effectiveness of ambulatory oxygen in COPD patients not on LTOT compared to usual care and the relative cost-effectiveness of different methods of delivering ambulatory oxygen.

Chapter 3 details the results of the systematic review; whether AOT has any effect on exercise or quality of life outcomes. It also discusses if the effects of AOT on exercise are field test specific.

Aims 2 and 3
Chapter 2 of this thesis also sets out the methodology and statistical methods used to investigate the skeletal muscle biological response and clinical effectiveness of AOT in patients with exercise induced desaturation (EID). EID is defined as a nadir <88% (81) on
ambulation is common in patients with chronic obstructive pulmonary disease (COPD). It affects patients with advanced and less advanced disease with evidence suggesting that they have worse health related quality of life, mortality and exercise tolerance (83) than non-hypoxaemic patients who do not exhibit this phenomenon (82). The reason for observed exercise limitation is unclear and hypotheses have been discussed in section 1.4.1 but is thought to reflect muscle hypoxia exacerbated by exertion. It is well established that hypoxia has a role in perturbing muscle function, e.g. impairing protein synthesis and myogenesis by inhibiting the mTOR pathway (148) and contributes to muscle wasting via degradation of MyoD (149). Hypoxia has also been linked to mitochondrial dysfunction (151) and a reduction in the proportion of Type I muscle fibres (152), suggesting a reduced endurance exercise capacity, which may be exacerbated by the oxidative stress that is increased in skeletal muscle mitochondria on exposure to acute hypoxaemia (162). Inflammation is a key concept in COPD with a number of cytokines (discussed in 1.6.0) implicated in underlying aetiology of skeletal muscle abnormalities. Whilst numerous studies have assessed the impact of AOT on exercise performance (163), none have assessed the longer term effect of AOT on skeletal muscle gene expression, systemic inflammation or physical activity. This is explored via a 12-week randomised controlled cross over trial with 2 week washout for which the methods and rationale of trial design are outlined in Chapter 2.

Chapter 4 documents the clinical results from the randomised controlled trial and discusses the impact of AOT on functional exercise capacity, physical activity and the inflammatory cytokine response to AOT.
Chapter 5 documents the skeletal muscle response to oxygen which has never been investigated previously. The muscle biopsies were subject to microarray analysis to explore differentially expressed genes or gene sets between oxygen and air. This enabled the identification of genes or gene sets involved in important skeletal muscle transcription. A hypothetical network interaction has been created between the clinical data set including exercise capacity, systemic inflammation and quality of life and the transcriptional changes seen in skeletal muscle.

Chapter 6 concludes the thesis.
Chapter 2

General Methods

2.1 Systematic Review

The review had 3 objectives, the methods for which had a degree of overlap but will be described separately here. As with all systematic reviews achievement of the objectives has been limited by the type and quality of the available published evidence. The objectives to assess were as follows:

**Objective 1** - The clinical effectiveness of ambulatory $O_2$ in COPD patients not on LTOT compared to usual care.

This was to determine the benefit of the addition of ambulatory $O_2$ to treatment regimens.

**Objective 2** - The relative clinical effectiveness of different methods of delivering ambulatory $O_2$ in COPD patients not on LTOT.

This was to determine the optimum mode of delivery of the intervention.

**Objective 3** - The cost-effectiveness of ambulatory $O_2$ in COPD patients

This included the cost-effectiveness of ambulatory oxygen in those not on LTOT compared to usual care, and the relative cost-effectiveness of different methods of delivering ambulatory $O_2$. 
For each objective the methods below describe the types of study included in the review, the population, intervention, comparator and outcomes assessed. This is the standard format for systematic review questions according to Cochrane guidance.

2.1.0 Objective 1 Clinical Effectiveness of Ambulatory Oxygen compared to Usual Care

**Study Design**
Randomised Control trials (RCTs), non RCTs and Cross over studies have been included. All studies had a follow up duration of more than 6 weeks. Previous reviews (100, 101) have either been of less than 6 weeks duration or single assessment studies limiting their ability to demonstrate longer term benefit. Therefore any study with duration of less than 6 weeks was excluded.

**Population**
The population for this objective included adult (18 years or over) patients suffering from stable chronic COPD but not on LTOT. The definition of COPD chosen was broad; any study description of patients defined as having COPD by spirometry (NICE) (7), radiological emphysema or chronic bronchitis, were included. ‘Stable’ was defined as not currently undergoing, or within 6 weeks of, an exacerbation of their disease. This definition was chosen because the majority of patients with exacerbations demonstrate recovery of symptom scores and lung function within this time frame (18, 164).

**Interventions**
Ambulatory oxygen therapy was defined as the use of supplemental oxygen during exercise and activities of daily living, consistent with the definition used in BTS guidelines (81).
**Comparators**
There were several suitable comparators, all of which were equivalent to medical air. Thus compressed air or gaseous mix equivalent to air were suitable, provided they were administered via a similar route to the intervention. Only studies in which the treatment difference between study arms was purely due to use of ambulatory oxygen were considered.

**Outcomes**
The primary outcomes were exercise capacity as measured but not limited to 6MWT distance, shuttle test distance and maximal power tests. Health related quality of life (HRQoL), rates of exacerbations, hospitalisation and/or health service utilization were also considered.

2.1.1 Objective 2 Clinical Effectiveness of methods of delivering ambulatory Oxygen.

The criteria for population, intervention and outcomes remained the same as objective 1 with the inclusion of:

- Patients who met LTOT criteria
- Studies with follow up of any duration included.

The rationale for this is as follows. The use of ambulatory oxygen delivery devices has largely been restricted to patients using LTOT given the evidence base supporting it, or other forms of supplementary oxygen. A number of studies (165, 166) have demonstrated that a proportion of LTOT patients also experience EID. The sole focus of this objective was to address the efficacy of the delivery device; thus included studies would compare
device against device and not ambulatory oxygen against placebo the above patient
group and study duration were included.

**Comparator**
Any alternative method of delivering ambulatory oxygen to that of the intervention arm
was considered a suitable comparator. Only studies where the difference between study
arms was purely due to variation in mode of ambulatory oxygen delivery were included.
Such variation could be due to the equipment (portable cylinders, liquid canisters, oxygen
conserving devices or concentrators) or the way the oxygen is inhaled i.e. interface,
(mask or nasal cannulae).

2.1.2 Objective 3-Cost-effectiveness of ambulatory O\textsubscript{2} in COPD patients not on
LTOT compared to usual care and the relative cost-effectiveness of different
methods of delivering ambulatory O\textsubscript{2}

The criterion for Population, Intervention and Comparator were the same as for aim 2-3
combined. Study design and Outcome criteria were:

**Study Design**
Cost-analysis, cost-effectiveness, cost–utility and cost–benefit studies were targeted.

**Outcomes**
Assessment of impact on Quality of life and also cost judged by; incremental cost-
effectiveness ratios

**Criteria for Exclusion from this Review**

Studies which included patients on any other form of oxygen therapy (such as LTOT or
short burst) apart from ambulatory oxygen therapy were excluded except if stated for
that objective. In addition studies that involved a mixed population were excluded, unless data on those patients relevant to the objective was presented and evaluated separately.

2.1.3 Search strategy

In order to maximise efficiency, two search strategies were undertaken. The literature search included the following databases; MEDLINE, MEDLINE in Process, EMBASE, Cochrane-(CENTRAL), Science Citation Index, NHS Economic evaluation database, PEDro, Health technology assessment database, ClinicalTrials.gov, CINAHL, and the Cochrane Airways specialised register. Following this the references of each included study as well as any review articles found were searched for additional articles that may contain further studies.

COPD treatment has changed considerably over the last 20 years (3, 8) consequently it may be that very old studies, particularly those that occurred prior to the introduction of LTOT, may not be relevant to current patients. For this reason, searches were started in 1980, just prior to the publication of the LTOT trials (167, 168), as these were a landmark point in the therapy of COPD, whose results were widely accepted worldwide shortly after publication. No language restrictions were applied and both published and unpublished studies were sought (via contacting authors directly via email). The search strategy is outlined in Appendix 1.
2.1.4 Study selection, data extraction and risk of bias

The search results were entered into reference management software (Endnote X5, Philadelphia USA) and duplicate entries electronically and manually removed. The remaining records were assessed for relevance to each objective in a two stage process. Stage 1 involved myself and another reviewer (Dr AM Turner) independently screening titles and where available abstracts against the inclusion/exclusion criteria to identify relevant studies. The aim of this stage was to remove irrelevant studies and thus those records on which a decision on relevance could not be made due to insufficient/ambiguous information. Full copies of all articles passing stage 1 were obtained. In stage 2, two reviewers (myself and Dr AM Turner) independently applied the inclusion/exclusion criteria to these articles. Any disagreements between the other reviewer and I were resolved by consensus or through consultation with a third reviewer (Dr Chirag Dave). A record of the studies excluded was kept along with the reason(s) for exclusion.

One reviewer independently extracted and recorded essential information derived from each included study using a piloted data extraction form); a second reviewer checked all numerical data. For Objective 1 and 2 for each study, the data required on (but not limited to) the following was recorded: Design, completeness of follow up length of follow up; country of origin; study design; sample size; patient inclusion and exclusion criteria; patient characteristics; intervention/comparator, adherence/compliance, outcome measures; statistical methods employed; findings, effect sizes and associated uncertainty.
For Objective 3 data on the following were sought, type of design/analysis and features relevant to this, patient characteristics; intervention/comparator and outcomes were quality of life, costs and incremental cost-effectiveness ratios.

The Methodological quality of the included RCTs was appraised by using the Cochrane risk of bias framework(169); for the comparative studies assessing the adequacy of sequence generation, allocation concealment and blinding for non-RCTs such as the observational studies (prospective and retrospective cohort study) were appraised using appropriate domains of the same tool. The Jadad Scale(170) was also used to assess methodological quality.

2.1.5 Statistical Methods

All trial data was combined using Review Manager 5.2 (Cochrane Collaboration). For objective 1 and 2, meta-analysis was undertaken for studies comparing the same interventions for key outcomes where clinical and methodological details between studies were considered to be sufficiently homogeneous. Thus, only results from the same exercise test protocols were analysed together (i.e. all constant power exercise tests, all functional exercise tests, all maximal exercise tests and all shuttle walk tests). Continuous data was synthesised as mean differences where possible as described below. Statistical heterogeneity was presented and interpreted using the I² statistic.

Data was pooled with the generic inverse variance method using change from baseline with the appropriate means and standard deviations for each study if provided. This method ensures larger studies with smaller standard errors are given greater weight than smaller studies with larger standard errors. For the studies that reported the pre and post
training means and respective standard deviations, in order to use the change in baseline outcome measure:

1) The pre training means were subtracted from the post training means:

2) The standard deviations (SD) for pre and post training were pooled.

Pre and post-test exercise outcomes reported for both intervention groups were from tests performed on compressed air.

A fixed effect was used in all analyses unless heterogeneity defined as ($I^2 > 30\%$) was present in which case a random effect was used. The meta-analyses are presented using forest plots from Review Manager 5.2. Data which was not in a format suitable for meta-analysis have been reported in narrative form.

### 2.2 Clinical Trial General Methods

The OM-COPD (oxygen for muscles in COPD) trial was a single centre double blind randomized crossover trial comparing 12 weeks of an oxygen/nitrogen mix (equivalent in oxygen concentration inspired by the patient to air) to 12 weeks of oxygen, used when performing activity, in the patients described below.

Patients were enrolled between September 2012 and April 2014. The trial design diagram is shown in figure 2.1. A mix equivalent to medical air, rather than medical air itself, was required to ensure that colouring of the cylinders could be done in a manner...
which allowed complete blinding. Gases were provided at a flow rate of 2l/min and were not to be used for any more than 4 hours of activity per day.

Subjects were randomized using the sequentially numbered, opaque sealed envelopes SNOSE technique(171). A crossover design was chosen to minimise differences due to inter-patient variability, which was likely to be greater than intra-patient variability in this group over the time frame proposed(172).

There was a washout of 2 weeks between interventions. The following were examined; HRQoL, activity levels, 6MWT distance, capillary blood gas, blood tests (for inflammatory cytokines) and spirometry pre and post intervention and muscle biopsy pre and post intervention. This resulted in 6 invasive procedures (3 biopsies, 3 ear lobe capillary blood gases, 3 blood tests) per patient – before the trial, after the first and after the second intervention. Activity monitoring and HRQoL were assessed at the mid-point and end of each intervention, together with a basic clinical assessment of general and respiratory health.

Of the outcomes studied the primary outcome was change in gene expression in skeletal muscle. The biological changes in muscle in response to exercise in patients with COPD have been investigated in several previous studies(153, 173). Many of these have used training programmes akin to pulmonary rehabilitation; at least over 8 weeks looking specifically at target genes or proteins in relation to mitochondrial bioenergetics or muscle hypertrophy, atrophic pathways. Eight weeks was sufficient to induce measurable changes between trained and untrained in patients with COPD. The length of time trial participants were exposed to each intervention in the clinical trial is based around this training timeframe. As it is accepted that training is more likely to be a more
potent stimulus to skeletal muscle change than standalone domiciliary activity a longer 12 week rather 8 week period was used. The hypotheses were that either oxygen upregulate genes/gene sets involved in mitochondrial biogenesis or skeletal muscle hypertrophy. This based on either oxygen having a direct action on skeletal muscle, i.e. mitigating the desaturation which occurred on exertion or that use of AOT would encourage participants to be more active and thus have a beneficial effect on skeletal muscle. As such a 2 week wash out period was used as this would give sufficient time to revert to “normal” activity.

Whilst a key aim of this trial was to examine the systemic response to oxygen, and in particular how this systemic response might influence the muscle, it was not possible to power the microarray analyses hence these were deemed exploratory; they are described further in chapter 5. Secondary outcomes were limited to exercise capacity, physical activity, quality of life and cytokine response.
Screening visit
Spirometry, 6MWT

Enrolment visit 1 (week 1) Start of trial
Consent, allocation by SNOSE
QOL, HADS, blood gas, venous blood
Data collection for COPD phenotypes
Muscle biopsy
Blood collection before
Pre trial activity monitor issued*

Visit 2 (1 week after visit 1): Collection of activity monitors
IMP/placebo** dispensing

Visit 3 (6 weeks after starting IMP/placebo):
QOL
Clinical check
Activity monitor issued

Visit 4 (12 weeks; end of IMP/placebo)
Spirometry, 6MWT
QOL, HADS, blood gas, venous blood
Data collection for COPD phenotypes
Muscle biopsy
Bloods as before
Activity monitor issued*

1-2 week break then dispensing of new product

Visit 5 (6 weeks after starting IMP/placebo)
QOL
Clinical check
Activity monitor issued

Visit 6 (12 weeks after starting IMP/placebo)
Spirometry, 6MWT
QOL, HADS, blood gas, venous blood
Data collection for COPD phenotypes
Muscle biopsy
Bloods as before
Activity monitor issued*

Follow up visit (6 weeks after IMP/placebo end)
Post trial activity monitor issued
Collect monitor
QOL, HADS
Spirometry

Figure 2.1: Trial design diagram.
2.2.0 Ethics and governance

The trial was conducted in compliance with the principles of the Declaration of Helsinki (1996) and the principles of Good Clinical Practice (GCP). Prior to the commencement of the clinical trial I completed GCP in clinical trial management. The trial protocol and initial ethical approval was undertaken by the PI in conjunction with me. Subsequent trial management including but not limited to organising patient visits, data collection, completing adverse event forms, performing muscle biopsies, submitting substantial amendments and maintaining the trial master file was undertaken by me. Development safety update reports (section 2.2.9) along with summary of product characteristics for medical oxygen were completed and sent to Medicines and Healthcare products regulatory agency (MHRA) on a yearly basis. During the clinical trial a number of new standard operating procedures (SOPS) were introduced by the sponsor. Internal trial procedures were modified where possible to bring them in line with the new SOPS e.g. the delegation of adverse event reporting to trial PI/investigators by sponsor. Adverse events were reported to the MHRA as part of the development safety update. Suspected unexpected serious adverse reactions were reported to the sponsor.

2.2.1 Participant selection

Subjects were recruited from adult secondary care respiratory clinics. Informed written consent was obtained from all participants prior to enrolment. The clinical trial has ethical approval from the regional ethics committee; key trial documents are shown in the appendix 2
25 patients with COPD were recruited. Enrolled patients had radiological emphysema or spirometrically defined COPD, according to British Thoracic Society standards (i.e. FEV1/FVC <0.7 and FEV1<80% predicted), and no co-morbidities that limited their mobility. All patients had oxygen saturations greater than or equal to 94% at rest and exhibited EID to less than 88% on exertion, as documented during a formal 6MWT. All participants were clinically stable, defined as being more than 6 weeks since their most recent exacerbation.

Exclusion criteria were as follows:

- Age – less than 18
- Immobile due to other medical conditions
- On LTOT
- Unable to understand or retain information
- Uncontrolled angina symptoms
- Evidence of clinically significant harm from oxygen therapy (decompensated type 2 respiratory failure).

All participants underwent the procedures described below as part of the clinical trial, which are summarized in the flowchart (Figure 2.1).
2.2.2 Demographic data

Basic demographic data (gender and date of birth) was collected using a Case Report Form (CRF)-appendix 2. The CRF included lung function at enrolment or that within 6 months of enrolment, the participant clinical phenotypes; delineated by bronchitis, emphysema or bronchiectasis and also medical research council (MRC) dyspnoea score.

2.2.3 Spirometry and Arterial blood gas sampling

All spirometry was performed by ARTP (association for respiratory physiology and technology) accredited respiratory physiologists within the lung function department. Values obtained were compared to predicted values derived from standard reference equations for Caucasian adults (European Coal and Steel reference values). Blood gas sampling was obtained using the earlobe blood gas sample technique; a well validated alternative to arterial blood gases(174). If any subject had elevated carbon dioxide (>6kPa) on their baseline blood gas this was repeated after giving oxygen at 2l/min for 20 minutes in order to ensure that the subject was unlikely to come to any harm from using oxygen during the study.

2.2.4 Muscle biopsy

Percutaneous needle biopsy offers a less invasive alternative to conventional open biopsy with satisfactory muscle yield (up to 300mg).

Muscle biopsy was performed percutaneously from the lateral vastus lateralis under local anaesthesia (2% lignocaine) and strict asepsis using the Bergstroms technique(175) shown.
in diagram (figure 2.2 and 2.3). Samples were flash frozen using a dry ice acetone bath and subsequently stored at -80°C. Samples were subsequently used for RNA extraction and microarrays, as detailed in 2.3.3 and 2.4.

Figure 2.2. Equipment used for muscle biopsy sampling.

Figure 2.3. Bergstrom’s Procedure

2.2.5 Blood Sampling

Plasma was prepared from venous blood which was collected in EDTA blood tubes. The venous blood was centrifuged at 1000g for 10mins with the resultant supernatant (plasma) stored in 0.5ml aliquots at -80°C. Plasma levels of TNF-α, interleukin 6 (IL-6), interleukin 8
(IL-8) and interferon gamma (IFN-\(\gamma\)) were analysed using enzyme linked immunosorbent assays (Ebioscience).

2.2.6 HRQoL and Activity Monitoring

HRQoL was assessed using the COPD assessment test (CAT) accessed from www.catestonline.co.uk and the Hamilton Anxiety and Depression Scale(176). Both of these patient reported questionnaires are well validated(177) and were chosen due to their ease and speed of completion.

Activity monitoring was performed using Actigraph Tri-axial accelerometers. Participants wore the activity monitor around their waist for five days only removing it during sleep and bathing/showering. Five days of home monitoring has been shown previously to adequately overcome day to day variation in activity levels at all stages in COPD(178) and provides a quantitative, objective measure of exercise capacity and energy expenditure in a real-life setting. Data was validated and scored using Actilife version 6 using the Freedson Adult cut off points(179) and expressed as vector magnitude units/min. This accelerometer has been validated by the PROactive consortium to give an accurate indication of physical activity in patients with COPD(180).

2.2.7 6MWT

Participants underwent 6MWT in a 25metre corridor in accordance with ATS guidelines(93). A practice 6MWT was not completed. Patients were encouraged every minute of the 6MWT using two phrases: “Keep up the good work” or “You are doing
well”. Patients were allowed to stop and rest during the test, but were instructed to resume walking as soon as they felt able to do so.

### 2.2.8 Blinding, Treatment allocation and Statistical analysis

There is a universal colour code for medical gas supply cylinders in the United Kingdom. Medical air cylinders are white and black whilst oxygen cylinders are white, therefore if standard cylinders were used blinding could not be achieved. For the purpose of the clinical trial all cylinders were white in colour. A nitrogen/oxygen mix equivalent to air was used in place of air cylinders. All cylinders were prepared by BOC Group PLC and delivered to the clinical trial pharmacy where they were labeled A and B. The code break was held by the clinical trial pharmacist alone and was not revealed to trial investigators until the completion of the trial at the point when which results analysis was undertaken.

Statistical analysis was carried out using SPSS version 22 Armonik, New York, IBM Corp. Normality of data was assessed using Spiro Wilk tests. Throughout the thesis normally distributed data is shown as mean (standard deviation) and non-normally distributed data as median (interquartile range). All statistical analyses were completed prior to the un-blinding of treatment allocation by coding periods as Treatment A and B. For cross-over trial data analysis clinical variables were firstly tested for evidence of carry over effects, i.e. the sum of values over both treatment periods were compared between those who received ambulatory oxygen first or air first and assessing whether there was significant difference between them. Given that no carry-over effects were observed for clinical variables the order of treatment was not accounted for. Therefore change from
baseline for each treatment period was evaluated using paired statistical tests for primary and secondary clinical outcome data; T-tests and Wilcoxon tests were used for parametric and non-parametric data respectively.

2.2.9 Trial monitoring and safety

Trial monitoring was undertaken on more than 2 separate occasions by the trial sponsor. Monitoring visits were used to facilitate trial management and also to ensure procedure were in line with GCP. All monitoring queries were discussed with the PI and co-investigators with action points from monitoring queries dealt with by me.

Adverse events (AEs) defined as any untoward medical occurrence in an enrolled subject, including occurrences which are not necessarily caused by or related to oxygen were recorded at follow up visits by myself and another co-investigator.

2.3 Clinical Trial Laboratory Methods

2.3.0 Enzyme linked immunosorbent assay

This section describes the general technique used to measure plasma levels of IL-6, IL-8, interferon gamma and Tnf-α. The specific details for each assay were followed from the manufacturers protocol.

A quantitative sandwich ELISA was used in which the sample for analysis is quantified against the concentration of known standards; samples of predetermined concentration used to set up a standard curve. The final fluorescence/colour generating step is specific to each ELISA is performed prior to reading the plate in standard microplate reader. All samples were run in duplicate on a 96 well plate as shown in figure 2.4. The intra assay
The coefficient of variation for samples was less than 10%. If this was not the case samples were re-analysed.

The sandwich ELISA process is demonstrated in figure 2.5.

<table>
<thead>
<tr>
<th>A</th>
<th>Std1</th>
<th>Std1</th>
<th>S1</th>
<th>S1</th>
<th>S9</th>
<th>S9</th>
<th>S17</th>
<th>S17</th>
<th>S25</th>
<th>S25</th>
<th>S33</th>
<th>S33</th>
</tr>
</thead>
<tbody>
<tr>
<td>B</td>
<td>Std2</td>
<td>Std2</td>
<td>S2</td>
<td>S2</td>
<td>S10</td>
<td>S10</td>
<td>S18</td>
<td>S18</td>
<td>S26</td>
<td>S26</td>
<td>S34</td>
<td>S34</td>
</tr>
<tr>
<td>C</td>
<td>Std3</td>
<td>Std3</td>
<td>S3</td>
<td>S3</td>
<td>S11</td>
<td>S11</td>
<td>S19</td>
<td>S19</td>
<td>S27</td>
<td>S27</td>
<td>S35</td>
<td>S35</td>
</tr>
<tr>
<td>D</td>
<td>Std4</td>
<td>Std4</td>
<td>S4</td>
<td>S4</td>
<td>S12</td>
<td>S12</td>
<td>S20</td>
<td>S20</td>
<td>S28</td>
<td>S28</td>
<td>S36</td>
<td>S36</td>
</tr>
<tr>
<td>E</td>
<td>Std5</td>
<td>Std5</td>
<td>S5</td>
<td>S5</td>
<td>S13</td>
<td>S13</td>
<td>S21</td>
<td>S21</td>
<td>S29</td>
<td>S29</td>
<td>S37</td>
<td>S37</td>
</tr>
<tr>
<td>F</td>
<td>Std5</td>
<td>Std6</td>
<td>S6</td>
<td>S6</td>
<td>S14</td>
<td>S14</td>
<td>S22</td>
<td>S22</td>
<td>S30</td>
<td>S30</td>
<td>S38</td>
<td>S38</td>
</tr>
<tr>
<td>G</td>
<td>Std6</td>
<td>Std6</td>
<td>S7</td>
<td>S7</td>
<td>S15</td>
<td>S15</td>
<td>S23</td>
<td>S23</td>
<td>S31</td>
<td>S31</td>
<td>Blank</td>
<td>Blank</td>
</tr>
<tr>
<td>H</td>
<td>Std7</td>
<td>Std7</td>
<td>S8</td>
<td>S8</td>
<td>S16</td>
<td>S16</td>
<td>S24</td>
<td>S24</td>
<td>S32</td>
<td>S32</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Fig 2.5 Sandwich Elisa process.

The plate is coated with a capture antibody.

The sample is added and any antigen present binds to the capture antibody.

A detection antibody is added which also binds to the antigen.

An enzyme linked antibody is added which binds to the detection antibody.

A substrate is added and is converted by the enzyme to its detectable form.
2.3.1 RNA Extraction

RNA was extracted from muscle biopsy samples using the QIAGEN RNAeasy kit (Manchester, UK) following the manufacturer’s protocol detailed below. This kit was chosen because it provides a reliable, relatively quick and consistent method of producing high quality RNA which can be used for downstream processes such as microarray analysis.

1. “The muscle sample was homogenized by adding 700µl of QIAzol lysis reagent.
2. The homogenate was incubated at room temperature (15-25°C) for 5 minutes.
3. 140µl of chloroform was added to the homogenate and shaken for 15 seconds
4. The mixture from step 3 was incubated at room temperature for 2-3 minutes before being centrifuged at 12,000g at 4°C.
5. The upper aqueous phase was transferred to a new collecting tube using a Pasteur pipette where it was then mixed with 525µl of 100% ethanol.
6. 700 µl of the sample including any precipitate was pipetted, into an RNeasy® Mini column in a 2 ml collection tube. This was then centrifuged at ≥8000 x g for 15 s at room temperature. Any follow through was discarded.
7. The above step was repeated with the remaining sample.
8. 700 µl of Buffer RWT was added to the RNeasy Mini column and centrifuged for 15 s at ≥8000 x g. Any follow through was discarded.
9. 500 µl of Buffer RPE was pipetted onto the RNeasy Mini column and centrifuged for 15 s at ≥8000 x g. Any follow through was discarded.
10. 500 µl of Buffer RPE was added to the RNeasy Mini column and centrifuged for 2 min at ≥8000 x g.
11. The RNeasy Mini column was transferred to a new 1.5 ml collection tube. 30–50 µl of RNase-free water was pipetted directly onto the RNeasy Mini column membrane and centrifuged for 1 min at ≥8000 x g before eluting.”
Muscle tissue

Muscle tissue lyzed with QIAzol. Ethanol added to the muscle tissue homogenate and sample centrifuged.

Sample added to RNA column with addition of buffer and sample then centrifuged.

Binding of RNA

Sample washed and eluted to yield total RNA.

Fig. 2.6: RNA extraction process.
2.3.2 RNA amplification

This section describes the process of RNA amplification used for microarray analysis. This was required as following RNA quality assessment (using absorbance) some of the extracted RNA was found to be degraded. RNA amplification of intact and degraded was achieved using the Whole Transcriptome Amplification kit Sigma Aldrich (Gillingham, Dorset, UK). This method has been validated(181) to effectively amplify degraded RNA maintaining transcripts levels representative of intact unamplified.

Protocol for RNA amplification

Library Synthesis Reaction

The Library synthesis buffer and solution were thawed and mixed thoroughly. Any precipitate was dissolved by briefly heating the mixture to 37°C.

1. 100ng of RNA was added to 2.5µL of the Library Synthesis Solution.

2. Nuclease-free water was added to bring the total to 16.6 µL.

3. The resultant solution was mixed and incubated at 70°C for 5 minutes then 18°C.

4. 2.5 µL Library synthesis solution, 3.9 µL Water and 2 µL of library synthesis enzyme were added.

5. Incubated in a thermal cycler using the following plan:
   18°C for 10 minutes
   25°C for 10 minutes
   37°C for 30 minutes
   42°C for 10 minutes
   70°C for 20 minutes
   4°C to hold
6. The 25µL samples were divided into 5 X 5µl aliquots on a fresh plate

Amplification reaction

The amplification mix and 10nM dNTP were thawed.

1. A master mix was prepared by adding 301µL of nuclease-free water, 37.5µL amplification mix, 7.5 µL WTA dNTP mix, and 3.75 µL amplification enzyme.

2. 70 µL of master mix was added to 5µL of the sample from step 6 of the library synthesis reaction

3. Incubated in a thermal cycler:
   a. 94°C for 2 minutes
   b. 17 cycles of 94°C for 30 seconds and 70°C for 5 minutes
   c. End cycle

4. The resulting WTA DNA was stored at -20°C.

2.4 Microarrays

The genetic expression microarray analysis was outsourced to the Biosciences department at the University of Birmingham at a cost of £4900. This included dye labelling, hybridisation, array scanning and feature extraction. The microarray experimental design was undertaken by myself.

Two channel microarray microarrays were performed in a matched pair design i.e. each patient's baseline muscle sample was hybridised along with their corresponding muscle sample following each intervention (baseline muscle sample with air treatment sample, baseline with oxygen treatment sample). The two channel microarray design in this setting was significantly cheaper than a single channel analysis as the same information
could be gleaned using half the arrays. Therefore, each array represented the log ratio between baseline condition and ambulatory oxygen/control and subsequent analysis comparing Air treatment vs Oxygen.

Six hundred nanograms of cDNA from each sample were converted to labelled cDNA coupled to a fluorescent dye (Cy3 for baseline samples and Cy5 for samples following interventions) using Agilent SureTag labelling kit (Agilent, 5190-3400, Cheshire UK). These were competitively hybridised to 8x60k microarrays (Agilent Technologies G4851; Cheshire UK), washed and scanned, then data extracted from the scanned image using Feature Extraction (version 10.7.3, Agilent Technologies). A schematic diagram explaining the microarray experiment procedure is shown in figure 2.7
mRNA is extracted from the muscle cells and labelled with two dyes (Cy3-green and Cy5-red) during the synthesis of cDNA by reverse transcriptase. The cDNA is hybridised to the microarray slide where each cDNA molecule representing a gene binds to the complementary DNA sequence. Following this the microarray slide is then excited with a laser various wavelengths to detect the red and green dyes. Green spots indicate hybridisation with control samples only (muscle exposed to air), red hybridisation with test targets (muscle exposed to ambulatory oxygen), yellow hybridisation with both samples and black no hybridisation.

Fig 2.7: Schematic diagram detailing the microarray process.
2.4.0 Normalisation

Normalisation and subsequent microarray analysis was undertaken by myself in the program Bioconductor R.

The package “marray” was used for microarray normalisation. Normalisation is the process which eliminates sources of variation which affect microarray experiments. These can arise from differing quantities of initial mRNA between samples or differential dye labelling (dye bias). The process of normalisation is based on the general principle that in a microarray experiment only a small proportion of genes will show changes in expression between two different conditions. An MA plot is modified scatterplot used to visualise the red-green intensities from an array. A, is the average log intensity of the two channels and M is the relative expression between the two channels also known as the log-ratio. In an MA plot the points should be localised around the zero line in a situation where there are no technical artifacts. Deviations from this zero line are due to non-biological reasons and are therefore removed in the normalisation process. The “loess” method is a within array normalisation method which was used to normalise the microarray data. Figure 2.8 shows the same array MA plot before and after normalisation.
Figure 2.8: MA plots a) before and b) after normalisation
The significance of microarray package (SAM) was used to perform the microarray analysis of differential gene expression between ambulatory oxygen and air. Exploratory analyses of microarray using gene set enrichment and principal component analysis are further explained in analysis of microarrays chapter 5.
Chapter 3.

Systematic Review

This review aims to clarify the longer term efficacy of AOT in those with EID and exertional dyspnoea when judged by outcomes measures of exercise capacity and quality of life. It also evaluates whether the use of oxygen conserving devices is warranted. Previous reviews have been limited by their short duration (<6 weeks) therefore, whether acute eligibility tests for AOT translate into longer term benefit is unclear. In addition, no previous review has evaluated the devices by which AOT is delivered. As discussed in the methods (section 2.1.5), only trials of similar exercise outcomes have been compared i.e. ISWT vs ISWT. Pulmonary rehabilitation (PR) studies have been analysed separately to domiciliary as they are not directly comparable. Although the desired and hypothesised effect of AOT use in both PR and domiciliary studies was to improve exercise capacity analysing them together would conflate the effects of exercise and oxygen.

Some of the results and text from this chapter have been published in the peer reviewed Journal of the COPD foundation: *Chronic Obstr Pulm Dis* (Miami). 2016; 3(1): 419-434.

3.1 Results

Twenty-three studies (620 patients) were included in the systematic review: nine studies evaluated the clinical effectiveness of ambulatory oxygen and thirteen studies evaluated the impact of the delivery device. Generally the studies were small with primary outcomes focused on exercise capacity, Borg dyspnoea scores and exercise saturations. Figure 3.1 summarises the trial flow in the PRISMA format for reporting systematic reviews.
Figure 3.1 Prisma flow diagram
3.1.0 Included Studies

The included studies have been summarised in table 3.1 (clinical effectiveness) and table 3.2 (delivery devices).

3.1.1 Risk of Bias

Allocation concealment, adequate sequence generation, blinding and Jadad score were used to assess this (table 3.3). The Jadad score was poor in 12 of the 23 studies, good in 9 and excellent in 2 of the studies. 9 of the studies had adequate randomisation process; mostly undertaken by computer random number generation or Latin square sequencing. Allocation concealment was adequate in 7 studies; undertaken by a mixture of central randomisation and the SNOSE technique. Blinding was adequate in 6 studies; undertaken by blinding the assessor in the trial or use of identical cylinders arranged by the cylinder suppliers. In a number of the studies especially the older (pre 1995) sequence generation, allocation concealment and/or blinding was unclear or high risk. This information was not available in the individual manuscripts or after contacting the authors.
<table>
<thead>
<tr>
<th>Author</th>
<th>Inclusion</th>
<th>Exclusion</th>
<th>Study type</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Sample Size</th>
<th>Methods</th>
<th>Outcomes</th>
<th>Results Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>McDonald et al(182)</td>
<td>a) COPD</td>
<td>b) PaO2&gt;60mmHg/8kPa</td>
<td>c) Clinically stable</td>
<td>d) Exertional dyspnoea sufficient to interfere with ADLs</td>
<td>e) Current non smokers</td>
<td>Crossover double blinded</td>
<td>Oxygen 4l/min</td>
<td>Air 4l/min</td>
<td>26</td>
</tr>
<tr>
<td>Rooyackers et al(183)</td>
<td>a) COPD b) SpO2 &lt; 90% at maximal exercise c) &gt; 15mmHg/2.00kPa increase in alveolar-arterial difference in PO2 from rest to maximal exercise</td>
<td>a) PaO2 &lt; 64mmHg/8.53kPa b) Mean nocturnal SaO2 &lt; 90% c) Mean pulmonary artery pressure &gt; 25mmHg d) Neuromuscular or cardiovascular disease</td>
<td>Parallel un-blinded</td>
<td>Oxygen 4l/min</td>
<td>Air</td>
<td>12 Air group, 12 O2 group</td>
<td>10 week supervised PR program. 5 sessions/week</td>
<td>a) PFTs b) Maximal cycle ergometry (watts) c) Endurance cycling time d) 6MWT e) CRQ f) Borg Scores</td>
<td>Improvement in peak WR in air group only p&lt;0.01. Improvement in 6MWT and total CRQ scores compared to baseline in both groups p&lt;0.01</td>
</tr>
<tr>
<td>Eaton et al(184)</td>
<td>a) COPD b) &lt;88% SpO2 on exertion c) Resting PaO2 &gt; 7.3kPa d) Clinically stable</td>
<td>a) Limiting angina or significant musculoskeletal disability</td>
<td>Crossover-double blinded</td>
<td>Oxygen 4l/min</td>
<td>Air</td>
<td>41 O2 group, 15 Air group</td>
<td>Supervised 12 week domiciliary oxygen/air use</td>
<td>a) CRQ b) HADs c) SF-36 d) 6MWT e) Borg Scores</td>
<td>No significant difference between groups in 6MWT p=0.4 Improvement in total CRQ scores for home O2 period compared to home air p=0.002</td>
</tr>
<tr>
<td>Emtner et al(185)</td>
<td>a) COPD; FEV1 &lt; 50% predicted b) 45-80 years old</td>
<td>a) Symptomatic cardiovascular co-morbidities or other disease</td>
<td>Parallel double blinded</td>
<td>Oxygen 3l/min</td>
<td>Air</td>
<td>14 O2 group, 15 Air group</td>
<td>Supervised 7 week exercise program with 3 sessions/week</td>
<td>a) Maximal cycle ergometry (watts) b) Constant power cycle ergometry</td>
<td>Improvement in peak exercise tolerance test in both groups p&lt;0.05. Endurance in constant</td>
</tr>
<tr>
<td>Study Authors and Year</td>
<td>COPD Characteristics</td>
<td>RCT Design</td>
<td>Treatment Details</td>
<td>Exercise Parameters</td>
<td>Comparison</td>
<td>Results</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>----------------------</td>
<td>------------</td>
<td>-------------------</td>
<td>---------------------</td>
<td>-----------</td>
<td>---------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonoyama et al (186)</td>
<td>a) COPD b)&lt;88% SpO2 on 6MWT c) Dyspnoea interfering with ADLs</td>
<td>N of 1 RCTs</td>
<td>Oxygen 2l/min</td>
<td>Air 2l/min</td>
<td>27</td>
<td>Unsupervised 6 weeks domiciliary oxygen/air use</td>
<td>a) CRQ, b) SF-36 c) Borg Scores</td>
<td>Improvement in 5MWT and Borg dyspnoea scores for home O2 vs home air p=0.04. No significant difference in HRQoL between home O2 or home air</td>
<td></td>
</tr>
<tr>
<td>Janaudis-Ferreira et al (187)</td>
<td>a) COPD b) FEV1,70% c) PaO2&gt;8kPa at rest d) Clinically stable</td>
<td>Parallel single blinded</td>
<td>Oxygen 5l/min</td>
<td>Air 5l/min</td>
<td>10 Air group, 10 O2 group</td>
<td>Supervised 8 week training program</td>
<td>a) 6MWT b) time &lt;90% saturations c) Borg Score</td>
<td>Improvement in 6WMT in both groups compared to baseline p&lt;0.008 Air group and p&lt;0.005 O2 group. Greater proportion of patients achieve MCID for 6MWT in air group p=0.01</td>
<td></td>
</tr>
<tr>
<td>Moore et al (188)</td>
<td>a) COPD b) PaO2 7.3kPa c) MRC dyspnoea&gt;3</td>
<td>Parallel double blinded</td>
<td>Oxygen 6l/min</td>
<td>Air 6l/min</td>
<td>75 cylinder air, 68 oxygen</td>
<td>Unsupervised 12 weeks domiciliary oxygen/air use</td>
<td>a) 6MWT b) CRQ c) BDI/TDI d) HADs</td>
<td>No significant difference between CRQ dyspnoea score, 6MWT or BDI/TDI scores between groups.</td>
<td></td>
</tr>
</tbody>
</table>
Table 3.1: Clinical effectiveness of Ambulatory oxygen studies.

5MWT 5 minute walk test, 6MWT 6 minute walk test, CRQ chronic respiratory disease questionnaire, HADS Hamilton Depression and Anxiety Scale, WR work rate, ESWT endurance shuttle walk test, PFTs Pulmonary Function Test, SGRQ Saint George’s Respiratory Questionnaire, BDI/TDI baseline/transitional dyspnoea scores, MCID minimal clinically important difference.
<table>
<thead>
<tr>
<th>Author</th>
<th>Inclusion</th>
<th>Exclusion</th>
<th>Study type</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Sample Size</th>
<th>Methods</th>
<th>Outcome</th>
<th>Results Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>M Soffer et al(191)</td>
<td>COPD or restrictive ventilatory disease. SpO2&lt;90%</td>
<td>NR</td>
<td>Non-RCT</td>
<td>DODS</td>
<td>CFNC</td>
<td>20 (13 COPD)</td>
<td>Treadmill exercise</td>
<td>a)O2 conservation ratio at 90% SpO2 b)% O2 savings</td>
<td>DODs requires lower flow rate to achieve 90% saturations compared to CFNC. P&lt;0.05 (data from COPD patients alone)</td>
</tr>
<tr>
<td>R Carter et al (192)</td>
<td>COPD Exercise desaturation Resting SpO2 ≤90%</td>
<td>NR</td>
<td>Cross over</td>
<td>DODs</td>
<td>CFNC</td>
<td>10</td>
<td>Treadmill exercise test (1-1.5mpH)</td>
<td>SpO2 on exercise</td>
<td>DODs achieves statistically higher SpO2 on exercise compared to CFNC p&lt;0.001</td>
</tr>
<tr>
<td>B Tiep et al(193)</td>
<td>COPD</td>
<td>No cardiovascular or orthopaedic limitations to exercise</td>
<td>Non-RCT</td>
<td>DODs</td>
<td>CFNC</td>
<td>9</td>
<td>Treadmill exercise test</td>
<td>O2 flow setting required to achieve SpO2&gt;90%</td>
<td>DODs requires lower flow rate to achieve 90% saturations p&lt;0.0001</td>
</tr>
<tr>
<td>Bower et al(194)</td>
<td>Chronic lung disease Clinically stable</td>
<td>NR</td>
<td>Cross over</td>
<td>DODS</td>
<td>CFNC</td>
<td>5 COPD 1 COPD/scoliosis</td>
<td>Treadmill exercise test</td>
<td>a)Oxygen usage percentage b)exercise SpO2</td>
<td>No significant difference in exercise SpO2. DODS mean O2 utilisation is 44% that of CFNC O2 utilisation</td>
</tr>
<tr>
<td>S. Braun et al (195)</td>
<td>COPD: FEV1/FVC ratio &lt;60%, LTOT</td>
<td>NR</td>
<td>Cross over</td>
<td>DODS (5 devices)</td>
<td>CFNC</td>
<td>10</td>
<td>12minute walk test</td>
<td>Average and lowest SpO2 at rest and exertion</td>
<td>No significant difference between the mean of the lowest SpO2 during exercise between intervention and comparator</td>
</tr>
<tr>
<td>C Roberts et al (196)</td>
<td>COPD Exercise desaturation &lt;90% Clinically stable</td>
<td>NR</td>
<td>Cross over</td>
<td>DODs</td>
<td>CFNC</td>
<td>15</td>
<td>6MWT</td>
<td>a)6MWT b)Time spent &lt;90% SpO2</td>
<td>CFNC significantly improved 6MWD and reduced Time &lt;90% SpO2 (compared to baseline) whereas DODs only improved 6MWT</td>
</tr>
<tr>
<td>Study</td>
<td>Criteria Description</td>
<td>Patients</td>
<td>Setup</td>
<td>O2 Setting</td>
<td>n</td>
<td>Exercise Test</td>
<td>Outcome Measures</td>
<td>Findings</td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------</td>
<td>-------</td>
<td>----------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>A. Cuvelier et al (197)</td>
<td>COPD-ATS criteria Clinically stable FEV1/FVC&lt;65% FEV1&lt;55% PaO2&lt;60mmHg at rest/PaO2&gt;60mmHg with evidence of exercise desaturation</td>
<td>NR</td>
<td>Cross over</td>
<td>Refilled O2 cylinders – HomeFill system</td>
<td>Standard commercial O2 cylinders</td>
<td>10</td>
<td>Successive 6MWT carrying standard O2 and refilled O2 cylinders</td>
<td>a) 6MWD b) mean SpO2 at end of 6MWT</td>
<td>No significant difference between 6MWD or SpO2 between cylinder types.</td>
</tr>
<tr>
<td>B Tiep et al (198)</td>
<td>Chronic lung disease Desaturation on exercise Clinically stable All patients using supplementary O2</td>
<td>NR</td>
<td>Non-RCT Crossover</td>
<td>DODS</td>
<td>CFNC</td>
<td>10 (9 COPD)</td>
<td>Treadmill exercise test. O2 flow required to maintain saturations between 92 and 94%</td>
<td>O2 flow setting required to achieve SpO2&gt;90%</td>
<td>No significant difference in SpO2 at higher DODS setting. DODS confers 4.3 fold O2 saving on exercise</td>
</tr>
<tr>
<td>W. Chatila et al (199)</td>
<td>COPD-GOLD criteria Clinically stable the preceding 3 months Cardiovascular disease</td>
<td>NR</td>
<td>Non-RCT crossover</td>
<td>Vapotherm (High flow oxygen 20l/min)</td>
<td>Low flow oxygen (2.5-6l/min)</td>
<td>10 (5 completed exercise test)</td>
<td>Cycling unloaded bicycle</td>
<td>a) VT b) VE c) Work of Breathing d) Inspiratory time fraction d) RR/VT</td>
<td>No significant difference in outcome measure (a, b or c) between Vapotherm or Low flow oxygen</td>
</tr>
<tr>
<td>C Fuhrman et al (200)</td>
<td>COPD FEV1&lt;50 %, PaO2&lt;65mmHg. Current or former smoker No exacerbations in preceding 3 months Symptomatic cardiovascular disease. Any condition with contraindication to exercise testing</td>
<td>NR</td>
<td>Cross over</td>
<td>DODS (4 devices)</td>
<td>CFNC</td>
<td>13</td>
<td>6MWT</td>
<td>a) SpO2 at rest and exercise b) 6MWT</td>
<td>No significant difference in 6MWD with any DODS device compared with CFNC</td>
</tr>
<tr>
<td>Study Reference</td>
<td>Disease Description</td>
<td>Oxygen Delivery System</td>
<td>Device Type</td>
<td>Exercise Test</td>
<td>METs</td>
<td>SpO2 on Exercise</td>
<td>Comparison</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------------</td>
<td>------------------------</td>
<td>-------------</td>
<td>--------------</td>
<td>------</td>
<td>------------------</td>
<td>------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S. Strickland et al (201)</td>
<td>COPD-GOLD Stage 4, SpO2&lt;90%, LTOT Clinically stable preceding 6 weeks</td>
<td>Symptomatic Cardiovascular disease, Physical limitations precluding walking</td>
<td>Cross over</td>
<td>a)Liquid O2 system, b)HomeFill compressed O2 system, c)Portable O2 concentrator</td>
<td>Standard commercial O2 cylinders</td>
<td>39</td>
<td>6MWT</td>
<td>No significant difference between SpO2 between interventions or comparator</td>
<td></td>
</tr>
<tr>
<td>A Palwai et al (202)</td>
<td>Obstructive lung disease, SpO2&lt;90% at rest or on exertion. Hypoxaemia warranting use of supplementary O2.</td>
<td>NR</td>
<td>Cross over</td>
<td>DODS (4 devices)</td>
<td>CFNC</td>
<td>13</td>
<td>Treadmill exercise test</td>
<td>Significantly higher METs achieved with CFNC p=0.006</td>
<td></td>
</tr>
<tr>
<td>Casaburi et al (203)</td>
<td>COPD FEV1&lt;60%, PaO2&lt;8kPa Clinically stable preceding month</td>
<td>Uncontrolled heart failure, Orthopedic, neurological or cognitive limitations to exercise, Current smokers</td>
<td>RCT Parallel</td>
<td>Lightweight aluminium cylinders</td>
<td>E cylinders</td>
<td>22</td>
<td>Unsupervised domestic activity</td>
<td>No significant difference in oxygen utilisation or patterns of activity between lightweight and standard cylinder</td>
<td></td>
</tr>
<tr>
<td>S Marti et al (204)</td>
<td>COPD and ILD, Exercise desaturation&lt;88%</td>
<td>Active smoker, Use of AO therapy prior to study, Recent exacerbation</td>
<td>Crossover</td>
<td>DODS/PRC</td>
<td>CFNC</td>
<td>28 COPD 31 ILD</td>
<td>6MWT using intervention/comparator</td>
<td>Exercise desaturation corrected in 79% of patients with DODs and CFNC and in 86% with PRC (data for COPD patients alone). No significant difference between devices</td>
<td></td>
</tr>
</tbody>
</table>

Table 3.2 Impact of device on Ambulatory oxygen delivery studies. DODs Demand oxygen devices, PRC Pendant reservoir cannulae, NR not reported, ATS American Thoracic Society, METS Metabolic equivalents
Table 3.3: Risk of bias in the included studies.
3.2 Clinical effectiveness of ambulatory oxygen

3.2.0 Exercise Capacity

4 RCTs (182, 183, 187, 188) used 6MWT distance in assessing exercise capacity. In the PR (pulmonary rehabilitation) studies (183, 187) the common effect (weighted mean difference) was 21.97 metres in favour of the control group. This result was mirrored in the meta-analysis of the domiciliary studies (182, 188); common effect 0.56 metres in favour of control. However, neither result was statistically significant (95% CI -77.25 to 33.32) and (95% CI -26.96 to 28.08) respectively, Figure 3.2. 2 PR RCTs (189, 190) used ESWT; they differed substantially in their results and therefore the pooled figure may be less meaningful. It was not statistically significant, common effect 150.02 seconds in favour of oxygen (95% CI -124.74 to 427.77 seconds, Figure 3.2). 2 PR RCTs (183, 185) used incremental work rate exercise testing via cycle ergometry to assess exercise capacity and found no difference with oxygen; 1.45 watts in favour of control (95% CI -13.54 to 10.64 watts), Figure 3.2). 2 PR RCTs (183, 185) measured constant power exercise tests using cycle ergometry. There was a strong trend toward longer exercise time with oxygen (2.76 minutes longer (95% CI -0.07 to 5.58 minutes, Figure 3.2).
Figure 3.2 Forest plots showing the effect of ambulatory oxygen therapy on exercise capacity.

Two studies (both domiciliary) (184, 186) could not be used in the meta-analysis as one study provided p values only(184) and the other was the only one to use 5MWT(186).
Neither showed any statistical benefit of long term ambulatory oxygen on 6MWT distance (p=0.9) or 5MWT distance for individual participants.

Borg dyspnoea Scores

End of test Borg score were measured in 2 of the meta-analysed PR studies that used 6MWT(182, 183, 187) and 2 RCTs using incremental work exercise testing(183, 185). Heterogeneity between the studies was not significant ($I^2=0\%$). Neither were statistically significant; effect 0.16(-0.61 to 0.93) and 0.25(-0.81 to 1.31) respectively; Figure 3.3).

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>oxygen Mean SD Total</th>
<th>Control Mean SD Total</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Janssens-Ferreira 2009</td>
<td>1.5</td>
<td>0.3</td>
<td>10</td>
<td>0.5</td>
</tr>
<tr>
<td>Ponsiglino 2007</td>
<td>1.3</td>
<td>0.3</td>
<td>12</td>
<td>0.3</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>22</td>
<td>22</td>
<td>0.16 ($0.64$, $0.90$)</td>
<td></td>
</tr>
</tbody>
</table>

3.2.1 Quality of life

This was measured by CRQ (chronic respiratory questionnaire) in 7 studies(182-186, 188, 189) 3 of which were PR studies. In the PR studies there was no statistical difference between oxygen and control in any domain, however there was a strong trend to
statistical significance in CRQ emotion and fatigue favouring oxygen; p=0.06 and p=0.09 respectively (Figure 3.4). In the domiciliary studies the effect in all domains was in favour of oxygen treatment, significant only in dyspnoea (p=0.002) and fatigue (p=0.01) (Figure 3.5).

Figure 3.4 Forest plots showing the results of ambulatory oxygen on HRQoL in the Pulmonary Rehab studies.
Figure 3.5 Forest plots showing results of ambulatory oxygen on HRQoL in domiciliary studies.
3.3 Impact of device on ambulatory oxygen delivery

14 studies evaluated a variety of oxygen conserving devices (OCDs) and cylinder types (191-204) (table 3). Modes of delivery included DODs (demand oxygen devices), PRC (Pendant reserve cannulae) and continuous flow nasal cannulae (CFNC). In some studies multiple OCDs were compared. Where this was the case, the most effective OCD was used in the meta-analysis comparing it to standard CFNC.

5 OCDs studies (192, 194, 196, 200, 204) were used in two separate meta-analyses. Tests for heterogeneity were not significant (both $I^2=0$).

3.3.0 Exercise capacity

3 of the 5 meta-analysed studies compared DODS against standard CFNC using 6MWT as an outcome measure (196, 200, 204). DODS and CFNC did not differ (CI -10.28 to 1.60), Figure 3.6).

Exercise oxygen saturations

Oxygen saturations were used in 2 of the 5 studies (192, 194) with methods of delivery being PRC and DODs respectively. Oxygen saturations were 2.03% higher with OCDs compared to CFNC, (95% CI 0.09 to 3.98, p=0.04, Figure 3.6). In contrast, Roberts et al demonstrated that DODs caused a significantly longer period of desaturation <90% than CFNC p<0.001.

3.3.1 Oxygen utilisation

Three studies (191, 193, 198) evaluated the ability of OCDs versus standard CFNC to conserve oxygen in patients during exercise by calculating an oxygen conservation ratio at 90% SpO2 (i.e. the relative difference in oxygen flow required to maintain oxygen
saturation with both devices at 90% SpO2). 2 studies used DODs (193, 198) and 1 PRC (191). Although a higher DODS setting was required to maintain equivalent oxygen saturations, DODs still conferred 2.9-7.6 fold oxygen saving which was significant when compared to standard CFNC  $p<0.001$. A similar result was demonstrated with PRC; oxygen utilisation was significantly lower than CFNC $p<0.05$ (191).

3.3.2 Other outcomes

Individual studies demonstrated no significant difference in exercise capacity with either refilled cylinders or portable oxygen concentrators when compared to standard commercial cylinders (197, 201). Patterns of either home activity or oxygen utilisation were not significantly different when lightweight cylinders were used compared to heavier E cylinders (203).

Figure 3.6 Forest plot showing the effect of OCDs on exercise capacity and exercise saturations
3.4 Cost effectiveness

There were no published studies found from the searches which assessed cost incremental ratios or cost effectiveness for ambulatory oxygen in addition to usual care. Since there were no studies that assessed this, and clinical effectiveness could not be proven in any domain, it was not possible to answer the question of whether ambulatory oxygen is cost-effective. However it may be relevant to consider what the potential cost of ambulatory oxygen would be if used widely in the UK. The prevalence of patients with COPD on 3 medicinal preparations (e.g. LABA/ICS,SABA and LAMA) and likely severe disease is 8.7%(2). Studies indicate the prevalence of EID in severe COPD at approximately 30%(80, 82). There are approximately 820,000(2) people with COPD in the UK and thus a conservative estimate of patients with EID in the UK is approximately 21,000. Previous studies have indicated variable ambulatory oxygen usage from 40-50 minutes daily(182, 188) to 3.5 hrs(186). Using tariff data from Hertel et al(205) (daily unit cost £14.70) estimated annual costs would be £3.85 million if all patients were treated for 40-50 minutes per day. This is a considerable burden to the health system, particularly if effectiveness is not well established. The results from the included studies imply that continuing to prescribe based on acute response which is reassessed in those who have completed pulmonary rehabilitation may be a way of limiting cost, and possibly treating those likely to benefit most at home.

3.5 Discussion

This review evaluated the use of ambulatory oxygen in three separate ways: efficacy against placebo, optimum mode of delivery and cost. Firstly, we have shown that
ambulatory oxygen is unlikely to be effective at improving functional exercise capacity or symptoms of breathlessness in unselected patients with EID, although there may be some patients who respond well. Secondly we have shown that use of OCDs is appropriate, in that outcomes are similar or better to CFNC but at lower oxygen consumption. Since the review showed no significant overall effect of oxygen, and there were no published cost-effectiveness studies we were unable to calculate an incremental cost effectiveness ratio (ICER). Each area of the results will be discussed here in turn.

**Clinical effectiveness of ambulatory oxygen**
The prescription of ambulatory oxygen therapy in COPD is governed by an improvement in exercise capacity or Borg dyspnoea scores, wherein a 10% improvement in distance walked or reduction ≥ 1 in Borg Score indicates it should be used in patients with EID> 4%(78). The majority of our results suggest that there is not a benefit of this magnitude (Figures 3.2 and 3.3). It is important to highlight that in the included studies the definition of EID was not uniform, ranging from mild (<92%) to more severe desaturation (<88%). Since results for some outcomes were heterogeneous it is important to consider how patient selection influenced results. Two studies (182, 188) used exertional dyspnoea as their main inclusion criterion and were analysed separately, although 1/3 of patients in the Moore et al(188) study also exhibited EID. Few studies specified “acute responders” (i.e. those with >10% improvement in walking distance); The only study (189) which did used ESWT as the outcome measure and showed significant improvement in those randomised to ambulatory oxygen compared to compressed air, implying that appropriate patient selection is important in optimising clinical outcome. Interestingly however, 7 studies (182-186, 188, 190) included a single assessment acute oxygen test for all participants as part of their protocol. All but one (190) demonstrated a significant
mean improvement in exercise capacity for participants with acute oxygen therapy compared to compressed air which is in line with a previous Cochrane review (100). Whether the acute effects of oxygen persist in the long term in trained or untrained participants was addressed in 2 of the included studies (183, 184) as they all included a repeat acute oxygen test at the end of the study period. Rooyackers et al (183) and Eaton et al (184) both demonstrated that this acute effect was no longer statistically significant when using 6MWT as the outcome measure. It would therefore seem that any acute improvement in walking distance observed in a single assessment study is not maintained. This has implications for clinical practice as prescriptions for ambulatory oxygen based on improvements in exercise capacity observed in single assessment studies as suggested by guidelines (78) are not sustained or are minimal in the longer term. However, what currently determines the longer term efficacy of AOT is the subjective assessment of whether patients feel it has helped them increase their own physical activity. Where patients feel there has been no benefit; AOT is removed.

The way in which exercise capacity was measured may also be relevant to the interpretation of results. Largely it was measured using field tests (ESWT or 6MWT) which particularly in the case of the 6MWT have been suggested to relate more to activities of daily living (96, 206). The meta-analysis of exercise capacity with respect to 6MWT slightly favoured the control group and showed no benefit of ambulatory oxygen, implying that in normal daily life it would not be expected to help patients be more active. In the ESWT meta-analysis, although the result was not statistically significant in favour of oxygen therapy it may be clinically significant. The MCID for the ESWT is estimated at 45-85 seconds (207). The common effect of 150 seconds exceeded this although this must be approached with caution because the heterogeneity between the
two studies (189, 190) was considerable. Both enrolled patients exhibiting EID>4% and predominantly severe COPD. During the ESWT in the Dyer et al (189) study patients had their oxygen cylinders carried by an assistant whereas this was not the case in Ringbaek et al (190). It is recognised that any improvement in exercise capacity can be negated by the weight of the ambulatory oxygen system if carried by patients alone (196, 208), thus it is possible the Dyer study overinflated the benefits of treatment in real life by providing assistance. The meta-analysis of endurance cycle time strongly favoured oxygen treatment and was close to approaching statistical significance. Furthermore this is likely to be an underestimate of the effect of ambulatory oxygen treatment as 16 endurance tests in the oxygen group were terminated at 30 mins compared to 6 endurance tests in the control group (185). The responsiveness of constant work rate test such as the ESWT and cycle endurance to intervention is far better than 6MWT (209) which may explain the discrepancy between these different exercise outcome results. However at present no MCID for cycle ergometry has been established and its relationship to activities of daily living is unclear. Thus far no study of ambulatory oxygen therapy has used home activity or activities of daily living as an outcome measure. Real world performance of ambulatory oxygen has been largely gauged by 6MWT results. It is now possible to measure home activity with a number of validated accelerometers (180). This was part of the rationale for including home activity as an outcome measure in the Ambulatory oxygen study for muscles in COPD trial (NCT01722370) which forms chapter 4 of this thesis. Given that 6MWT is also an outcome measure we will be able to explore the relationship between them.
Some studies(183, 185, 187, 189, 190) were carried out as part of pulmonary rehabilitation. Although no statistical benefit of long term ambulatory oxygen was demonstrated, exercise capacity (particularly 6MWT) in the pulmonary rehabilitation studies exceeded that of the domiciliary studies(182, 188) whether patients were randomised to ambulatory oxygen or placebo, figure 2.1 and 2.2. What is also clear is the improvement in 6MWT distance gained by pulmonary rehabilitation far exceeds that gained by ambulatory oxygen(183). This supports current guidelines(78) in that any assessment of ambulatory oxygen therapy should be made following pulmonary rehabilitation.

Finally, it is important to consider the meta-analyses possible using CRQ domains. In general there was a benefit of ambulatory oxygen on QoL, which was most pronounced in the dyspnoea and fatigue domains; the others were not statistically significant but showed a strong trend in the same direction. However, the effect size was only 0.28 and 0.17 in the statistically significant domains. Although the MCID for PR adjuncts has not been established it is less than the proposed 0.5 points which is considered to represent the MCID for an individual CRQ domain(210). This explains the apparent discrepancy between Borg score and CRQ dyspnoea score meta-analyses; neither were clinically significant, thus they concur, despite the fact that statistically the CRQ score was better with oxygen. The effect size is also considerably less than the effect on CRQ of pulmonary rehabilitation (0.62 points) (211) confirming that assessment for ambulatory oxygen should only be done after rehabilitation.

**Impact of device on ambulatory oxygen delivery**
The mode of delivery of ambulatory oxygen therapy largely encompasses the cylinder type and the interface used. Oxygen conserving devices (DODS/PRC) have been used for
many years and the theory supporting their use has been discussed elsewhere (193). In short “classic” DODs devices deliver oxygen during the initial phase of inspiration alone whilst PRC stores oxygen during exhalation to be delivered at the next inspiratory phase. The role of OCDs is to conserve oxygen however in doing so must perform equivalently to standard CFNC in ameliorating oxygen desaturation. Some studies (192, 194, 196, 200, 204) included in the meta-analysis indicate that oxygen conserving devices perform equivalently to standard CFNC at maintaining exercise oxygen saturation and 6MWT. Importantly however, it is likely that oxygen conserving devices achieves these outcomes at a much lower oxygen utilisation than CFNC. This is likely to have implications in terms of oxygen cylinder usage and subsequent cost. Although the primary role of OCDs is not to improve exercise performance over CFNC, patients use these devices on the premise that they are ambulatory. Thus it is reassuring that functional performance is not negated by the weight of the system.

It is important to note that there was considerable variation between OCDs and their performance and in the meta-analyses the best performing OCD was used. Notably in the study by Palwai et al (202) one of the DODs systems performed no better than ambulation on room air. Also there may be some patients that do not tolerate OCDs and their use may cause further desaturation. This is supported by the study by Marti et al (204) in which use of DODs failed to correct EID in approximately a fifth of participants. This has been explained by a change in respiratory pattern on more strenuous exertion where by the predominance of mouth breathing rather than nasal a fails to trigger the flow sensor(196).
Oxygen cylinders have historically been the main method of delivering portable oxygen, however newer devices such as portable concentrators are now available. These devices have variable weight with cylinders weighing between 3.4-8kg and portable concentrators between 3-4kg. As mentioned previously the weight of the ambulatory oxygen system (cylinder in this case) is important factor as the portable oxygen system should be carried by the patient during their ambulatory oxygen assessment and following this in their ambulatory activity. The weight of the portable oxygen systems has previously been cited as one of the reasons why patients with COPD have poor concordance with ambulatory oxygen prescriptions(212). An interesting observation from one of the studies (203) is that ambulatory cylinder weight had no impact on home activity. One would hypothesize that a lower weight would facilitate ambulation. This was not the case despite prior efforts of focused education on increasing oxygen treatment understanding and ambulation.

The comparison of standard cylinders (197) to refillable (Homefill), portable concentrators and lightweight cylinders demonstrated no difference in exercise capacity (6MWT), oxygen saturations or time used. From this one can conclude that most portable oxygen systems perform equivalently and when used should be coupled with oxygen conserving devices in the first instance. Currently when ordering ambulatory oxygen, the HOOF (Home oxygen order form) system tends to select OCD devices for those who are most active which is in line with current evidence(81).

There are a number of limitations to the meta-analysed data in this chapter. The quality of data in from the published papers was poor to average limited by small sample sizes and high risk of selection and detection bias especially in the older studies. In addition,
patient selection and heterogeneity of outcomes may limit the generalisability of the results. There were no published studies on cost effectiveness of AOT. Whilst cost effectiveness has been evaluated to some extent in inhaled therapies in COPD the lack of data in this area with respect to AOT may be due to the difficulty analysing specific outcomes. Inhaled therapies have been shown to reduce exacerbations rates; mild to severe and consequently in many cases healthcare utilisation. These outcomes can be defined by cost, especially in the context of hospital admissions where which exacerbations are grouped under a Healthcare Resource Group (HRG) with an indicated cost(205). AOT main effect is to increase functional exercise capacity and negate desaturation. Whilst AOT will have an effect on QoL and exercise capacity it is difficult to define the economical impact of these benefits. Finally as alluded to in this section, outcomes in this chapter did not include other clinically relevant endpoints such as exacerbations or mortality largely due to paucity of information.

**Conclusion**

Although limited by patient selection and heterogeneity in outcomes this review has shown that in unselected patients with EID AOT is unlikely to provide lasting clinically meaningful improvements in exercise capacity, when judged by the 6mwt or in BORG scores. However, some patients may respond well and derive benefit either clinically or subjectively. Pulmonary rehabilitation should be undertaken before AOT assessment as the improvement in exercise capacity from PR far exceeds any improvement when standalone oxygen is given to patients in a domiciliary setting. When AOT is prescribed, OCDs should be use in preference to CFNC as they are likely to achieve similar oxygen saturations and mitigate oxygen desaturation at lower total oxygen usage.
Several studies in this review where in the setting of pulmonary rehabilitation, which have been shown to improve exercise outcomes (213) with the resistance component improving markers of muscle myogenesis (214). Domiciliary studies whether supported by AOT have never used skeletal muscle myogenesis or gene expression as an outcome measure. Since there is no exercise component in these studies; benefits in exercise or skeletal muscle outcomes must either be derived from a direct action of oxygen or improvements in physical activity; one of the assumptions made when AOT is prescribed. Moreover, no study included in this review measured physical activity directly by use of activity monitors or using patient reported questionnaires of activity during the study period. Therefore, it is unclear what affect AOT would have on patient physical activity and whether this translates to improved exercise or skeletal muscle outcomes. This is the subject of investigation in chapter 4.
Chapter 4

Clinical Outcomes

This chapter outlines the clinical results from the Ambulatory oxygen for muscles in COPD trial (NCT01722370); the methods for which are discussed in chapter 2.2. This study investigated the role of AOT on skeletal muscle gene expression, systemic inflammation, physical activity, exercise capacity and quality of life.

Patients were recruited between September 2012 and August 2014 and randomised to 12 weeks of AOT or placebo air in a cross over fashion. Skeletal muscle biopsies were taken at trial enrolment (baseline sample) and after each intervention. Markers of systemic inflammation and exercise capacity were measured at the same timepoints as above. In addition to measuring physical activity at trial enrolment and after each intervention, physical activity was also measured at the midpoint of each intervention, i.e. at 6 weeks. The study design diagram is shown in figure 4.0
Screening visit
Spirometry, 6MWT

Enrolment visit 1 (week 1) Start of trial
Consent, allocation by SNOSE
QOL, HADS, blood gas, venous blood
Data collection for COPD phenotypes
Muscle biopsy
Blood collection before
Pre trial activity monitor issued

Visit 2 (1 week after visit 1): Collection of activity monitors
IMP/placebo dispensing

Visit 3 (6 weeks after starting IMP/placebo):
QOL
Activity monitor issued

1-2 week break then dispensing of new product

Visit 4 (12 weeks; end of IMP/placebo)
Spirometry, 6MWT
QOL, HADS, blood gas, venous blood
Data collection for COPD phenotypes
Muscle biopsy
Bloods as before
Activity monitor issued

Visit 5 (6 weeks after starting IMP/placebo)
QOL
Activity monitor issued

Visit 6 (12 weeks after starting IMP/placebo)
Spirometry, 6MWT
QOL, HADS, blood gas, venous blood
Data collection for COPD phenotypes
Muscle biopsy
Bloods as before
Activity monitor issued

Follow up visit (6 weeks after IMP/placebo end)
Post trial activity monitor issued
Collect monitor
QOL, HADS
Spirometry

Figure 4.0: Study design Diagram
4.1 Patient characteristics

Twenty five participants were recruited to the clinical trial following the initial screening of thirty two patients. All participants had completed pulmonary rehabilitation within 2 years prior to trial enrolment and demonstrated exercise induced desaturation to a nadir <88%. All but one patient had obstructive lung disease with a FEV1/FVC ratio of <70% with the remaining patient having radiological upper zone predominant emphysema.

Seventeen patients completed the trial. The reasons for non-completion were that 1 patient required LTOT, 3 were lost to follow up and 4 withdrew consent. The trial study plan is shown in figure 4.1.

![Trial flow diagram](image)

Figure 4.1: Trial flow diagram
In general the recruited patients had spirometrically severe COPD, were very symptomatic and had anxiety/depression scores indicative of clinically significant psychological co-morbidity. There was considerable variability in baseline exercise capacity, as demonstrated by the 6 minute walk test distance and there was a wide range of body mass indices (BMI). Table 4.1 shows the baseline demographic and clinical data.

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>67.35(7.45)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (M:F)</td>
<td>7:10</td>
</tr>
<tr>
<td>FEV1 absolute (litres)</td>
<td>1.18(0.7)</td>
</tr>
<tr>
<td>FEV1% predicted</td>
<td>50(23.6)</td>
</tr>
<tr>
<td>FVC absolute (litres)</td>
<td>2.27(0.72)</td>
</tr>
<tr>
<td>FVC % predicted</td>
<td>80.5(18.87)</td>
</tr>
<tr>
<td>Desaturation nadir %</td>
<td>86(85-88)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>28.77(19.2-30.07)</td>
</tr>
<tr>
<td>Baseline 6MWT distance (metres)</td>
<td>223(143.9)</td>
</tr>
<tr>
<td>Baseline CAT score</td>
<td>27.94(6.45)</td>
</tr>
<tr>
<td>Baseline HAD Score</td>
<td>17.17(5.97)</td>
</tr>
<tr>
<td>Baseline home activity (VMU/min)</td>
<td>251.3(157.3-430.07)</td>
</tr>
</tbody>
</table>

Table 4.1: Baseline demographic data for trial participants. Data expressed as mean (Standard deviation), Median(25th-75th Quartile)

### 4.2 Cylinder usage

Cylinders weighed approximately 4kg. Oxygen flow rates were set at 2l/min and patients were instructed to use this flow rate when performing routine physical activity. The mean number of cylinders used during oxygen treatment was 5 (1.62) compared to 4.82(2.21)
during the air treatment phase \( (p=0.78) \). The cylinders provided by BOC had a run time of approximately 5hrs at 2l/min. Given the mean cylinder usage, this would equate to less than one hour; approximately 30mins air/oxygen use daily.

### 4.3 Exercise capacity and Home Activity

At baseline 6MWT distance correlated significantly with baseline lung function (FEV1\%) \( (r=0.63, p=0.007, \text{ figure 4.3}) \) but no other clinical variable. 6MWT distance was not significantly different in patients with high (BMI>25) or low (BMI<25) \( p=0.399 \). The extent of exertional desaturation did not correlate with 6MWT distance during air or oxygen treatment (Spearman’s \( R=-0.001, p=0.97 \) and Spearman’s \( R=0.11, p=0.68 \) respectively.

![Figure 4.2: Correlation of baseline 6MWT and FEV1\% predicted \( r=0.63 \ p=0.007 \)](image-url)
Exercise capacity (6MWT) increased from baseline in both arms of treatment. The magnitude of improvement was greater during ambulatory oxygen treatment (34.06 metres compared to 16.25 metres). However, neither of these improvements from baseline was statistically significant p=0.279 and p=0.51 for ambulatory oxygen and air treatments respectively. Use of the tri-axial accelerometer showed that patients were generally inactive with no patient spending more than 10% of the time in moderate to vigorous physical activity at any point during the trial. Home activity improved from baseline during AOT both at trial midpoint and at trial end. Neither of these changes were statistically significant. Midpoint home activity was not significantly different to home activity at the end of the treatment phase during AOT or air treatment; p=0.91 and p=0.86 respectively. Table 4.2 summarises these results.

<table>
<thead>
<tr>
<th></th>
<th>Air</th>
<th>Oxygen</th>
<th>Air vs Baseline</th>
<th>Oxygen vs Baseline</th>
<th>Air vs Oxygen</th>
</tr>
</thead>
<tbody>
<tr>
<td>6MWT</td>
<td>16.25m (99.25)</td>
<td>34.06m (125.33)</td>
<td>P=0.51</td>
<td>P=0.279</td>
<td>P=0.65</td>
</tr>
<tr>
<td>Home Activity At Trial midpoint</td>
<td>241.75(169.7-376.8)</td>
<td>279(207.3-415.86)</td>
<td>P=0.99</td>
<td>P=0.37</td>
<td>P=0.41</td>
</tr>
<tr>
<td>Home activity Trial end (VMU/min)</td>
<td>238.3(171.3-374.38)</td>
<td>278.9 (207.4-413.43)</td>
<td>P=0.875</td>
<td>P=0.308</td>
<td>P=0.32</td>
</tr>
</tbody>
</table>

Table 4.2: Table shows the change from baseline in 6MWT distance following interventions and home activity (VMU/min) at the end of each intervention period.

Interestingly home activity following oxygen treatment correlated significantly with 6MWT following ambulatory oxygen treatment (Spearman’s R=0.751, p=0.005). This
relationship however was not present at baseline (Spearman’s R=0.399, p=0.199) or following air treatment (Spearman’s R=0.441, p=0.152, figure 4.3a-c).

![Figure 4.3 a-c) Correlation of home activity with 6MWT distance at baseline, following air (Treatment A) and ambulatory oxygen (Treatment B)](image)

4.4 Health related quality of life and Anxiety and Depression

All recruited patients had baseline CAT scores of more than 20 indicating that COPD had a clinically significant impact on their quality of life. As with exercise capacity the response to treatment was heterogeneous. Following oxygen treatment 11/17 patients had reduced (improved symptom) scores compared to 8/17 following air treatment. The mean change from baseline was -1.59(6.86) following oxygen treatment and 0.64(4.24) following air. Neither were statistically significant (p=0.354 and p=0.538 respectively).

All but one patient at baseline had evidence of clinically significant anxiety and depression. Following both interventions there was a reduction (improved symptoms) in
HADs score; -2.47(4.45) with oxygen treatment and -1.82(4.57). Table 4.3 summarises these results.

<table>
<thead>
<tr>
<th></th>
<th>Air</th>
<th>Oxygen</th>
<th>Air vs Baseline</th>
<th>Oxygen vs Baseline</th>
<th>Air vs Oxygen</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAT</td>
<td>0.64(4.24)</td>
<td>-1.59(6.86)</td>
<td>P=0.35</td>
<td>P=0.54</td>
<td>P=0.26</td>
</tr>
<tr>
<td>HADs</td>
<td>-2.47(4.45)</td>
<td>-1.82(4.57)</td>
<td>P=0.13</td>
<td>P=0.04</td>
<td>P=0.79</td>
</tr>
</tbody>
</table>

Table 4.3: Change from baseline scores for HADs and CAT.

Only the improvement in HADs from baseline following oxygen treatment reached statistically significance; p=0.04 compared to p=0.13 following air treatment, however there was no significant difference between AOT and air treatment. Figure 4.4 shows the individual HADs patient scores during treatment phases.

![HADs Score and Treatment](image)

Figure 4.4: HADs score during treatment arms

4.5 Systemic Inflammation
The results of the plasma cytokine levels in response to oxygen and air treatment are shown in table 4.4. TNF alpha levels were generally low and did not show significant change following either intervention.

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Air</th>
<th>Oxygen</th>
<th>Air vs Baseline</th>
<th>Oxygen vs Baseline</th>
<th>Air vs Oxygen</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-6 pg/ml</td>
<td>19.01(10.88-63.47)</td>
<td>28.61(10.52-62.72)</td>
<td>12.17(7.82-41.91)</td>
<td>P=0.94</td>
<td>P=0.04</td>
<td>P=0.35</td>
</tr>
<tr>
<td>IL-8 pg/ml</td>
<td>5.29(4.35-7.33)</td>
<td>6.33(5.08-8.03)</td>
<td>5.57(4.44-6.64)</td>
<td>P=0.48</td>
<td>P=0.58</td>
<td>P=0.89</td>
</tr>
<tr>
<td>IFN-g pg/ml</td>
<td>181.25(99.73-273.84)</td>
<td>215.06(132.37-372.07)</td>
<td>267.92(123.73-285.87)</td>
<td>P=0.31</td>
<td>P=0.35</td>
<td>P=0.76</td>
</tr>
<tr>
<td>TNF-α pg/ml</td>
<td>0.57(0.45-0.81)</td>
<td>0.54(0.48-1.13)</td>
<td>0.48(0.4-1.05)</td>
<td>P=0.53</td>
<td>P=0.37</td>
<td>P=0.92</td>
</tr>
</tbody>
</table>

Table 4.4: Systemic cytokine response to oxygen and air during clinical trial.

Plasma interferon gamma levels rose following both treatments but this change was not significantly different from baseline. The only significant change from baseline during the clinical study was a reduction in plasma IL-6 levels following oxygen treatment although there was between group difference was not significant. Individual patient responses of IL-6 and treatment are shown in figure 4.5.
4.6 Discussion

The secondary aims of this study were to determine whether ambulatory oxygen therapy had any long term impact on functional exercise capacity, quality of life or systemic inflammation. The results from the systematic review analysis (chapter 3) suggest that it would have little impact on these clinical outcomes save for quality of life. The benefits of this study in comparison to others presented in chapter 3 are that the duration of the study is far longer than any previous study which assessed ambulatory oxygen in a domiciliary setting. It also investigated, systemic inflammatory response and home activity alongside functional exercise capacity, as measured by the 6MWT. The hypothesised mechanisms by which AOT may mitigate EID and improve exercise capacity
have been discussed in 1.4.1 and 1.5.1. Briefly they include, improved V/Q ratios and arterial oxygen concentration, reduction in peripheral chemoreceptor activity, reduction in peripheral/central fatigue and reduction in skeletal muscle lactic acid production. Collectively these mechanisms are likely to result in either improved arterial oxygenation or reduction in the sensation of dyspnoea which may both beneficially effect exercise capacity or activity. Central to this therein is the use of AOT. During the trial cylinder usage both for AOT and air was low; roughly equating to less than 30mins daily use. It is unlikely therefore that usage was sufficient to mediate either direct action of oxygen or that AOT encouraged participants in the trial to be more active. The effects of AOT on functional exercise capacity and home activity are discussed in turn.

Functional exercise capacity has been shown to be reduced in COPD patients\(^{(215)}\) with a number of factors determining poor 6MWT performance (defined as a 6MWT distance <350metres)\(^{(216)}\). Determinants of 6MWT distance are complex, however airflow limitation and the presence of depressive symptoms are two variables which have been shown to influence it\(^{(216)}\). The significant positive correlation between FEV1 % predicted and 6MWT in the data figure 4.3 supports this although at best only explains 39% of the variance in baseline 6MWT in the cohort of patients enrolled. Low BMI has been also linked to poor 6MWT performance\(^{(217)}\). However in this cohort 6MWT distance at baseline did not differ when the cohort was dichotomised too high and low BMI. This in part may be due to the small numbers of patients in the study. Also, it is acknowledged that BMI is a poor surrogate for fat free mass which is linked to sarcopenia and reduced exercise capacity\(^{(218)}\). The improvement in 6MWT distance compared to baseline following AOT was almost double that of air and greater than that shown in other
domiciliary studies (182, 188). This improvement although not statistically significant it is important to explore if it has any clinical relevance. Evidence from the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End Points) cohort suggests that the MCID (minimum clinically important difference) for 6MWT is 30metres and represents increased risk of death from exacerbations(219). Since some patients enrolled in the study improved by more than the MCID and the study population was smaller than intended at the outset, thus could be underpowered, it would be worthwhile to conduct a larger study to determine if the improvement is genuine or not.

Domestic activity is also reduced in patients with COPD. The results from the clinical study suggest that baseline activity in the enrolled participants was relatively low (median 238.3 VMU/min) with very little time spent doing moderate or vigorous activity. This is consistent with prior observational work in our local population(220) gathered as preliminary data prior to this trial. This study showed the patients with COPD spent a greater proportion of time sedentary and far less doing moderate to vigorous physical activity. A VMU of 290/min roughly equates to a walking speed on a treadmill of 1mph(221), which is significantly slower than in health (~4 mph). The reduced activity levels in the enrolled patients are consistent with a number of other studies (203, 220).

The study by Casburi et al (203) demonstrated physical activity was low VMU 108.9 (48.6) albeit in patients receiving LTOT therapy.

Domestic activity improved following oxygen treatment although this was not statistically significant. The trend to improved domestic activity with oxygen therapy was also demonstrated in a study by Sandland et al (166) which included heterogeneous COPD population of patients with EID (nadir ≤ 90%) and those on LTOT. Interestingly there was
not a significant change in home activity at the trial midpoints i.e. when participants were using either intervention. This again indicates that AOT usage did not encourage increased activity in this cohort of participants. At present no MCID for data derived from accelerometers has been established so the clinical relevance of the improved activity with oxygen in not clear. Interestingly however the correlation between home activity and 6MWT during oxygen treatment was strongly significant (Spearman’s Rho 0.751 p=0.005); a relationship that was not present at baseline nor following air treatment. This indicates firstly that the two variables correlate well, which one of the cited benefits of the 6MWT and secondly that the improvement in 6MWT with ambulatory oxygen is likely to be relevant as it may also have a clinically meaningful translation to home day to day activity.

In the future the measurement of physical activity in patients with COPD is likely to involve the use of structured questionnaires. Whilst accelerometers such as Actigraph have been well validated in this group of patients the ability of these devices to capture patients’ experience/perceptions of activity is doubtful. Patients often limit physical activity to avoid symptoms(222) and may find themselves modifying their lifestyle because of this. This important information would not be gleaned from an accelerometer alone and has led to the formation of two questionnaires; daily proactive physical activity in COPD and clinical proactive physical activity in COPD which have shown promise in terms of their validity and reliability.

Health related quality of life (HRQoL) and anxiety and depression were assessed using the CAT and HADs scores. The CAT and HADs are measured out of 40 and 28 respectively with higher scores indicating worse symptoms. There was a trend to improved scores
following ambulatory oxygen therapy, significant only for HADs. The CAT assessment has not been previously used in studies of domiciliary ambulatory oxygen therapy. Previous studies used CRQ(182, 184, 188) which encompass 4 domains; fatigue, dyspnoea, emotion and mastery. The results from the systematic review in chapter 3 show use of ambulatory oxygen in a domiciliary setting significantly improved dyspnoea and fatigue alone; p=0.002 and p=0.01 respectively. Although these were significant improvements neither were clinically relevant; both effect sizes falling below the MCID. The trend to improvement in CAT score in this study concurs with the above and not likely to be clinically relevant given the MCID estimated for CAT is 2 points(223).

This study suggests that ambulatory oxygen therapy has a greater effect on anxiety and depression compared to the functional impact of COPD symptoms. Anxiety and depression are common co-morbidities in COPD with prevalence ranging between 13-46%(224). Both are likely to adversely affect quality of life and treatment adherence(225) and as alluded to earlier depressive symptoms also detrimentally affect functional performance i.e. 6MWT. The management is multifaceted and involves use of anti-depressants, cognitive behavioural therapy and pulmonary rehabilitation. Here we show use of ambulatory oxygen influences anxiety and depression; significantly improved HADs score following treatment. Although there is no direct comparison, CRQ mastery and emotion scores which cover similar themes to HADs have shown a trend to improvement with oxygen use in studies of ambulatory oxygen therapy(182, 184) which supports this. Of note the HADs score also improved following air treatment. It is well recognised that many patient enrolled into clinical trials have improved quality of life even if randomised to placebo. This is in part due to the regular review visits patients undertake during a
clinical trial; in this case 6. However the role of “placebo” air is likely be important. The patient perception of oxygen in COPD is complex. Many patients see the use of oxygen therapy as a milestone of disease progression and are keen to avoid its use(226). Contrary to this the perception of oxygen therapy for some is that of a treatment which will improve dyspnoea, fatigue or help them do more(227). The perception that dyspnoea and hypoxia are interlinked and remedied solely by oxygen therapy seems to be a common view for some patients with COPD. From experience there is an intrinsic attachment to oxygen therapy when it is prescribed and there is some degree of anxiety if patients are told they no longer need it. It is highly plausible that placebo air would be more prone to this placebo effect given the above.

Systemic inflammation is thought to be a key component in COPD and implicated in the aetiology of SKMD as discussed in chapter 1. The cytokines measured in the study showed a differential response to ambulatory oxygen treatment. Plasma IL-6 and to some degree TNF α were reduced compared to baseline following oxygen treatment, with the reduction in plasma IL-6 reaching statistical significance although there was not a between group difference. Both TNF α and IL-6 are pro-inflammatory cytokines, recognised to be altered in COPD(228). TNF α signalling is mediated through two cell surface receptors (TNFR1 and TNFR2) whilst IL-6 classically via the IL-6 receptor(229-231). Both have been shown to activate the Nf-kB (nuclear factor Kappa B), which under normal conditions is present within the cytoplasm in an inactive state, bound to an inhibitory protein. Stimulation via either TNF α or IL-6 leads to an intracellular signalling cascade resulting IKK (inhibitor of kB kinase) phosphorylation of the Nf-kB/inhibitor complex which releases NF-kB to the nucleus of the cell. Here, NF-kB co-ordinates the
transcription of a number of chemokines, cytokines and ubiquitin proteasome pathway (UbP) leading to muscle atrophy(229). TNF α and IL-6 have been shown to cause muscle atrophy and impair myogenic differentiation in murine and in vitro studies(232, 233). Elevated levels of IL-6 have also been associated with radiological evidence of quadriceps wasting in COPD patients(141).

In contrast plasma IL-8 and IFN-g levels rose compared to baseline following oxygen treatment. The role of IFN-g in skeletal muscle signalling is not completely understood. Some studies have demonstrated that IFN-g is required for efficient skeletal muscle regeneration (234, 235). However in a murine model over expression of IFN-g at the neuromuscular junction caused a necrotizing myopathy (236). Muscle repair and differentiation occurs following a number of stimuli including exercise and is likely to have occurred during the trial period following episodes of exertion in the participant cohort. One would hypothesize that the elevated levels from baseline in both treatments (although not significant) represents this. IL-8 levels have been inversely correlated with quadriceps muscle strength albeit during exacerbations of COPD (140) and may also activate the NF kB pathway in the same way as TNF α and IL-6. Although plasma levels of IL8 rose during oxygen treatment, the rise was not significant.

There are a number of limitations to these results. Practice walks where not undertaken during the 6MWT. The standards for performing the 6MWT were published after patients were enrolled into the clinical trial. It is recognised that there is a learning effect when undertaking the 6MWT and this may have over inflated the benefits of oxygen therapy. Cylinder usage was low although mean usage however between the two treatments did not differ. This is consistent with previous data from local COPD patients showing that
activity levels were low (220), such that we feel the low usage of cylinders represents a true reflection of activity levels. The clinical trial was double blinded with cylinder flow rates were regulated at 2l/min. We accept that this may not have ameliorate EID in all participants. The cytokines measured were from the systemic circulation; changes in the systemic circulation may not directly represent those which occur at the muscle level and there is some evidence to suggest that this may be negligible (237). It is also likely the study was underpowered to detect differences in the clinical outcomes measured. Assessment of quadriceps strength is a notable omission from the study outcomes. This would have aided in the phenotyping of patients with skeletal muscle dysfunction and not just those with reduced exercise capacity. However we were limited in this by lack of the equipment to do this at our hospital enrolment and clinical site.

Conclusion

Ambulatory oxygen therapy use in patients with exertional hypoxaemia did not significantly alter functional exercise capacity, home physical activity which is low in this population of patients or quality of life. The reduction in plasma IL-6 from baseline would need to be investigated further however in this cohort of patients AOT did not reduce systemic inflammation. The low cylinder usage during the trial is likely a key mediating factor in all of these outcomes.
Chapter 5

Gene expression response to Ambulatory Oxygen and Air

This chapter outlines the gene expression results for the Ambulatory oxygen for muscles in COPD trial; the general and statistical methods of which are discussed in chapter 2. The results from chapter 4 suggest that AOT may have little effect on skeletal muscle gene expression given the lack of effect on clinical outcomes. Skeletal muscle biopsies were taken at trial enrolment (trial diagram, page 96) and at the end of each intervention with muscle biopsies undergoing transcriptomic analysis to explore differentially expressed genes during AOT and air treatment. Microarrays rather than target gene or protein analysis were used as it lends itself more to exploratory analysis when evaluating high through put gene expression changes. Differential gene expression was undertaken using the R Bioconductor platform. The microarrays experimental design was two channel meaning that each baseline sample of muscle was hybridised with an intervention sample i.e. baseline sample with sample following AOT. Using this design enabled a direct comparison of air vs AOT.

5.1 Demographic Data

Eight patients underwent muscle biopsy at all three time points; at baseline and following air or oxygen interventions. The remainder of the patients refused further biopsies stating pain or difficulty with ambulation as the main reasons. They were therefore excluded from the microarray data analyses.

The demographic data for the patients included in the gene expression analyses is shown in table 5.1
<table>
<thead>
<tr>
<th>Age (years)</th>
<th>67.13 (8.74)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M:F)</td>
<td>5:3</td>
</tr>
<tr>
<td>FEV1%</td>
<td>48.88 (26.2)</td>
</tr>
<tr>
<td>Baseline 6MWT (metres)</td>
<td>226.88(158.2)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>29.72(18.54-31.10)</td>
</tr>
<tr>
<td>O2 saturations at baseline (%)</td>
<td>93(1.4)</td>
</tr>
<tr>
<td>Nadir O2 saturations during 6MWT</td>
<td>84.6(4.0)</td>
</tr>
<tr>
<td>pH</td>
<td>7.4(0.01)</td>
</tr>
<tr>
<td>pCO2 (kPa)</td>
<td>5.5(0.45)</td>
</tr>
<tr>
<td>pO2 (kPa)</td>
<td>8.36(0.89)</td>
</tr>
<tr>
<td>HCO3 (mmol)</td>
<td>25.3(1.57)</td>
</tr>
<tr>
<td>CAT</td>
<td>29.5 (5.5)</td>
</tr>
<tr>
<td>HAD</td>
<td>18.75(5)</td>
</tr>
<tr>
<td>Activity (VMU/min)</td>
<td>226.18(65.4)</td>
</tr>
<tr>
<td>TNFα pg/ml</td>
<td>0.55(0.17)</td>
</tr>
<tr>
<td>IL-6 pg/ml</td>
<td>29.93(22.1)</td>
</tr>
<tr>
<td>IL-8 pg/ml</td>
<td>6.25(3.7)</td>
</tr>
<tr>
<td>IFGγ pg/ml</td>
<td>187.5(77.8)</td>
</tr>
</tbody>
</table>

Mean (SD), median (25th -75th Centile)

Table 5.1: Demographic data for patients included in gene expression data analysis.

5.2 Microarray Quality Assessment

Array data quality can be affected during the experimental process. When analysing arrays together the quality of each individual array needs to be assessed. The quality of microarray data was assessed using the “arrayQualityMetrics”(238) in Bioconductor.
This package enables each individual microarray to be evaluated separately and in conjunction with the other microarrays to detect arrays where which the data quality may have been subject to errors during the experimental process, e.g. hybridisation or dye labelling. This can take the form of boxplots (representing summaries of the signal intensity distributions of the arrays, figure 5.1) or a heatmap (representing the distance between arrays, figure 5.2). The detected arrays are outliers and if used may compromise the accuracy of final output gene expression data.

Figure 5.1 Box plot of individual normalised microarray data (log2 Ratio of red and Green channels). The microarray for 9BaselineTreatmentA was identified as an outlier.
Outlier detection was performed by looking for arrays for which the sum of the distances to all other arrays was exceptionally large. In this analysis array 5 (corresponding to patient 9 Baseline treatment (A)) was identified as an outlier.

Patient 9’s microarray data was therefore excluded from analysis as it failed both quality metrics.

5.3 Gene Expression

Microarray data pre-processing (discussed in chapter 2.4 methods) was performed prior to differential gene expression. Differential gene expression during ambulatory oxygen and air treatments was explored using the Significance Analysis of Microarrays (SAM) (240) in R. The SAM package allocates a score to each gene on the basis of change
in gene expression relative to the standard deviation of repeated measurements. In cases where genes with scores greater than an adjustable threshold occur SAM uses permutations of the repeated measurements to estimate the percentage of genes identified by chance (false discovery rate, q value). A two-class paired analysis (i.e. comparing oxygen vs. treatment in the same patients) was undertaken.

At a single gene level differential expression between ambulatory oxygen and air was not detectable.

Since differential expression at a single gene level was not detectable, for the purpose of gene set enrichment analyses (GSEA) all genes that were up or down regulated during each intervention period were extracted. A pre-ranked gene list based on the SAM score was then used for GSEA in the web based program BROAD(241, 242). The SAM score was chosen over fold change for the formation of the pre-ranked list. Although fold change analysis may yield more reproducible gene expression data(243, 244) it does not take into account the variance of the expression values measured. The SAM score compares the difference in mean expression levels between two groups also taking into account the variability of the data not only from the gene tested, but also from other genes exhibiting a similar degree of change(245). This results in more accurate inference of gene expression change when the number of replicates is small(246).

11,479 genes were identified (gene list of top 400 genes in appendix 3 for GSEA. Positive values correspond to genes up-regulated during Treatment period A (Air) whilst negative values correspond to up-regulated genes during Treatment Period B (Ambulatory oxygen).
5.3.0 Gene Set Enrichment Analysis (GSEA)

GSEA was performed using the web based program BROAD Institute(241, 242). GSEA is a computation method that determines whether a priori set of genes show significant differences between two biological or phenotypic states. Genes are ranked based on their correlation between their expression and in this case the biological states or air and AOT. The aim of GSEA is to determine whether the genes are randomly distributed or are dichotomised to the top or bottom of the list. The latter occurs in genes which demonstrate biological or phenotypic distinction. GSEA has 3 core processes which are used to derive its results; enrichment score calculation, estimating the significance of enrichment scores and adjustment for multiple hypothesis testing(241, 242).

Enrichment Score

“The enrichment score (ES) determines the degree to which a gene set is represented at the extremes of a ranked list”. The calculation is made by walking down the list increasing a running sum statistic (magnitude depending on correlation between gene and phenotype) when the gene is encountered in the set or decreasing it when it not encountered (241, 242). Thus scores which are highly negative or positive are likely to demonstrate highly represented gene sets.

Significance of Enrichment Score

The statistical significance of enrichment score is based on an empirical phenotype based permutation test. A null distribution for the enrichment score is generated by permuting data for the phenotypes i.e. oxygen versus air and computing the enrichment score of the gene sets for this data. “The statistical significance of the observed score is then calculated relative to the null distribution”(241, 242).
Adjustment for multiple testing.

The enrichment score for each gene set is normalised (NES) to account for the size of the set.

\[
NES = \frac{\text{actual ES}}{\text{Mean (ESs against all permutations of dataset)}}
\]

The false discovery rate (FDR) is then calculated for each NES. The FDR is the estimated probability that a gene set with a given NES signifies a false positive finding (241).

The gene sets used in the analyses were derived from the Kyoto Encyclopaedia of genes and genomes (KEGG) which are a manually curated list of genes. These KEGG pathways indicate current knowledge of molecular interactions or networks for various metabolic and cellular processes. The output from BROAD indicate which gene sets for individual KEGG pathways were up or down-regulated for the phenotypes (air versus oxygen) when the pre ranked list of identified genes were used (appendix 3). Disease specific pathways were removed from the KEGG analysis to optimise biological interpretability of the results. To undertake GSEA using Broad, KEGG version 5.0 was used as the gene set database, collapse data set option was set to false as the up/down regulated probes had already been annotated with gene symbols as part of the pre-processing (chapter 2.4) and the weighted scoring system for enrichment was applied.
### 5.3.1 GSEA Results

The results of the GSEA analysis using KEGG pathways are shown in table 5.2a and 5.2b.

<table>
<thead>
<tr>
<th>KEGG pathway</th>
<th>Size of Gene Set</th>
<th>ES</th>
<th>NES</th>
<th>FDR q value</th>
</tr>
</thead>
<tbody>
<tr>
<td>RIBOSOME</td>
<td>82</td>
<td>-0.75</td>
<td>-3.62</td>
<td>0</td>
</tr>
<tr>
<td>OXIDATIVE_PHOSPHORYLATION</td>
<td>117</td>
<td>-0.58</td>
<td>-2.96</td>
<td>0</td>
</tr>
<tr>
<td>PROTEASOME</td>
<td>42</td>
<td>-0.67</td>
<td>-2.78</td>
<td>0</td>
</tr>
<tr>
<td>SPLICEOSOME</td>
<td>104</td>
<td>-0.51</td>
<td>-2.57</td>
<td>0</td>
</tr>
<tr>
<td>PROPANOATE_METABOLISM</td>
<td>28</td>
<td>-0.66</td>
<td>-2.49</td>
<td>0</td>
</tr>
<tr>
<td>AMINOACYL_TRNA BIOSYNTHESIS</td>
<td>27</td>
<td>-0.64</td>
<td>-2.42</td>
<td>0</td>
</tr>
<tr>
<td>FATTY_ACID_METABOLISM</td>
<td>34</td>
<td>-0.62</td>
<td>-2.40</td>
<td>0</td>
</tr>
<tr>
<td>RNA_DEGRADATION</td>
<td>41</td>
<td>-0.58</td>
<td>-2.36</td>
<td>0</td>
</tr>
<tr>
<td>UBIQUITIN_MEDIATED_PROTEOLYSIS</td>
<td>96</td>
<td>-0.48</td>
<td>-2.36</td>
<td>0</td>
</tr>
<tr>
<td>VASOPRESSIN_REGULATED_WATER_REABSORPTION</td>
<td>32</td>
<td>-0.59</td>
<td>-2.31</td>
<td>1.62E-04</td>
</tr>
<tr>
<td>FOCAL_ADHESION</td>
<td>160</td>
<td>-0.41</td>
<td>-2.19</td>
<td>1.52E-04</td>
</tr>
<tr>
<td>PYRUVATE_METABOLISM</td>
<td>34</td>
<td>-0.56</td>
<td>-2.18</td>
<td>2.58E-04</td>
</tr>
<tr>
<td>ADHERENS_JUNCTION</td>
<td>57</td>
<td>-0.48</td>
<td>-2.17</td>
<td>2.44E-04</td>
</tr>
<tr>
<td>NEUROTROPHIN_SIGNALING_PATHWAY</td>
<td>100</td>
<td>-0.42</td>
<td>-2.10</td>
<td>6.80E-04</td>
</tr>
<tr>
<td>ANTIGEN_PROCESSING_AND_PRESENTATION</td>
<td>64</td>
<td>-0.46</td>
<td>-2.10</td>
<td>6.46E-04</td>
</tr>
<tr>
<td>VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION</td>
<td>37</td>
<td>-0.52</td>
<td>-2.10</td>
<td>6.16E-04</td>
</tr>
<tr>
<td>INSULIN_SIGNALING_PATHWAY</td>
<td>114</td>
<td>-0.40</td>
<td>-2.07</td>
<td>0.001261</td>
</tr>
<tr>
<td>LYSOSOME</td>
<td>90</td>
<td>-0.42</td>
<td>-2.01</td>
<td>0.001882</td>
</tr>
<tr>
<td>CITRATE_CYCLE_TCA_CYCLE</td>
<td>26</td>
<td>-0.55</td>
<td>-2.01</td>
<td>0.001814</td>
</tr>
<tr>
<td>NUCLEOTIDE_EXCISION_REPAIR</td>
<td>36</td>
<td>-0.49</td>
<td>-1.96</td>
<td>0.002849</td>
</tr>
<tr>
<td>GLYCOLYSIS_GLUCONEOGENESIS</td>
<td>50</td>
<td>-0.45</td>
<td>-1.93</td>
<td>0.003951</td>
</tr>
</tbody>
</table>
Table 5.2a Enriched KEGG pathways up-regulated during ambulatory oxygen treatment

<table>
<thead>
<tr>
<th>KEGG pathway</th>
<th>Size of Gene Set</th>
<th>ES</th>
<th>NES</th>
<th>FDR q value</th>
</tr>
</thead>
<tbody>
<tr>
<td>OLFACTORY_TRANSDUCTION</td>
<td>125</td>
<td>0.27574</td>
<td>2.04</td>
<td>0.01992</td>
</tr>
</tbody>
</table>

Table 5.2b Enriched KEGG pathway up-regulated during air treatment.

Enrichment plots for the top two KEGG pathways up-regulated during ambulatory oxygen treatment and the KEGG pathway up-regulated during air treatment are shown below (figures 5.3a-5.3c).
Figure 5.3a. Enrichment plot for KEGG ribosome pathway

The enrichment plot for the ribosome pathway shows the primary genes involved towards the bottom end of the list. The enrichment score is the furthest deviation from zero shown here at the lowest point of the plot; score -0.75 (scale -1 to 1). The “leading edge subset” of a gene set are the genes which contribute most to the enrichment score. The rank at max is a metric which measures a gene's correlation with a particular phenotype, in this case AOT and is the position in the ranked list at which the maximum enrichment score was achieved.
Figure 5.3b Enrichment plot for KEGG oxidative phosphorylation; up-regulated during oxygen treatment.
The rank at max in this enrichment plot corresponds to the positive genes in the set (during air treatment). In contrast to the leading edge subsets in figures 5.3a-b the subset in this enrichment plot is broad and not concentrated at either end ranking generally indicating a poorly represented gene set.
The enrichment plots for both Ribosome and Oxidative phosphorylation show gene set correlations towards the bottom of the list with a relatively tightly packed leading edge subset; particularly in the case of KEGG ribosome. Both have relatively high enrichment scores (max -1 to 1). In contrast the KEGG pathway of olfactory transduction; although significant has low enrichment score with its leading edge genes distributed throughout the list.

27 KEGG pathways met the FDR<1% cut off. 26 enriched pathways were up-regulated during oxygen treatment whilst only 1 KEGG pathway was up-regulated during air treatment (table 5.3b). The enriched KEGG pathways up-regulated during ambulatory oxygen treatment could be clustered into three functional groups; mitochondrial bioenergetics, protein turnover and metabolic pathways (figure 5.4).

Figure 5.4: Functional grouping for KEGG pathways upregulated during oxygen treatment.
The mitochondrial bioenergetic pathway of oxidative phosphorylation (OXPHOS) was chosen for further examination due to (a) its biological relevance and (b) being in the top two enriched pathways. A correlation based analysis was conducted with the patient clinical outcome data using principal components as described below.

5.4 Principal component analysis

Principal component analysis is a data reduction technique. Using a mathematical algorithm it reduces the dimensionality of a data set whilst retaining as much of the possible variation within it. It accomplishes this by identifying the directions (principal components) in which the variation in the data is maximal. When applied to microarray data it can be used to perform cluster gene analysis, find dominant patterns of gene expression or to summarise transcriptional activity of a “gene set”. Here it has been used to summarise the transcriptional activity of the KEGG oxidative phosphorylation pathway. This was achieved by using the “prcomp” function in R (239) taking the normalised microarray data and genes from the leading edge subset of the OXPHOS pathway to compute the first principal component.
The red vertical line shows the cut off for the component that accounts for the most variance; the first principal component retained 86% of the variance. This indicates that the transcriptional state of the involved genes in the OXPHOS pathway can be summarised by this variable. The diagram below is a biplot (fig 5.6); a visual representation of the two principal components, microarray observations and the OXPHOS genes as vectors (red). The first principal component (PC) is in the horizontal axis and second component on the vertical axis. The genes involved are predominantly moving along the horizontal axis (1st PC) highlighting again that the 1st PC account for the majority of the variance.
Figure 5.6: Biplot of OXPHOS gene and principal components.

The biplot can also be used to analyse which patients (microarray observations) demonstrated a response to treatment in line with the summarised OXPHOS pathway. The major transcriptional direction of vector (genes) is from right to left. Each patient has two microarray observations on the biplot corresponding to Treatment A (Air) and B (oxygen). The patients where whom their “B” observations lie to the left of the “A” indicate a greater transcriptional change occurred during oxygen treatment. This suggests that there were 4 responders (subjects 7, 18, 20, 24) and 3 non responders (subjects 3, 10 and 13) to ambulatory oxygen therapy. This is also evident from the heatmap of the gene enriched the OXPHOS pathway (figure 5.7). Analysis of baseline
characteristics between these two groups did not demonstrate any significant differences between lung function, age, BMI or systemic inflammation (p>0.05).
Figure 5.7 Heatmap of genes enriched in OXPHOS pathway: Patient arrays horizontal and genes listed vertically.

Red indicates increased expression, blue reduced expression and white mean.
A correlation based analysis using Spearman’s Rank was undertaken between transcriptional activity of the OXPHOS pathway and patient clinical outcomes (table 5.3a) for those who underwent muscle biopsies. Pearson’s correlation test (adjusted for age and FEV1%) was used to assess the strength of the relationship between transcriptional activity and clinical data with one tailed hypothesis significance testing.

The results are shown in table 5.3b below.
Table 5.3a: Clinical outcome data for trial patients whom underwent muscle biopsies. Results shown are change from trial enrolment baseline for each clinical variable in each of the subjects.

<table>
<thead>
<tr>
<th>Subject</th>
<th>Δ6MWT</th>
<th>ΔCAT</th>
<th>ΔHAD</th>
<th>ΔIL-6pg/ml</th>
<th>ΔIFN-γ pg/ml</th>
<th>ΔIL-8pg/ml</th>
<th>ΔTNF-α pg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Air</td>
<td>O₂</td>
<td>Air</td>
<td>O₂</td>
<td>Air</td>
<td>O₂</td>
<td>Air</td>
</tr>
<tr>
<td>3</td>
<td>38</td>
<td>167</td>
<td>-9</td>
<td>-5</td>
<td>-2.43</td>
<td>-0.19</td>
<td>2.27</td>
</tr>
<tr>
<td></td>
<td>O₂</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-0.07</td>
</tr>
<tr>
<td>7</td>
<td>0</td>
<td>199</td>
<td>8</td>
<td>0</td>
<td>-12.21</td>
<td>-49.69</td>
<td>3.15</td>
</tr>
<tr>
<td></td>
<td>O₂</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.03</td>
</tr>
<tr>
<td>10</td>
<td>97</td>
<td>93</td>
<td>-4</td>
<td>-4</td>
<td>-5</td>
<td>-6</td>
<td>7.96</td>
</tr>
<tr>
<td></td>
<td>O₂</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>135.95</td>
</tr>
<tr>
<td>13</td>
<td>-9</td>
<td>73</td>
<td>4</td>
<td>0</td>
<td>-3</td>
<td>-8</td>
<td>-5.91</td>
</tr>
<tr>
<td></td>
<td>O₂</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>18.15</td>
</tr>
<tr>
<td>18</td>
<td>-60</td>
<td>-54</td>
<td>1</td>
<td>-1</td>
<td>0</td>
<td>3</td>
<td>27.90</td>
</tr>
<tr>
<td></td>
<td>O₂</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>198.29</td>
</tr>
<tr>
<td>20</td>
<td>65</td>
<td>66</td>
<td>7</td>
<td>2</td>
<td>-1</td>
<td>-4</td>
<td>4.25</td>
</tr>
<tr>
<td></td>
<td>O₂</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>93.32</td>
</tr>
<tr>
<td>24</td>
<td>39</td>
<td>78</td>
<td>0</td>
<td>-8</td>
<td>-6</td>
<td>-6</td>
<td>4.22</td>
</tr>
<tr>
<td></td>
<td>O₂</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-64.36</td>
</tr>
</tbody>
</table>

Table 5.3a: Clinical outcome data for trial patients whom underwent muscle biopsies. Results shown are change from trial enrolment baseline for each clinical variable in each of the subjects.
Table 5.3b: Correlation of OXPHOS pathway and patient clinical data using Spearman’s Rank.

<table>
<thead>
<tr>
<th>Clinical outcome</th>
<th>Oxygen r</th>
<th>p value</th>
<th>Air r</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>6MWT</td>
<td>0.75</td>
<td>p=0.07</td>
<td>-0.70</td>
<td>p=0.09</td>
</tr>
<tr>
<td>CAT</td>
<td>0.50</td>
<td>p=0.20</td>
<td>0.18</td>
<td>p=0.38</td>
</tr>
<tr>
<td>HAD</td>
<td>0.60</td>
<td>p=0.14</td>
<td>0.64</td>
<td>p=0.12</td>
</tr>
<tr>
<td>Il-6</td>
<td>-0.81</td>
<td>p=0.05</td>
<td>0.42</td>
<td>p=0.24</td>
</tr>
<tr>
<td>Il-8</td>
<td>0.15</td>
<td>p=0.41</td>
<td>0.28</td>
<td>p=0.32</td>
</tr>
<tr>
<td>IFNγ</td>
<td>-0.36</td>
<td>p=0.27</td>
<td>0.25</td>
<td>p=0.35</td>
</tr>
</tbody>
</table>

The strongest correlation between clinical variables and transcriptional activity of OXPHOS pathway was IL-6 during ambulatory oxygen treatment; showing a significant inverse relationship, p=0.05. 6MWT and OXPHOS activity showed a strong relationship during both treatments; strongly positively correlated during oxygen treatment and a strong inverse relationship during air treatment.

A hypothetical interaction between selected genes contributing to KEGG pathways, KEGGS pathways, cytokine and clinical outcomes is shown in figure 5.8.
Figure 5.8 Interaction between KEGG pathways, genes and clinical data.
5.5 Discussion

This work has shown that although differential expression at single gene level is absent, GSEA demonstrates important up-regulated pathways involving aspects of mitochondrial function which accompanied ambulatory oxygen treatment. Skeletal muscle mitochondrial function has been shown to be abnormal in COPD, with respect to both reduced mitochondrial density and biogenesis (139, 247). Mitochondria are the main producers of ATP via the Tricarboxylic acid cycle (TCA) and OXPHOS and constitute one of the main producers of reactive oxygen species (ROS), which activate pathways leading to cell apoptosis (118, 248). Thus, defects in mitochondrial function will adversely affect both energy production and cell death. The results from our analysis indicate that hypoxia maybe contributing to the abnormal mitochondrial function in the studied patients. Furthermore a previous study (153) which used a systems biology approach to elucidate the potential drivers for skeletal muscle abnormalities found that at an individual gene level a number of histone deacetylase enzymes could discriminate between healthy and diseased muscle; all of which correlated with oxygen utilization.

Under hypoxemic conditions hypoxia inducible factor alpha (HIF-α) is up-regulated due to reduced protein degradation by the von Hippel Lindau Protein (249). HIF-α has been shown to suppress the peroxisome proliferator activator receptor (PPAR) pathway (250), one the key exponents of mitochondrial oxidative metabolism. Activation of PGC1-α (peroxisome proliferator activator receptor γ cofactor α) up-regulates genes involved in the TCA cycle and OXPHOS via nuclear respiratory factors 1 and 2. (251). Both OXPHOS and TCA are oxygen dependent and were significantly up-regulated during oxygen treatment compared to that of air in the KEGG pathway GSEA analysis. This is in line with
other studies which have used biomarkers of TCA and OXPHOS function; citrate synthase and complex III respectively to show these are reduced during hypoxia (252, 253). The enriched pathways during AOT could be manually separated into three functional groups (figure 5.4) there is a degree of overlap between groups 1 and 2. For example, in beta oxidation a component of fatty acid metabolism generates acetyl-coA and NADPH (nicotinamide adenine dinucleotide phosphate) which enters the TCA cycle and electron transport chain respectively (254). Evidence from both human and murine studies suggests that there is a tendency for beta oxidation to be reduced following hypoxic stimuli and as a consequence reducing mitochondrial energy production (253, 255). The last functional group of protein turnover indicate that both pathways of protein synthesis and protein degradation were significantly up-regulated during oxygen treatment. Whilst protein synthesis is important in gaining muscle mass it is interesting that the ubiquitin proteasome pathway (UbP) is also up-regulated. This is the key proteolytic pathway which underpins muscle atrophy. Cross sectional studies have shown markers of the UbP, specifically MuRF1 (muscle ring finger protein) and Atrogin 1, to be elevated in COPD patients with low muscle mass compared to controls (127). The up-regulation of both pathways during oxygen treatment suggests that muscle mass homeostasis is tightly regulated and the genes involved in this process are differentially affected by hypoxia. Alternatively, it is possible that fibre type-specific changes—atrophy in Type II and maintenance in Type I – produce simultaneous up-regulation in both protein synthesis and degradation genes. The only KEGG pathway up-regulated during air treatment to the FDR threshold of <1% was olfactory transduction. The reasons for this pathway being up-regulated are not clear. It has no relationship to muscle function or mitochondrial energy production.
The correlations between OXPHOS transcriptional activity and clinical data were generally strongest during AOT. The significant inverse relationship between IL-6 and OXPHOS is interesting. This suggests that the cellular process of OXPHOS is deleteriously affected by increasing levels of IL-6. Given that, IL-6 was also significantly reduced compared to baseline during AOT, the relationship between inflammation (especially this cytokine) and impaired cellular mitochondrial process seem highly plausible. A previous study also demonstrated a significant relationship between systemic inflammation and the expression of energy metabolism genes in skeletal muscle from COPD patients, where CXCL10 and CXCL9 were significantly inversely correlated to the OXPHOS and TCA pathways (256). Van den Burst et al (257) previously demonstrated a relationship between loss of muscle oxidative phenotype and reduced endurance in patients with COPD. This is supported by the correlations we observed between functional exercise capacity and OXPHOS transcriptional activity during both treatments. During the air treatment phase i.e. “control arm” an inverse relationship was noted suggesting that continued hypoxia during exertion had a negative impact on OXPHOS. The reverse was true during AOT.

There are a number of limitations to these results. Primarily, the sample size used for the microarray data analysis was small. Only 8 of the 17 patients underwent muscle biopsies that could be used in the microarray data analysis at all-time points, due to the unavoidable factor of patient refusal. Overall recruitment to the trial was extended to account for dropouts, but due to time and funding constraints no additional amendments to extend recruitment and account for these refusals could be justified, given that the number who might be needed was not known. This is because no formal power
calculations were undertaken, as the exploratory endpoint of change in gene expression had never been measured previously with respect to treatment with oxygen therapy. Nevertheless previous studies using gene expression in muscle as an endpoint have demonstrated differences with a few as 10 patients (173), hence why a pilot of this size was justifiable. Analysis of the participants who completed muscle biopsy compared to those who continued in the trial with secondary outcome data show that they do not differ significantly with respect to age p=0.91, FEV1% p=0.85, baseline 6MWT p=0.92 , oxygen saturations p=0.2, desaturation nadir p=0.34 or baseline BMI p=0.88. Therefore, although the dropout rate from was higher than expected the sample included was representative of all trial participants. The correlation gene expression analyses were single tailed which can lead to inaccurate of biased results. Nevertheless, the associations demonstrated have been supported by previous literature(256, 257) and thus warrant further investigation.

Gene set enrichment analysis was performed on the resulting microarray gene results as, after correcting for multiple hypotheses testing, no individual gene met the threshold for statistical significance. GSEA is useful in this context as small changes in a number of genes encoding the same pathway may have more biological relevance to a cellular process than a single gene(241) especially if the changes in the studied biological system are subtle. GSEA is a robust and commonly used tool to further explore microarray data in the presence or absence of identified genes.

Conclusion
Ambulatory oxygen treatment did not result in detectable statistically differentially expressed genes after correction for multiple hypotheses testing. Although differential expression was undetectable, GSEA analysis revealed important pathways of mitochondrial bioenergetics that were up-regulated in muscle following ambulatory oxygen treatment suggesting that intermittent hypoxia is likely to be contributing to abnormal mitochondrial function in these patients. In addition, use of computational analysis revealed a significant inverse relationship between levels of inflammation and oxidative phosphorylation suggesting a potential link between systemic inflammation and aberrant mitochondrial function. Analyses were limited by the size of the population studied and their relative inactivity, such that periods of hypoxia due to activity may have been infrequent and short in duration.
Chapter 6 Discussion Summary

6.1 Summary of Results

This thesis concerns the role of ambulatory oxygen in patients with COPD and exercise induced desaturation. It specifically assesses its clinical efficacy with regard to exercise capacity, quality of life, clinical device efficacy and effect on skeletal muscle gene expression via the randomised clinical trial: detailed in chapter 4.

6.2 Clinical efficacy

Ten studies including OM COPD evaluated the role of AOT to improve exercise capacity. The modality of the exercise test and the context in which the test were carried out varied. Five of the studies were supervised; associated with a structured exercise program, whereas the rest were domiciliary with instructions given to patients when to use AOT. It is therefore important to understand that due to the heterogeneity of the studies included firm conclusions with regard to AOT clinical efficacy may be limited. Functional exercise capacity was measured by 6MWT in the majority of studies which did not use endurances tests. In both supervised PR and domiciliary studies AOT had limited benefit of improving 6MWT with all studies bar the OM COPD favouring control. The latter study showed a non-significant improvement in 6MWT with AOT, which may have clinical relevance in patients with COPD and EID in relation to mortality from hospitalisation. The magnitude of improvement in functional exercise capacity was far greater in the supervised studies than domiciliary. Clearly the impact of structured physical exercise programs and the subsequent physiological adaptation gained from
exercise is superior to any benefit gained from AOT. All of the endurance test studies or
constant work rate tests were supervised. Collectively they demonstrate that AOT is
likely to have benefit in improving endurance/time exercised if judged by this modality
with all studies favouring the AOT mirrored also in the meta-analyses (chapter 3). These
observations taken together suggest either there are different mechanism by which AOT
affects these different tests or endurance tests are more sensitive to therapies such as
AOT or both. The main postulated mechanisms for AOT efficacy are to reduce carotid
body activation and cause a subsequent reduction in respiratory rate. Since dyspnoea is a
limitation to exercise tolerance in patients with COPD, a reduction in respiratory rate and
sensation of dyspnoea is likely to improve exercise capacity. A reduction in dynamic
inflation has also been observed in one study(72). A number of studies have shown that
endurance test are more responsive to interventions than the 6MWT when bronchodilators have been used(258). Given that bronchodilators reduce hyperinflation
in a similar mechanistic fashion to AOT it seems highly plausible that endurance test
should respond better to AOT than the 6MWT(258). The design of the exercise tests are
also very different. The 6MWT is self paced while endurance tests such as ESWT are
externally paced (calculated from an externally paced incremental shuttle walk).
Evidence suggests that the cardiorespiratory response in patients with COPD differ when
either test is undertaken. During endurance tests heart rate, minute ventilation and
respiratory rate increase close to maximal levels whereas these three indices are sub-
 maximal during a 6MWT. One could hypothesize that any treatment which reduces
dynamic hyperinflation is unlikely to demonstrate benefit if the test used causes a sub-
 maximal response especially in respiratory rate and minute ventilation and therefore
unlikely to evoke a “hyperinflation” physiological threshold.
The Chronic respiratory disease questionnaire (CRQ), HADs and CAT examined the impact of AOT on HRQoL. In both supervised PR and domiciliary studies AOT demonstrated statistically significant benefit over control when the CRQ was used. The CRQ covers themes such as anxiety, physical function and breathlessness. The OM COPD trial described in chapter 4 used the HAD and CAT which when combined cover similar areas to the CRQ. Whilst a statistically significant improvement in HADs score was noted after AOT occurred, a marked improvement in the control arm also occurred, a phenomenon often seen in the placebo arm of clinical trials. Despite the statistical improvement in both CRQ and HAD, the clinical relevance is doubtful as all the improvement s in CRQ fall below the MCID and no MCID for HADs has been established. What is clear from the results is that AOT seems to give patients the perception that they are less breathless and more in control of their disease. The perception of dyspnoea in COPD is complex, with a number of bio-pyschological factors involved. The apparent benefit in HRQoL may come from a number of altered perceptions of safety, symptom relief, possible placebo effect and motivational factors.

6.3 Device Efficacy

The results from chapter 3 indicate that whilst there is considerable variation in OCDs devices their performance is superior to CFNC in maintaining exercise saturations and 6MWT. The OCDs achieve these outcomes at much lower oxygen utilization than CFNC. This is likely to have implications in terms of oxygen cylinder usage and subsequent cost as although initial outlay for OCDs is higher the longer term benefit of lower oxygen utilisation will more than recoup this. It is important that the choice of OCDs is tailored
to the individual taking into account whether they are predominately mouth or nasal breathers as the effort of ambulation or exercise increases. Since most of the OCDs are triggered by nasal inspiratory flow a change to mouth breathing during increased effort would render these OCDs less useful and cause desaturation to the user.

6.4 Changes in Skeletal Muscle gene expression

There is a wealth of data to suggest that skeletal muscle in patients with COPD differs to controls with respect to reduction in proportion of type 1 fibres(152), abnormal mitochondrial density(133), increased oxidative stress and loss of oxidative phosphorylation phenotype(257). The difficulty has been in trying to determine the main driver to these alterations. Hypoxia is implicated in its pathogenesis. The pilot clinical trial (chapter 4) investigated the role of oxygen supplementation during activity in patients with COPD and exercise induced desaturation. The hypothesis was that peripheral muscle hypoxia is increased specifically in these patients on exertion especially in those with low activity levels. Administration of AOT would either encourage participants to be more active and via activity have a favourable effect on gene expression or have a direct effect on muscle in its own right. Unfortunately at a single gene level there was no detectable difference in gene expression between AOT or air treatment. The study aimed to recruit 25 participants however there was a high dropout rate due to many participants not being able to tolerate serial muscle biopsies. Although it is unlikely given the results from chapter 4&5 that AOT directly impacts on muscle results may have been more favourable had it been the total number recruited were involved in the gene expression analysis. In addition, participant activity was low and did not change significantly during the trial indicating that AOT did not encourage
participants to become more active. Furthermore, linked to low activity was low cylinder usage during the trial period; equating to roughly 30mins per day. Given both the low activity and cylinder usage it is not surprising that no gene or cytokine changes were demonstrated. Participants were given clear instructions on when and how to use cylinders, however a more detailed discussion prior to trial enrolment on the merits and rationale for usage should have been undertaken. Other reasons for absence of detectable change in gene expression have been discussed in section 4.2.5.

The results of the GSEA demonstrate upregulation of multiple mitochondrial and cell homeostasis pathways during AOT. Given that these pathways were not upregulated during air treatment the attenuation of hypoxia during exertion would seem to be contributing to these changes. The study by Turan et al(153) also suggested hypoxia as the cause for the abnormal response in COPD muscles with an underlying epigenetic mechanism. They were able to show that the expression of a number of oxygen correlated histone modifiers could discriminate between healthy and COPD muscle; sirtuins and histone deacetylases. Hypoxia can lead to an altered redox state which has been shown to be abnormal in COPD (154, 259). Sirtuins are NAD⁺ dependent deacetylases and their activity especially SIRT1 and SIRT3 are sensitive to changes in NAD⁺ to NAD⁺/NADH ratio which is adversely affected by hypoxia. Enhanced SIRT activity, namely SIRT3 is associated with improved mitochondrial function and exercise performance. Murine studies of mice lacking SIRT3 show abnormalities of a number of mitochondrial proteins associated with impaired electron transport chain activity and fatty acid metabolism(260). Indeed the transcriptional correlation analysis showed strongly positive correlation between OXPHOS and 6MWT during AOT almost reaching
statistical significance with the converse was true during air treatment. Collectively one could speculate would suggest that hypoxia is implicated in the altered muscle gene expression and regulation causing abnormal mitochondrial function indicated by the results of the GSEA.

The results from chapter 4 showed that IL-6 was the only cytokine which demonstrated significant change during the clinical trial with reduction in plasma IL-6 during AOT compared to baseline values albeit with no between group differences. The transcriptional correlation analysis also showed a significant inverse relationship between plasma IL-6 and the mitochondrial OXPHOS pathway suggesting that lower IL-6 levels confer enhanced OXPHOS activity. The role of IL-6 on muscle biology is complex with a few studies showing both pro-myogenic and atrophic effects of the cytokine(261). Exercise especially endurance or eccentric causes acute inflammation within skeletal muscle and studies have shown that IL-6, IL-6 mRNA rise dramatically during acute exercise(262). The adaptations noted following regular exercise lead to reduction of oxidative damage and improved mitochondrial biogenesis (largely mediated by PCG-1α). Thus to adapt appropriately episode of acute inflammation during exercise are required. Regular exercise may reduce basal IL-6 levels and also the magnitude of response to IL-6 and the efficiency of the bioenergetic changes(262). Whilst acute changes seem to be beneficial, murine studies have shown that IL-6 over expression can cause mitochondrial dysfunction (263) a process which can be rectified with physical activity. A number of epidemiological studies have also shown a negative relationship between physical activity and IL-6 levels. Therefore it is possible that the use of AOT ameliorates basal IL-6 levels akin to exercise in the cohort of patients in the study.
6.5 Future Work

6.5.0 Ambulatory oxygen Efficacy

The clinical efficacy of AOT in improving exercise capacity is largely dependent on the exercise test modality chosen. The evidence suggests that AOT use does result in statistically significant improvements in endurance or constant work rate exercise tests. The results from the systematic review would have been useful to inform the exercise modality chosen in the clinical trial (chapter 4). Although this thesis via the clinical trial adds to the evidence that AOT has limited role in statistically improving 6MWT, the effect of AOT would have been better assessed by an endurance shuttle walk test which would have been achievable at the trial site. If the 6MWT was to be used in future to assess the longer terms benefits of AOT any future trial should only enrol acute responders; i.e. participants with 10% improvement in 6MWT following AOT use.

6.5.1 Inflammatory response to AOT

Inflammation is one of the hypothesized aetiological factors in abnormal muscle function predominantly via NfkB activation. The inflammatory response can either be systemic or local. It is highly plausible that changes in systemic inflammation may not reflect those at the muscle level and may indicate a different mechanism. The OM COPD trial did demonstrate a significant reduction in plasma IL-6. It is unclear whether muscle IL-6 mRNA would show a similar pattern. It would be important to assess both local and systemic inflammation in future studies. Systemic inflammation could be assessed as
described in chapter 2 whilst local inflammation assessed by extracting RNA from muscle subsequently using the appropriate probes and primers to quantify this.

6.5.2 Gene Expression

The pilot study of AOT effect on skeletal muscle gene expression has given some insight to how its use may perturb some of the deleterious changes observed in COPD patients. Since this study was small and recruitment falling short of target the number of participant included in a future similar would need to be significantly larger. Data from previous studies(173, 264) indicate that between 200 and 1100 genes maybe differentially expressed in exercise in COPD patients or those with reduced fat free mass. Assuming approximately 18000 are not differentially expressed genes, 0.9 power to detect a fold change of 2 between treatments and an anticipated standard deviation of 0.6 (matched pair design) (265) a sample size of 19 in each arm would be required. This would firstly help confirm the results from the clinical trial (chapter 4) and may yield individual differentially expressed genes. This information would be used in concert with cytokine data to further explore the relationship between hypoxia, inflammatory response and changes in gene expression. The clinical trial work tentatively suggests that mitochondrial functions such as oxidative phosphorylation are important in the aetiology of muscle dysfunction. As mentioned above one of the key problems with the OM COPD trial was recruitment. This in part may have been due to the number of skeletal muscle biopsies participants had to undertake; 3. An alternative approach would use a randomised double blind parallel trial of AOT vs Air over a similar time period as the OM COPD trial, with muscle again as the primary end point. However, one would analyse target OXPHOS proteins e.g. (complexes 1-4) and also genes of the OXPHOS pathways
such as PGC-1 alpha, PPAR from skeletal muscle at baseline and at the end of the trial. The analysis of target proteins may prove more fruitful as one would expect any change from AOT usage to be over a period of weeks/month. In contrast changes in relative expression of genes involved in mitochondrial or muscle hypertrophy occur over hours to a day following sufficient stimuli e.g. exercise.
Appendix 1

Search Strategy –Clinical and DeviceEfficacy
1. chronic obstructive pulmonary disease/

2. copd.mp.

3. smoking-related lung disease$.mp.

4. lung emphysema/

5. exp bronchitis/

6. (chronic respiratory adj (disease or disorder)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

7. (chronic obstructive lung adj (disease or disorder)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

8. (chronic obstructive pulmonary adj (disease or disorder)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

9. (chronic obstructive airway adj (disease or disorder)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

10. (chronic obstructive respiratory adj (disease or disorder)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

11. chronic ventilatory failure.mp.

12. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11

13. oxygen therapy/

14. exp ambulatory care/

15. 13 and 14

16. ((ambulat$ or portable or supplemental or O2) adj2 (oxygen or therap$)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
17. 15 or 16
18. 12 and 17

**Search Strategy - Cost effectiveness**

1 chronic obstructive lung disease/ (67861)
2 copd.mp. (37001)
3 smoking-related lung disease$.mp. (97)
4 lung emphysema/ (14765)
5 exp bronchitis/ (45660)
6 (chronic respiratory adj (disease or disorder)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (1569)
7 (chronic obstructive pulmonary adj (disease or disorder)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (34872)
8 (chronic obstructive lung adj (disease or disorder)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (68620)
9 (chronic obstructive airway adj (disease or disorder)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (337)
10 (chronic obstructive respiratory adj (disease or disorder)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (106)
11 chronic ventilatory failure.mp. (92)
12 or/1-11 (130339)
13 oxygen therapy/ (19975)
14 exp ambulatory care/ (38150)
15 13 and 14 (123)
16 ((ambulat$ or portable or supplemental or O2) adj2 (oxygen or therap$)).mp. (9268)
17 15 or 16 (9324)
18 12 and 17 (932)
19 cost benefit analysis/ (65629)
20 cost effectiveness analysis/ (90660)
21 cost minimization analysis/ (2303)
22 cost utility analysis/ (4841)
23 economic evaluation/ (8349)
24 (cost or costs or costed or costly or costing).tw. (403593)
25 (economic$ or pharmacoeconomic$ or price$ or pricing).tw. (210580)
26 (technology adj assessment$).tw. (4263)
27 or/19-26 (614168)
28 18 and 27 (95)
CONSENT FORM

Study Number: ERN-11-1670

Patient Identification Number for this trial:

Title of Project:

Name of Researcher:

Please initial box

I confirm that I have read and understand the information sheet dated............... version...............for the above study. I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.

I understand that my participation is voluntary and that I am free to withdraw at any time without giving any reason, without my medical care or legal rights being affected.

I understand that relevant sections of my medical notes and data collected during the study, may be looked at by individuals from the University of Birmingham, from regulatory authorities or from the NHS Trust, where it is relevant to my taking part in this research. I give permission for these individuals to have access to my records.

I agree to my GP being informed of my participation in the study.

I agree to take part in the above study.

Name of Patient ................................................................. Date........................

Signature..................................................................................................................

Name of Person taking consent ................................................................. Date........................

Signature..................................................................................................................

When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in medical notes.
Appendix 2.8

**Can muscle dysfunction in COPD be altered by oxygenation in patients with intermittent hypoxia on exertion?**

**Proforma Visit 0**

Patient ID ______________  D.O.B ______________

Age

Sex  Male  □  Female  □

O2 sats ______

ABG (0.21) ______

<table>
<thead>
<tr>
<th></th>
<th>Measured</th>
<th>Predicted</th>
<th>%Predicted</th>
<th>Lower Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FVC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Chronic bronchitis

Emphysema

Bronchiectasis

Common comorbidities: IHD □  DM □  Heart failure (R or L) □  Osteoporosis □  GORD □

MRC dyspnoea score ______

CAT score ______

HAD score ______

<table>
<thead>
<tr>
<th>Component</th>
<th>/21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety</td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>/21</td>
</tr>
</tbody>
</table>
6MWT Distance  __________

Samples collected

Serum sample Results

Activity monitor data

<table>
<thead>
<tr>
<th>Activity Level</th>
<th>Time Spent per Day Hours:mins</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Day 1</td>
</tr>
<tr>
<td>Sedentary</td>
<td></td>
</tr>
<tr>
<td>Light</td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Vigorous</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
</tr>
</tbody>
</table>

Proforma for clinic visits 14, 28, 34 and 35 would be broadly similar

Extra information collected at those time points:

**ADVERSE EVENTS**

Recent exacerbation requiring hospital admission  Y □  N □

Recent exacerbation treated in community  Y □  N □

Adverse event

Clinic visit wk8 and 22 would just include (HAD, CAT and extra info collected as above).
<table>
<thead>
<tr>
<th>KIAA0355</th>
<th>TOMM20</th>
<th>RASSF1</th>
<th>AKT2</th>
</tr>
</thead>
<tbody>
<tr>
<td>ING1</td>
<td>JDP2</td>
<td>ACAD9</td>
<td>DOK1</td>
</tr>
<tr>
<td>WARS</td>
<td>PSMD6</td>
<td>DYNC1L2</td>
<td>LMBRD1</td>
</tr>
<tr>
<td>USP1</td>
<td>KLHDC2</td>
<td>XLOC_010470</td>
<td>DROSHA</td>
</tr>
<tr>
<td>SAC3D1</td>
<td>IGSF8</td>
<td>TPPP</td>
<td>ARFIP1</td>
</tr>
<tr>
<td>LZTS2</td>
<td>BST2</td>
<td>CELF5</td>
<td>ADIPOR1</td>
</tr>
<tr>
<td>PNKD</td>
<td>USP35</td>
<td>RNF130</td>
<td>MXD4</td>
</tr>
<tr>
<td>XLOC_014512</td>
<td>MYADM</td>
<td>SURF4</td>
<td>EMC4</td>
</tr>
<tr>
<td>TGF81</td>
<td>CRIP1</td>
<td>DDX49</td>
<td>BNIP3L</td>
</tr>
<tr>
<td>RPS6KA2</td>
<td>SLC40A1</td>
<td>C1QA</td>
<td>TMEM221</td>
</tr>
<tr>
<td>TRAP1</td>
<td>CRNDE</td>
<td>INTS10</td>
<td>PHYHD1</td>
</tr>
<tr>
<td>XLOC_007868</td>
<td>CTNS</td>
<td>MRC2</td>
<td>SNRPF</td>
</tr>
<tr>
<td>COL1A2</td>
<td>C11orf83</td>
<td>PDXK</td>
<td>FTL</td>
</tr>
<tr>
<td>SPON2</td>
<td>FAM174B</td>
<td>LOC101927712</td>
<td>NOB1</td>
</tr>
<tr>
<td>SYT6</td>
<td>AHNAK2</td>
<td>TBC1D9B</td>
<td>GPATCH3</td>
</tr>
<tr>
<td>LRRCA8</td>
<td>IRF2BPL</td>
<td>FBXO10</td>
<td>NDUF4F6</td>
</tr>
<tr>
<td>LOC102725379</td>
<td>SERPINB1</td>
<td>UBE2H</td>
<td>PREP</td>
</tr>
<tr>
<td>RAB31</td>
<td>GOLGA3</td>
<td>PEA15</td>
<td>SETBP1</td>
</tr>
<tr>
<td>ARPC5</td>
<td>C20orf24</td>
<td>PLEKHB2</td>
<td>DPCD</td>
</tr>
<tr>
<td>LARP6</td>
<td>LOC101928089</td>
<td>CDC123</td>
<td>EHD2</td>
</tr>
<tr>
<td>PLOD1</td>
<td>LFNG</td>
<td>COPRS</td>
<td>LIG1</td>
</tr>
<tr>
<td>AGMAT</td>
<td>KANSL1</td>
<td>SND1</td>
<td>ZNF667-AS1</td>
</tr>
<tr>
<td>GZMA</td>
<td>TKT</td>
<td>C2orf47</td>
<td>TMEM59</td>
</tr>
<tr>
<td>SLC25A39</td>
<td>SMIM4</td>
<td>XLOC_013142</td>
<td>TMEM11</td>
</tr>
<tr>
<td>BCL2L1</td>
<td>COL4A3BP</td>
<td>RNPEP</td>
<td>MCFD2</td>
</tr>
<tr>
<td>CDK11A</td>
<td>FLNA</td>
<td>SSNA1</td>
<td>RPRML</td>
</tr>
<tr>
<td>SZRD1</td>
<td>GUCA2B</td>
<td>MRPS11</td>
<td>C1orf174</td>
</tr>
<tr>
<td>BCAP31</td>
<td>USP38</td>
<td>LGALS3</td>
<td>XLOC_004260</td>
</tr>
<tr>
<td>NSUN5</td>
<td>TTC40</td>
<td>APIB1</td>
<td>NUPR1</td>
</tr>
<tr>
<td>REST</td>
<td>EMC8</td>
<td>TXNRD3</td>
<td>PNPLA2</td>
</tr>
<tr>
<td>CEP63</td>
<td>LRRD1</td>
<td>AKR1C3</td>
<td>SUMO2</td>
</tr>
<tr>
<td>ATP6V0A1</td>
<td>GAPATCH4</td>
<td>DPP7</td>
<td>FAM71E1</td>
</tr>
<tr>
<td>SLC14A1</td>
<td>C2orf88</td>
<td>XLOC_008233</td>
<td>TRADD</td>
</tr>
<tr>
<td>SMAD4</td>
<td>AVPI1</td>
<td>ARAP1</td>
<td>GPBP1</td>
</tr>
<tr>
<td>ZNF189</td>
<td>CDR1</td>
<td>MET</td>
<td>PI16</td>
</tr>
<tr>
<td>CTDP1</td>
<td>SSR1</td>
<td>IGFBP5</td>
<td>LINC00943</td>
</tr>
<tr>
<td>PMPCA</td>
<td>MMGT1</td>
<td>PHLDB1</td>
<td>RANBP9</td>
</tr>
<tr>
<td>UGDH</td>
<td>BCL2</td>
<td>RBM17</td>
<td>XLOC_003147</td>
</tr>
<tr>
<td>GPKOW</td>
<td>HIST1H3I</td>
<td>TBX1</td>
<td>FNDC1</td>
</tr>
<tr>
<td>CSorf22</td>
<td>TMEM120A</td>
<td>PEAK1</td>
<td>MIR143HG</td>
</tr>
<tr>
<td>ALDH3A2</td>
<td>EBLN3</td>
<td>EML4</td>
<td>SARNP</td>
</tr>
<tr>
<td>TAPBP</td>
<td>CCDC22</td>
<td>CHRD1L</td>
<td>MRPL54</td>
</tr>
<tr>
<td>NUP85</td>
<td>C16orf58</td>
<td>RAI1</td>
<td>RPS17</td>
</tr>
<tr>
<td>KEAP1</td>
<td>RAB5C</td>
<td>VSTM4</td>
<td>VMA21</td>
</tr>
<tr>
<td>TAOK3</td>
<td>FAM120AOS</td>
<td>PRMT2</td>
<td>CYHR1</td>
</tr>
<tr>
<td>FRA10AC1</td>
<td>GADL1</td>
<td>ABCD1</td>
<td>SCPEP1</td>
</tr>
<tr>
<td>CYB5A</td>
<td>TMEM237</td>
<td>ADAR</td>
<td>RGCC</td>
</tr>
<tr>
<td>WDR61</td>
<td>LOC390705</td>
<td>ZFAS1</td>
<td>ACACB</td>
</tr>
<tr>
<td>KIAA0226</td>
<td>TUBA1C</td>
<td>CCDC3</td>
<td>MGLL</td>
</tr>
<tr>
<td>----------</td>
<td>--------</td>
<td>-------</td>
<td>------</td>
</tr>
<tr>
<td>FAM213A</td>
<td>IL15</td>
<td>ENDO1</td>
<td>LMAN2</td>
</tr>
<tr>
<td>CHCHD7</td>
<td>ATP2B4</td>
<td>FAM20B</td>
<td>HY1</td>
</tr>
<tr>
<td>TOR1AIP2</td>
<td>F8A1</td>
<td>HSP90B1</td>
<td>RAP1GAP2</td>
</tr>
<tr>
<td>TOR1AIP1</td>
<td>NUDT1</td>
<td>MTERFD2</td>
<td>RMDN3</td>
</tr>
<tr>
<td>MRPS30</td>
<td>NCAM1</td>
<td>SLC39A3</td>
<td>SNCB</td>
</tr>
<tr>
<td>BBX</td>
<td>GUCD1</td>
<td>HPS1</td>
<td>ARHGEF11</td>
</tr>
<tr>
<td>BCKDHB</td>
<td>NFIL3</td>
<td>REXO2</td>
<td>URGCP</td>
</tr>
<tr>
<td>CSF1R</td>
<td>PMVK</td>
<td>SLC43A3</td>
<td>EPB41L4A-AS1</td>
</tr>
<tr>
<td>AIMP1</td>
<td>PPP1R8</td>
<td>TNXB</td>
<td>PLIN1</td>
</tr>
<tr>
<td>LPL</td>
<td>ATRA1D</td>
<td>RAB11B</td>
<td>RAB3GAP1</td>
</tr>
<tr>
<td>CROCC</td>
<td>BTBD9</td>
<td>RPL22L1</td>
<td>ITIH5</td>
</tr>
<tr>
<td>MRPL10</td>
<td>SPTAN1</td>
<td>PTPN2</td>
<td>TEMEM204</td>
</tr>
<tr>
<td>GNE</td>
<td>MICU1</td>
<td>EGFR-AS1</td>
<td>RAPGEF1</td>
</tr>
<tr>
<td>YIPF6</td>
<td>GPX4</td>
<td>C6orf226</td>
<td>TLE2</td>
</tr>
<tr>
<td>NDRG1</td>
<td>TMEM43</td>
<td>PLEKHO2</td>
<td>AKR1C1</td>
</tr>
<tr>
<td>FTO</td>
<td>HLA-DPB1</td>
<td>USP22</td>
<td>TMSB4X</td>
</tr>
<tr>
<td>C1orf43</td>
<td>TCF25</td>
<td>HTRA1</td>
<td>MRPL36</td>
</tr>
<tr>
<td>KANK2</td>
<td>SNORD38A</td>
<td>TRIM24</td>
<td>S100A13</td>
</tr>
<tr>
<td>MTDH</td>
<td>SLC25A6</td>
<td>PSEN2</td>
<td>TLN1</td>
</tr>
<tr>
<td>MARS</td>
<td>LRR2C8C</td>
<td>LYRM4</td>
<td>DDI2</td>
</tr>
<tr>
<td>RNF149</td>
<td>DNH1</td>
<td>KANK3</td>
<td>KCNS3</td>
</tr>
<tr>
<td>STK19</td>
<td>GGT5</td>
<td>LRR2C9</td>
<td>HERC2P4</td>
</tr>
<tr>
<td>ZNF32</td>
<td>BTBD1</td>
<td>COL1A1</td>
<td>C10orf71-AS1</td>
</tr>
<tr>
<td>TMEM1100</td>
<td>DHCR24</td>
<td>C22orf34</td>
<td>SUCO</td>
</tr>
<tr>
<td>ZFAND3</td>
<td>ARNT2</td>
<td>PFKFB3</td>
<td>CAV1</td>
</tr>
<tr>
<td>ISLR</td>
<td>CMIM3</td>
<td>HTRA2</td>
<td>DAG1</td>
</tr>
<tr>
<td>SELENBP1</td>
<td>MRPL45</td>
<td>COQ5</td>
<td>XRCC5</td>
</tr>
<tr>
<td>PTPN6</td>
<td>GUK1</td>
<td>LINC00657</td>
<td>GPX1</td>
</tr>
<tr>
<td>C12orf4</td>
<td>HAS3</td>
<td>FBXO7</td>
<td>ARHGDIA</td>
</tr>
<tr>
<td>COBL</td>
<td>LPCAT1</td>
<td>ORMDL2</td>
<td>OR3A3</td>
</tr>
<tr>
<td>IFI27</td>
<td>RPA3</td>
<td>LOC440864</td>
<td>MLLT4</td>
</tr>
<tr>
<td>HSPG2</td>
<td>YME1L1</td>
<td>HIST1H4I</td>
<td>BARD1</td>
</tr>
<tr>
<td>SPDYE4</td>
<td>NPC2</td>
<td>PTPN18</td>
<td>SIDT2</td>
</tr>
<tr>
<td>NT5C</td>
<td>TTC33</td>
<td>SKIV2L2</td>
<td>ZNF174</td>
</tr>
<tr>
<td>SERPINE1</td>
<td>RPL13A</td>
<td>ADPRHL1</td>
<td>C20orf166-AS1</td>
</tr>
<tr>
<td>EIF1AX</td>
<td>FHL2</td>
<td>SRRT</td>
<td>LYPLA2</td>
</tr>
<tr>
<td>RPL28</td>
<td>CTTN</td>
<td>XLOC_006689</td>
<td>CNP</td>
</tr>
<tr>
<td>IFTM2</td>
<td>XYL2</td>
<td>KLHL6</td>
<td>AKR7A2</td>
</tr>
<tr>
<td>MN1</td>
<td>KIAA1549L</td>
<td>PPP2R2D</td>
<td>SEPP1</td>
</tr>
<tr>
<td>MEF2A</td>
<td>KEL</td>
<td>SH3GL1P2</td>
<td>LOC100507144</td>
</tr>
<tr>
<td>PITX2</td>
<td>FOXP1</td>
<td>KARS</td>
<td>ECSIT</td>
</tr>
<tr>
<td>LSP1</td>
<td>SCAND1</td>
<td>NAA10</td>
<td>CHTF8</td>
</tr>
<tr>
<td>CHSY1</td>
<td>CYBA</td>
<td>MEDAG</td>
<td>STX2</td>
</tr>
<tr>
<td>NUCB2</td>
<td>ACTR3C</td>
<td>HIST1H2AC</td>
<td>FECH</td>
</tr>
<tr>
<td>IFI30</td>
<td>MARCKS</td>
<td>COA3</td>
<td>MUM1</td>
</tr>
<tr>
<td>CCDC6</td>
<td>GNGL10</td>
<td>SNCA</td>
<td>XLOC_007433</td>
</tr>
<tr>
<td>HIGD2A</td>
<td>SEPN1</td>
<td>PBX1</td>
<td>USP4</td>
</tr>
<tr>
<td>CAT</td>
<td>MRPS6</td>
<td>LRP1</td>
<td>ZCCHC24</td>
</tr>
<tr>
<td>YPEL5</td>
<td>STRAD8</td>
<td>AQP7</td>
<td>SLC25A46</td>
</tr>
<tr>
<td>CRELD1</td>
<td>TMSB10</td>
<td>CCDC80</td>
<td>COL6A4P2</td>
</tr>
<tr>
<td>----------</td>
<td>---------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>POLR2C</td>
<td>STT3A</td>
<td>DHDDS</td>
<td>EHMT1</td>
</tr>
</tbody>
</table>

Top 400 genes in ranked list in tables running from top to bottom.
References


